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Part I
GeNeral INtrODuCtION 
aND sCOPe Of the thesIs

Chapter 1
General Introduction and scope of the thesis

Introduction 11
1
ePIDeMIOlOGy
In 2008 there were approximately 386,300 new cases of bladder cancer (BC) worldwide.1 The 
highest incidence rates are found in Europe and the United States. BC is more predominant 
in males with a male:female ratio of 4:1. The incidence rates increase with age, with a peak 
incidence in the sixth decade of life. Under the age of 40, BC is highly uncommon with reported 
incidence rates varying between 1-2%.2-4 BC is a multifactorial disease, with smoking and oc-
cupational exposure as major risk factors in the developed countries. In less developed countries, 
mostly Africa and the Middle East, the major cause is chronic infection with Schistosoma hema-
tobium.1, 5 Bladder tumors related to schistosomiasis are mostly from the squamous cell type, 
whereas 90% of the bladder tumors in the developed countries are from the urothelial cell type. 
In this thesis we will only discuss bladder cancer from the urothelial type.
ClINICal PreseNtatION aND DIaGNOsIs
The major symptom in patients presenting with bladder cancer is painless microscopic or mac-
roscopic hematuria, i.e. blood in the urine. Patients presenting with hematuria form a large 
part of the urological population. Yet, only 5-20% of the hematuria is caused by BC. Therefore, 
hematuria is not a specific symptom and could be caused by various conditions, such as kidney 
stones, urinary tract infections, benign prostate hyperplasia or kidney diseases. Furthermore, 
not all patients with bladder cancer will present with hematuria. Other symptoms are dysuria, 
frequency, recurrent bladder infections or symptoms of obstruction. The gold standard for the 
detection of BC is white light cystoscopy (WLC). Cystoscopy is an endoscopic procedure as 
depicted in figure 1.1. The urologist places a rigid or flexible scope through the urethra into the 
bladder. The flexible glass fibers in the scope transfer the image from the tip of the scope to a 
Figure 1.1 (A) Investigation of the bladder by cystoscopy. (B) Bladder tumor visualized by white light cystoscopy. 
Source: www.stfranciscare.org and www.urology.ie
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screen. By using the cystoscope the urologist is able to examine the entire bladder wall. Yet, the 
sensitivity for the detection of BC is not optimal ranging from 46% to 80%.6-8 Especially flat 
malignant lesions (Carcinoma In Situ) are difficult to visualize and to distinguish from inflamma-
tory lesions and as a consequence some of these high-grade tumors are missed. To improve the 
diagnostic accuracy new endoscopic techniques are developed. Fluorescence or photodynamic 
cystoscopy (PDD) uses photoactive agents, e.g. 5-aminolevulinic acid (5-ALA) or hexaminolevu-
linate (HAL), which preferentially accumulates in tumor cells. Under blue light with a wavelength 
of 375-440 nm, the cells with the accumulated agent emit a red fluorescence, while normal 
bladder tissue remains blue.9 Sensitivity for PDD ranges from 76%-97% and is superior to WLC, 
especially for the detection of CIS. Yet, high false-positives rates are observed particularly after 
recent TUR, BCG treatment or urinary tract infections.8 Another newly developed technique 
is narrow band imaging (NBI). This technique enhances the contrast between mucosal and 
microvascular tissue by using a light source consisting of two different wavelengths (425 and 
540nm). This light only penetrates the superficial mucosal layer and is strongly absorbed by 
hemoglobin. The contrast between normal mucosa and capillaries helps to distinguish between 
normal urothelium and more vascularized malignant areas. NBI improves de detection of BC 
over WLC, with reported sensitivities of 85%-100%.10-13 However, comparable with PDD, high 
false-positives rates are observed.
Next to cystoscopy, urine cytology is performed. Urine cytology microscopically investigates 
urine for the presence of tumor cells. Urine generally contains normal urothelial cells shed from 
the urinary tract. A major limitation of urine cytology is its limited ability of detection low-grade 
(LG) tumor cells. A large meta-analysis by Lotan et al showed a median sensitivity for the detec-
tion of grade 1 tumors of 12%, 26% for grade 2 tumors and 64% for grade 3 tumors. Overall, 
the specificity is high (99%) both for low-grade and high-grade lesions.14
staGING aND GraDING
BC is classified according to the widely used TNM-system approved by the Union for Interna-
tional Cancer Control (UICC).15 The T-stage indicates the extent of local tumor invasion (Fig 1.2, 
table 1.1). The N-stages specify the spread of malignant cells to regional lymph nodes and the 
M-stage describes whether there are distant metastasis (Table 1.1). There are two main groups 
of bladder cancer: the non-muscle invasive bladder tumors (NMIBC) and muscle-invasive bladder 
tumors (MIBC). Ta-tumors, together with T1-tumors form the group of NMIBC. These tumors 
are limited to the urothelial cell layer (Ta) or grow into the lamina propria (T1). Carcinoma in 
situ (CIS), a flat tumor limited to the urothelial cell layer, is also considered as NMIBC. Despite 
its superficial growth character, CIS has a high malignant potential. The MIBCs comprise stage 
T2-, T3- and T4-tumors. These tumors invade the detrusor muscle (T2), the perivesical fat (T3) or 
grow into surrounding organs (T4). Most common sites of metastasis are lung, liver and bone.
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Figure 1.2 Different stages of bladder cancer. All urothelial cell carcinomas derive from the urothelial tissue 
layer called bladder lining. Source: www.cambridgeurologypartnership.co.uk
Table 1.1: 2009 TNM classification of urinary bladder cancer
t - tumor
Tx Tumor cannot be assessed
T0 No evidence of primary Tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ: ‘flat Tumor’
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades muscle
T2a Tumor invades superficial muscle (inner half)
T2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue
T3a Microscopically
T3b Macroscopically (extravesical mass)
T4 Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall
T4a Tumor invades prostate, uterus or vagina
T4b Tumor invades pelvic wall or abdominal wall
N - lymph nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single lymph node in the true pelvis
N2 Metastasis in multiple lymph nodes in the true pelvis
N3 Metastasis in a common iliac lymph node(s)
M - Distant metastasis
M0 No distant metastasis
M1 Distant metastasis
Source: TNM Classification of Malignant Tumours, 7th Edition, 2009.
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BC is graded by the WHO-grading system (table 1.2). Currently, two systems are used: the 
1973 WHO-grading system and the 2004 WHO-grading system (Fig 1.3). In the 1973 WHO-clas-
sifi cation urothelial tumors are divided based on the degree of differentiation into four different 
categories: papilloma and grade 1 to 3. A major limitation of the 1973 WHO-grading system is 
the not well-defi ned criteria for the three different tumor grades, resulting in high percentages 
of tumors classifi ed as grade 2. Furthermore, there is a great inter-observer variation.16-18 There-
fore, a new grading system was introduced in 1998 by the World Health Organization (WHO), 
which was fi nally adopted in 2004. It consists of papillary urothelial neoplasms of low malignant 
potential (PUNLMP), low-grade (LG) urothelial cancer, and high-grade (HG) urothelial cancer,19 
with detailed criteria for the different histologic conditions. Yet, the inter-observer variability is 
still high. Therefore, there is no consensus whether using the 1973 or 2004 WHO-system.20-23 In 
this thesis both systems have been used.
Table 1.2: WHO grading 1973 and 2004
1973 WhO grading
Urothelial papilloma
Grade 1: well differentiated
Grade 2: moderately differentiated
Grade 3: poorly differentiated
2004 WhO grading
Urothelial papilloma
Papillary urothelial neoplasm of low malignant potential (PUNLMP)
Low-grade papillary urothelial carcinoma
 High-grade papillary urothelial carcinoma
Source: EAU guidelines on non-muscle invasive bladder cancer, 2015
Figure 1.3 Grading classifi cation according the 1973 WHO system and the 2004 WHO system. Source: van 
Rhijn et al, Eur Urol, 2009
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treatMeNt
Transurethral resection (TUR) is the initial treatment for suspicious lesions and is performed to 
remove all visible tumor and to provide tissue for pathological assessment. The depth of tumor 
growth is of prognostic importance and defines the additional treatment. Hence, the pres-
ence of detrusor muscle in the TUR specimen is essential for accurate pathological evaluation. 
Furthermore, a radical TUR is crucial to achieve good prognosis.24 A second TUR is recommended 
in case the initial resection is irradical or when the detrusor muscle is absent in the primary 
pathological specimen. Moreover, a re-TUR is advised in case a high grade T1 tumor has been 
detected at the initial TUR.25 Pathological assessment of a re-TUR can result in a change of 
stage and further debulking of potential tumor cells has been shown to improve recurrence-free 
survival.25-27 In addition to TUR, the EAU guidelines recommend a single dose of postoperative 
chemotherapy for patients with Ta/T1 disease in order to reduce the chance of developing recur-
rence.28 Patients with non-muscle invasive disease with a high risk of recurrence or progression 
receive adjuvant instillations with Bacillus Calmette-Guérin (BCG) or chemotherapy in addition 
to the single postoperative dose. BCG invokes an immune response in the bladder which affects 
the cancer cells.29 In case of BCG treatment failure cystectomy should be considered.28
The treatment of muscle invasive bladder cancer depends on the extent of invasion and the 
presence of metastasis. In the absence of metastasis, radical cystectomy is the optimal treat-
ment, including removal of the bladder, adjacent organs and regional lymph nodes.30 Neo-
adjuvant chemotherapy prior to cystectomy improves overall survival.31 In case of metastatic 
disease, there are no curative options. Depending on patient’s performance status systemic 
chemotherapy could be considered.
PrOGNOsIs
Approximately 70% of bladder tumors are initially diagnosed as non-muscle invasive disease 
and 30% as muscle invasive disease. The overall prognosis of NMIBC patients is favorable with 
5-year survival rates over 90%. Yet, the recurrence rate in patients with NMIBC is high: 70% 
of the patients will develop at least one recurrence within five years.32 Currently, the recurrence 
and progression risk is calculated according to the EORTC risk tables (tables 1.3 and 1.4), includ-
ing several clinical pathological factors: tumor size, multiplicity, prior recurrence rate, tumor 
stage, tumor grade, and the presence of concomitant CIS.33 These EORTC risk scores were 
developed in 2006 based on results from 7 clinical trials. A limitation of this study was the low 
number of included patients treated with BCG. Nowadays, BCG is widely used as adjuvant 
intravesical therapy and it is known to reduce the risk of recurrence and progression.34 A recent 
meta-analysis reported adjuvant BCG treatment as important prognostic factor for high-grade 
T1 patients.35 Since the EORTC risk scores may not be accurate to predict prognosis in the BCG-
treated patient, the CUETO risk score were added to the guidelines in 2015. These risk scores 
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were specifically designed for patients treated with BCG.36 Recently, Vedder et al validated both 
risk scores on a large independent set of NMIBC patients and concluded that both risk scores still 
needed further improvement, especially for the prediction of recurrence risk.37 Similarly, Xylinas 
et al investigated both risk scores in a large group of NMIBC and found that EORTC and CUETO 
risk scores lack discriminative ability for disease recurrence and progression.38 Both risk scores 
are still highly dependent on the pathological review, which is subject to high interobserver and 
intraobserver variability. Molecular markers could be useful in the evaluation of tumor aggres-
siveness and support predicting prognosis. The search for new prognostic molecular markers is 
an ongoing investigation. Some of the promising prognostic markers are discussed in paragraph 
1.7.1.
10-20% of the NMIBC will eventually progress to muscle invasive disease. Patients with 
muscle invasive have a much worse prognosis compared to patients with NMIBC with 5-year 
survival rates ranging between 30% and 60%.30 Prognosis and treatment of MIBC is highly 
depending on tumor stage and grade. Patients with metastatic disease have a 5-year survival of 
only 10-15%.
Table 1.3: Weight scores for recurrence and progression risk
factor recurrence Progression
Number of tumors
 Single 0 0
 2 to 7 3 3
 ≥8 6 3
tumor size
 <3 cm 0 0
 ≥3 cm 3 3
Prior recurrence rate
 Primary 0 0
 ≤1 rec/yr. 2 2
 >1 rec/yr. 4 2
t category
 Ta 0 0
 T1 1 4
CIs
 No 0 0
 Yes 1 6
Grade
 G1 0 0
 G2 1 0
 G3 2 5
total score 0–17 0–23
CIS=Carcinoma in Situ. Source: Sylvester et al., Eur Urol 49: 466, 2006
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surveIllaNCe
The high recurrence rate in patients with NMIBC and the chance of developing progression 
requires an intensive and frequent follow-up. Current surveillance protocols are based on the 
EORTC risk calculator, which determines recurrence risk and progression (table 1.3 and 1.4).33 
Patients with tumors at low risk for recurrence and progression should have a cystoscopy at 
three months after initial TUR, according to the EAU guidelines.28 If no tumor is found, the 
next cystoscopy is advised at nine months and yearly thereafter for a period of 5 years. Patients 
with high-risk tumors should have cystoscopy in combination with urine cytology after three 
months. If negative, cystoscopy and cytology should be repeated every three months for two 
years. After two years without a recurrence the follow-up should be continued with a cystos-
copy every 6 months until 5 years and yearly thereafter. An in-between follow-up scheme is 
recommended to patients with intermediate risk-tumors (comprising approximately 30% of all 
patients) depending on personal and subjective factors. Patients with Tis should have the same 
follow-up schedule as high-risk patients, due to the high malignant potential of carcinoma 
in situ. All surveillance schedules begin from the start in case a recurrence is detected. This 
strict surveillance in combination with the high number of TURs makes BC one of the most 
expensive tumor types.39, 40 Furthermore, cystoscopy is an invasive procedure causing pain and 
physical discomfort. Many research have been done developing non-invasive tests based on 
urinary markers in order to reduce costs and patient burden.14, 41-43 Accuracy and reliability are 
the most important parameters in the development of a new urine test. Moreover, the ideal 
urinary marker is low in costs, easy to perform and highly reproducible. Many promising markers 
have been found, but large prospective validation studies and randomized controlled trials are 
lacking. Therefore, none of the newly investigated markers proved to be good enough to safely 
reduce or replace the number of cystoscopies. In paragraph 1.7.2. we discuss some of the 
potential urinary markers for BC surveillance.
Table 1.4: Probability of recurrence and progression according to total score
recurrence score
Probability of recurrence 1 year 
(95% CI)
Probability of recurrence 5 years  
(95% CI)
0 15% (10%, 19%) 31% (24%, 37%)
1–4 24% (21%, 26%) 46% (42%, 49%)
5–9 38% (35%, 41%) 62% (58%, 65%)
10–17 61% (55%, 67%) 78% (73%, 84%)
Progression score
Probability of progression 1 year 
(95% CI)
Probability of progression 5 years  
(95% CI)
0 0.2% (0%, 0.7%) 0.8% (0%, 1.7%)
2–6 1.0% (.4%, 1.6%) 6% (5%, 8%)
7–13 5% (4%, 7%) 17% (14%, 20%)
14–23 17% (10%, 24%) 45% (35%, 55%)
Source: Sylvester et al, Eur Urol 49: 466, 2006
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MOleCular Markers IN BlaDDer CaNCer
Prognostic markers
Currently, recurrence and progression risk are calculated based on the EORTC risk table as 
discussed above. This risk calculator includes clinical and pathological variables to predict the 
chance of developing recurrent or progressive disease. Yet, high interobserver and intraobserver 
variability is observed in the pathological assessment. Molecular markers could improve prog-
nostic accuracy in individual patients. Hence, the markers may be useful to identify patients with 
NMIBC, who will benefit from more invasive follow-up. Many research have been done in order 
to find the right marker for risk assessment and an extensive range of molecular alterations have 
been investigated to improve the prediction of prognosis. P53 is one of the most frequently 
investigated markers. Many studies revealed that p53 mutation or p53 overexpression is related 
to disease progression.44 Furthermore, FGFR3 mutations are found in up to 70% of all NMIBC 
and several studies reported the positive association of FGFR3 mutations on progression-free 
survival.45-48 The proliferation marker Ki-67 is also related to progressive disease and therefore, 
van Rhijn et al combined the FGFR3 mutation status and Ki-67 expression (assessed by staining 
with antibody MIB-1) into a new molecular grade. Molecular grade 1 (mG1) was defined as 
FGFR3 mutant and low expression of MIB-1, mG2 comprised FGFR3 wild-type tumors with 
low expression of MIB-1 or FGFR3 mutant tumors with high expression of MIB-1 and mG3 
included FGFR3 wild-type tumors with high expression of MIB-1.47 The progression-free survival 
was significant better in patients with low molecular grade compared to the higher molecular 
grades. Furthermore, the molecular grades proved to be better reproducible than the original 
pathological grade. The addition of molecular grade to the EORTC risk scores resulted in an 
improvement of progression-risk prediction.48 Dyrskjot et al developed a gene signature in 
order to predict progression in patients with NMIBC.49 This gene signature was validated on an 
independent multicenter set of NMIBC patients. Patients with the progression signature showed 
a cumulative progression probability of 40% over time, compared to a cumulative progression 
probability of less than 15% for patients with a non-progression signature.50 Sixty-six percent of 
the patients were correctly classified as progressors, with 66% specificity.
Aleman et al identified PMF-1 hypermethylation in bladder cancer and showed the relation 
between loss of PMF1 expression and overall survival.51 Alvarez-Mugica et al studied PMF1 
methylation and its association with clinical outcome in high-grade T1 BC patients treated 
with BCG.52 Higher progression rates were observed in patients without methylation of PMF1 
compared to those with methylated PMF1. Futhermore, shorter disease-specific survival was 
observed in the group with unmethylated PMF-1. In contrast to the study by Aleman et al, 
methylation of PMF1 appeared to have a favorable effect on clinical outcome in high-grade 
T1 BC patients treated with BCG. Methylation of Myopodin is also described as prognosticator 
in patients with high-grade T1 disease.53 Myopodin methylation in bladder cancer was first 
described by Cebrian et al and was associated with increasing tumor stage and tumor grade.54 
Furtermore, there was a relation with poorer survival. Alvarez-Mugica et al investigated Myo-
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podin methylation in patients with T1G3 disease and found significant shorter progression-free 
survival and disease-specific survival in patients with a myopodin-methylated tumor.53
Currently, no molecular markers are integrated in risk assessment or decision-making models in 
bladder cancer. The high heterogeneity within the different studies leads to irreproducible results 
and there is often lack of proper validation. Validation on large prospective multicenter patients 
series is needed before these prognostic markers can be introduced in the urological practice.
urinary biomarkers
Considering the high frequency of cystoscopy for the follow-up of NMIBC, urinary markers 
would be extremely useful for the detection of BC, particularly for the detection of recurrent 
disease. Since the sensitivity of urine cytology for the detection of low-grade tumors is low, 
extensive research has been done in order to find new urinary biomarkers. Many markers 
have been found with sensitivity superior to urine cytology and currently, some of the newly 
developed tests are FDA-approved (e.g. Bladder Tumor Antigen, ImmunoCyt, Nuclear Matrix 
Protein-22, and Fluorescent In Situ Hybridization).41, 55 Yet, none of the discovered markers have 
a significant role in bladder cancer surveillance, since marker performance is not high enough to 
safely reduce or replace the number of cystoscopies. Therefore, these urinary tests are only used 
in addition to cystoscopy. A major problem in studies investigating new markers is the selection 
of urine samples. Most studies included urine samples derived from patients with primary blad-
der tumors. The primary tumor is mostly larger in size and less well differentiated than recurrent 
tumors. Therefore, these tumors will shed more tumor cells in urine, resulting in high sensitivity. 
Subsequently, the marker sensitivity drops considerably when tested on urine samples derived 
from patients with a recurrent tumor.43 Therefore, it is important to include follow-up urines 
in the search for novel surveillance markers. Furthermore, large longitudinal and randomized 
controlled trials are lacking. These studies are important to emphasize the possible anticipatory 
effect of urine analysis, meaning that urinary makers could detect BC before it is visible by 
cystoscopy. Moreover, the sensitivity of cystoscopy varies from 46% to 80%, which could lead 
to ‘false-positive’ urine results, since the tumor might not detected by cystoscopy.6-8 Longitudinal 
analyses could anticipate on this. Zuiverloon et al investigated urine samples collected during 
follow-up from NMIBC patients with a FGFR3 mutant primary tumor. Urine analysis with the 
FGFR3 mutation assay revealed sensitivity for concomitant recurrence detection of 58%, with a 
positive predictive value (PPV) of 25%. The PPV increased when the time-interval was extended 
to 1 year: 55% of the positive urine samples were associated with a recurrence within a year 
and 81% of the positive urine samples were followed by a recurrence during the total follow-up 
period.56 In the same line, van der Aa et al analyzed urine from NMIBC patients during follow-up 
with microsatellite analysis (MA) and showed a sensitivity for concomitant recurrence detec-
tion of 58%. Extending the follow-up period resulted in a 2-yr risk for recurrence detection 
of 83% in case the MA analysis was persistently positive.57 Sanchez-Carbayo et al studied 106 
patients under BC surveillance and collected their urine samples over a year. Samples were tested 
with three different urinary assays: urinary tumor bladder antigen (dectection of CK8, CK18), 
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CYFRA-21-1 (detection of CK19) and NMP22 (detection of nuclear matrix proteins). 31 patients 
recurred within a year and in 30 patients recurrence was identified by urine analysis before it 
was visible by cystoscopy. Recently, Schmidtz-Dräger et al published the WHO consensus on 
molecular markers in bladder cancer surveillance. The authors emphasized the importance of 
prospective analyses to define the consequences of a positive and negative test results before 
these markers could be implemented in clinical decision making.58
Molecular assays
The diagnostic and prognostic markers discussed in this thesis are summarized below.
Mutation analysis
Fibroblast Growth Factor Receptor 3 gene mutations
Fibroblast growth factor receptor 3 (FGFR3) belongs to a family of structurally related tyrosine 
kinase receptors encoded by four different genes. Activating mutations in the FGFR3 gene are 
found in the germline of several autosomal dominant skeletal dysplasia syndromes, including hy-
pochondroplasia, achondroplasia, severe achondroplasia with developmental delay and acantho-
sis nigricans (SADDAN) and thanatophoric dysplasia types I and II.59, 60 The major cellular defect in 
these FGFR3-related skeletal dysplasias is the impaired chondrocyte proliferation. Unlike its role in 
chondrocytes, FGFR3 activation results in a mitogenic effect in epithelial cells and these respond 
to the FGFR3 activation by increased proliferation by constitutive activation of the RAS-MAPK 
pathway (Figure 1.5). Remarkably, the majority of FGFR3 mutations causing skeletal dysplasias 
also occur in cancer.61 Cappellen et al were the first in describing FGFR3 mutations in bladder 
cancer.59 After this initial study, there were several studies that have identified 11 different FGFR3 
mutations in bladder cancer.60 Extensive research has been done and demonstrated the associa-
tion of FGFR3 mutations with low tumor grade and stage. Approximately 70% of the non-muscle 
invasive bladder tumors harbor a mutation in the FGFR3 gene compared to less than 20% of the 
muscle-invasive bladder tumors.59, 62, 63 FGFR3 mutant tumors have a more favorable prognosis 
and are less likely to progress.45, 64, 65 Therefore, the FGFR3 analysis could be used as prognostic 
marker.46, 47, 63, 65 The absence of FGFR3 mutations in normal urothelium allows the use of FGFR3 
mutation analysis as a tumor marker.66 Previous studies demonstrated the ability of FGFR3 muta-
tion analysis for the detection of bladder cancer recurrences in voided urine (Figure 1.4).56, 67, 68
HRAS, KRAS, NRAS gene mutations
The oncogenes HRAS, KRAS, and NRAS are the founding members of a larger family of at 
least 35 related human proteins and belong to the class of small GTPases that function as 
an intermediary step in the RAS-MAPK signal transduction pathway. Activating mutations of 
the three RAS genes are frequently observed in different tumor types.69 The activated HRAS 
gene was first identified in a bladder cancer cell line by Der et al.70 Jebar et al studied RAS 
mutations in bladder tumors and found a mutation frequency of 13% in tumors of all stages 
and grades, most often HRAS and KRAS.71 Similar to the FGFR3 mutations, RAS mutations affect 
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the RAS-MAPK pathway and appear to be mutually exclusive with mutations in the FGFR3 gene 
(Figure 1.5).71-73 Assays detecting RAS mutations in voided urine have been shown to be able to 
detect (recurrent) BC.
Phosphatidylinositol-3,4 -bisphosphate 3-kinase (PIK3CA) gene mutations
The phosphoinositide 3-kinase Phosphatidylinositol-3,4 -bisphosphate 3-kinase (PIK3CA) 
encodes for the catalytic p110-alpha subunit of Phosphatidylinositol 3-Kinase (PI3K) class IA, 
which is active in the PI3K-AKT pathway. The PI3K-AKT pathway is responsible for coordinating 
a diverse range of cell functions including cell proliferation, survival, proliferation, migration and 
morphology (Figure 1.5).74, 75 Mutations in the PIK3CA gene are described in different tumor 
types such as colon, stomach, endometrium, ovary, thyroid, breast and glioblastomas.76 Also 
a high mutation frequency is observed in bladder cancer ranging between 13% and 27% and 
these mutations often coincide with FGFR3 mutations.73, 77, 78 Kompier et al investigated the 
mutation frequency of FGFR3, RAS and PIK3CA in bladder cancer and showed that 88% of the 
non-muscle invasive bladder tumors harbored a mutation in at least one oncogene.73 Mutations 
in PIK3CA are not prognostic but can be of use as a diagnostic tool.
Human Telomerase Reverse Transcriptase Gene Mutations
Telomerase is a ribonucleoprotein polymerase and the function of the enzyme is the preserva-
tion of the telomere ends by the addition of a telomere sequence repeat (TTAGGG). Normally, 
telomerase is only active in stem cells and repression of the enzyme in somatic cells will result 
in progressive shortening of the telomere ends. This will eventually lead to cellular senescence. 
There is cumulative evidence that cancer cells have the capability to overcome this senescence, 
Figure 1.4 FGFR3 SNaPshot analysis Wild-type (A) and Mutant (B)
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leading to unlimited cell division79, 80 Recently, somatic mutations in the gene coding for 
telomerase reverse transcriptase have been found in melanoma and in a small number of other 
tumors.81, 82 The presence of TERT mutations in bladder cancer and their relation to patient 
outcome are studied in this thesis. Also, the ability of TERT mutation analysis for the detection 
of recurrences in urine is investigated.
Methylation analysis
DNA methylation is an epigenetic aberration that may affect gene expression without a change 
in the nucleotide sequence. DNA methylation plays a critical role in genomic imprinting, X-chro-
mosome inactivation, and the regulation of tissue-specific gene expression.83, 84 DNA methylation 
is the addition of a methyl group to the 5’-carbon of cytosine in a CpG sequence catalyzed by 
DNA methyltransferase. The CpG dinucleotides tend to cluster in so-called CpG islands. These 
CpG islands are defined as regions of more than 200 bases consisting of at least 50% G and C 
nucleotides and a ratio of observed to statistically expected CpG frequencies of more than 0.6.85 
Approximately 60% of the gene promoters contain CpG islands, which are usually unmethylated 
and allow gene transcription. Aberrant DNA promoter hypermethylation, causing transcriptional 
silencing of tumor suppressor genes, is found in different tumor types (Fig 1.6). Gonzalez-Zulueta 
et al first described hypermethylation in bladder cancer.86 Since this initial study multiple genes 
with aberrant methylation have been identified in BC and showed association with age, gender, 
tumor location, stage, recurrence rate and progression.87-89 Aberrant methylation has also been 
detected in voided urine of BC patients and appears to be more sensitive for tumor diagnosis than 
urine cytology.90-94
Figure 1.5 RAS-MAPK and PI3K-AKT pathway. Source: Juanpere et al, Hum Pathol, 43: 1573, 2012
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Microsatellite analysis
Microsatellites are short repetitive segments of DNA that are frequently observed throughout 
the genome. The repeated unit is 1 to 6 nucleotides long. The frequency of the repeated 
sequence can be highly variable and often differs between the maternal and paternal allele. 
Therefore, it could be used for the detection of loss of heterozygosity (LOH). LOH is the loss 
of part of the chromosome and is frequently observed in different types of cancer. Loss of 
the long arm of chromosome 9 (9q) is thought to be an early and important event in bladder 
carcinogenesis. Also loss of chromosome 8, 10, 11 and 17 are frequently found in BC.95 Mao 
et al was the first describing the use of microsatellite analysis (MA) for the detection of primary 
BC in urine.96 Shortly thereafter, Steiner et al investigated whether MA could also be used for 
the follow-up of BC patients.97 Thereafter, many studies have been followed with sensitivity 
ranging from 75-92% and specificity between 79-100% for the detection of BC in patients 
under surveillance.41 A disadvantage of the MA is the need of blood as reference and moreover 
the technique is laborious and expensive. Therefore, van Tilborg et al developed a MA for the 
detection of recurrent BC without the need for blood as reference.98 This microsatellite analysis 
consisted of 12 probes for the detection of LOH in regions of chromosome 8, 9, 10, 11, and 17, 
resulting in a sensitivity of 58% for the detection of recurrent NMIBC in voided urine. Selection 
of six markers slightly reduced sensitivity to 55%. A smaller panel of markers without the need 
for blood analysis will reduce costs and workload.
Figure 1.6 Aberrant promoter methylation leading to gene silencing. Source: www.uscf.edu
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sCOPe Of the thesIs
The general scope of this thesis is the assessment of the clinical value of molecular markers in 
the diagnosis, surveillance and prognosis of bladder cancer (BC). The introduction in chapter 1 
gives a background of BC, including clinical presentation, diagnosis, treatment, current follow-
up and a summary of molecular markers discussed in this thesis.
Predicting prognosis in patients with NMIBC is highly dependable on clinical and pathological 
parameters, with stage and grade as important prognosticators. Yet, pathological assessment is 
subject to high interobserver and intraobserver variability. Molecular markers could contribute to 
a more accurate and objective review. In chapter 2 we show the validation of four prognostic 
methylation markers, previously determined by Kandimalla et al. Based on the methylation data, 
new molecular grades are defined that predict clinical outcome. In chapter 3 we investigate 
the presence of TERT mutations in bladder cancer and their relation to prognosis and patient 
outcome. Furthermore, we will evaluate the use of the TERT mutation analysis for recurrence 
detection in urine.
The third part evaluates the use of urinary markers for initial BC diagnosis and follow-up of patients 
with primary NMIBC. In chapter 4 we design a bladder cancer-specific MS-MLPA (BC MS-MLPA) 
including genes that are frequently methylated in bladder cancer. This assay will be tested on 
follow-up urines from patients with primary NMIBC to assess the true additional value of the BC 
MS-MLPA during follow-up. In chapter 5 we attempt to improve the detection rate of recurrent 
BC by combining different urinary assays. Pitfalls from chapter 5 will be used to improve recurrence 
detection in chapter 6, with a new combination of urinary assays. Chapter 7 focuses on the role 
of molecular markers in diagnosing BC in patients presenting with hematuria. We investigate the 
discriminative ability of a set methylation markers in combination with clinical variables in patients 
presenting with hematuria. Finally, a predictive model will be developed that differentiates between 
low chance and high chance for BC.
In the final part we investigate BC in patients <20yr. The incidence of BC <20yr is extremely 
low and therefore very limited data is available, regarding this particular age-group. Conflicting 
results have been published, yet tumors from these patients seem to lack genomic aberrations 
that are commonly found in the elderly. In chapter 8 BC from patients <20yr are investigated 
with methylation markers for polycomb group target genes (PcG’s). PcG’s play an important role 
in embryogenesis and previous research showed the methylation of PcG’s is frequently observed 
in different cancer types. We presumed that this may be an early event in carcinogenesis and 
therefore it might be observed in tumors from young patients. In chapter 9 tumors from the 
same patient group are examined for mutations that are commonly found in the elderly, such as 
the FGFR3, RAS and PIK3CA mutation.

Part II
MOleCular Markers 
aND BlaDDer CaNCer PrOGNOsIs

Chapter 2
stratification based on methylation of TBX2 
and TBX3 into three molecular grades predicts 
progression in patients with pta bladder cancer
W. Beukers, R. Kandimalla, R. Masius, M. Vermeij,  
R. Kranse, G.J. van Leenders, E.C. Zwarthoff
Mod Pathol. 2015;28:515-22
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Objective | The potential risk of recurrence and progression in patients with non-muscle invasive 
bladder cancer necessitates follow-up by cystoscopy. The risk of progression to muscle invasive 
bladder cancer is estimated based on the European Organisation of Research and Treatment 
of Cancer score, a combination of several clinicopathological variables. However, pathological 
assessment is not objective and reproducibility is insufficient. The use of molecular markers 
could contribute to the estimation of tumor aggressiveness. We recently demonstrated that 
methylation of GATA2, TBX2, TBX3, and ZIC4 genes could predict progression in Ta tumors. In 
this study we aimed to validate the markers in a large patient set using DNA from formalin-fixed 
and paraffin embedded tissue.
Material and methods | PALGA: the Dutch Pathology Registry was used for patient selection. 
We included 192 patients with pTaG1/2 bladder cancer of whom 77 experienced progression. 
Methylation analysis was performed and Log-rank analysis was used to calculate the predictive 
value of each methylation marker for developing progression over time.
results | Log-rank analysis showed better progression-free survival in patients with low methyla-
tion rates compared to patients with high methylation rates for all markers (p<0.001) during a 
follow-up of ten-years. The combined predictive effect of the methylation markers was analyzed 
with the Cox-regression method. In this analysis, TBX2, TBX3 and ZIC4 were independent pre-
dictors of progression. Based on the methylation status of TBX2 and TBX3, patients were divided 
into three new molecular grade groups. Survival analysis showed that only 8% of patients in 
the low molecular grade group progressed within five years. This was 29% and 63% for the 
intermediate and high molecular grade groups.
Conclusions | This new molecular grade based on the combination of TBX2 and TBX3 meth-
ylation is an excellent marker for predicting progression to muscle-invasive bladder cancer in 
patients with primary pTaG1/2 bladder cancer.
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INtrODuCtION
Bladder cancer is the fifth most common malignancy in the western world and presents a 
significant health problem.1 Clinically, 75-80% of bladder tumors are diagnosed as non-muscle 
invasive disease (Ta, T1, and Tis), while the remaining part is muscle invasive (T2-T4). Ta tumors 
represent the largest group of non-muscle invasive disease, accounting for approximately 70%.2 
These tumors are limited to the urothelial layer and are treated by transurethral resection. Overall, 
prognosis of these patients is favorable, especially for patients with G1/G2 disease. Although, 
high recurrence rates are observed, progression rates in patients with primary pTaG1/2 bladder 
cancer remain limited, ranging from 1-6%.3, 4 Yet, due to the high mortality rates associated with 
muscle invasive bladder cancer, a life-long follow-up by cystoscopy is required. Cystoscopy is an 
expensive and invasive procedure, causing pain and discomfort to the patient.5 The long survival 
of non-muscle invasive bladder cancer patients makes bladder cancer one of the most costliest 
cancers.6 Costs and patient burden could be reduced by lowering the number of cystoscopies 
in patients with pTaG1/2 disease. Hence, correct risk stratification is necessary in order to safely 
adjust the surveillance protocol. Currently, the risk of progression is highly based on the patho-
logical review. Yet, the reproducibility of pathology is modest and this may result in unwanted 
variations in patient management.2, 7-9 Therefore many studies have been performed investigat-
ing new prognostic markers for the prediction of progression.10-12 Nevertheless, there are still no 
accurate biomarkers available to predict progression in this large subgroup of patients.
Epigenetic aberrations, such as DNA hypermethylation, play an important role in the forma-
tion of many carcinomas and may serve as a cancer biomarker in the prediction of disease 
progression.13-15 Recently, Kandimalla et al studied genome-wide hypermethylation of CpG 
islands in association with tumor progression.16 They investigated 238 unique CpG islands 
in pTaG1/2 tumors with and without disease progression, i.e. progression to muscle invasive 
disease, metastasis or dead of disease. Four different CpG islands were selected, that were 
significantly associated with tumor progression, i.e. GATA2, TBX2, TBX3, ZIC4. In this study, the 
aim was to validate the clinical relevance of these four selected markers in a large set of patients 
with pTaG1/2 bladder cancer with and without progression.
MaterIal aND MethODs
Patient and tissue collection
Patients with primary pTaG1/G2 bladder cancer were included. The nationwide network and 
registry of histopathology and cytopathology in the Netherlands (PALGA)17 was searched for 
patients with progression of disease after resection of a primary pTaG1/G2 tumor and the tissue 
block and patient data were requested from the indicated pathology archives. Tumor tissue was 
used according to the code of secondary use of human tissue (www.federa.org). Progression 
was defined as progression to muscle-invasive disease, metastases or dead of disease. Patients 
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with pTaG1/G2 disease without progression were retrieved from our own pathology archive. All 
available cases were reevaluated by an expert uropathologist (GvL).
DNa Isolation and methylation analysis
Formalin-fixed paraffin-embedded tumor tissue was manually dissected from 20μm tissue sec-
tions based on an accompanying HE-stained section. Tumor tissues were dewaxed with xylene 
and ethanol. DNA was extracted using the QIAamp mini and Blood kit (Qiagen) according to 
manufacturer’s protocol.
Methylation analysis of GATA2, TBX2, TBX3 and ZIC4 was performed using the EZ DNA 
Methylation-Gold™ Kit (Zymo Research Corporation, Irvine, California, USA) according to the 
manufacturer’s protocol. As described by Kandimalla et al, DNA was treated with sodium bisul-
fite, followed by a bisulfite-specific PCR for the four regions of interest. For each PCR reaction 
a DNA input of 10ng and a PCR primer concentration of 20 pM was required. After PCR, a 
SNaPshot analysis was performed, using probes that annealed to the PCR product adjacent 
to the cytosine of interest. Probes were extended with a labelled dideoxynucleotide and the 
products were analysed on an automatic sequencer (ABI PRISM 3100 Genetic Analyzer, Applied 
Biosystems), with the label indicating the presence or absence of a methylated cytosine. Primers 
and probes are given in table 2.1. For each gene, the methylation percentage was calculated 
by dividing the height of the methylated peak by the sum of the height of the methylated and 
unmethylated peaks multiplied by 100%.16
Table 2.1: Primer and probe sequences
BsP primers       
ZIC4 TTTTTATTTTTTGAGGGTAAATATTTAGTA
ATCTCCAAAAAACCTCTAAAACAAC
TBX2 GTGGGGTTTTGGAATTTAGAATAGT
AACCACAAACTTAACCATCCACTAC
TBX3 TTTGTTAATGGTTTGTAAATTT
AAAATAAATTTATCACCCACC
GATA2 TATTGTTTTGTGTTTTTGGG
 AACAAATTACAAACAAATTATACCTAA      
sNaPshot probes      
Probe sequence (5’-> 3’) size (bp) strand uM Mt μM*
ZIC4 T10 TAAATTTTGTTTAAATTTTT 30 sense T C 0,2
TBX2 T45 GTTGATGGATATTGTAGT 63 sense T C 0,2
TBX3 T13 AATTTTGGGATTAAAAG 30 sense T C 0,2
GATA2 T20 ACAAACAAATTATACCTAAC 40 antisense A G 0,2
* Concentration per PCR reaction,
BSP= Bisulfite-specific PCR
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statistical analysis
Statistical analyses were completed using the IBM SPSS statistics 20. Chi-square test was used 
to determine relationships between different variables. Survival was estimated according to the 
Kaplan-Meier method and compared using log-rank tests. Multivariate Cox-regression analysis 
with backward elimination was used to calculate the independent prognostic value of the 
methylation markers. P-values <0.05 were considered statistically significant.
results
Patients and tumor characteristics
A total of 192 patients with primary pTa G1/G2 bladder cancer were included in this study. There 
were 115 patients without progression with a median follow-up of 84 months. 77 patients had 
progression of disease with a median time to progression of 38 months. Of these, 66/77 (86%) 
patients developed progression within 10 years. Patient and tumor characteristics are depicted 
in table 2.2. Male: female ratio in both groups was 3:1. Overall, primary tumors of the progres-
sors were higher grade (G2) compared to the primary tumors of the non-progressors, 70% vs. 
42% respectively (p<0.001). Seven patients were originally graded as low-grade according the 
WHO2004 grading system. These seven patients were excluded in multivariate Cox-regression 
analysis.
Table 2.2: Patient and tumor characteristics
 
Progressors
n=77
Non-progressors
n=115  
age
Mean (range) 68 (47-85) 63 (23-86)
  n (%) n (%) p-value
sex
Male 59 (77) 84 (73) 0.58
Female 18 (23) 31 (27)
stage
Ta 77 (100) 115 (100) -
Grade
Grade 1 18 (23) 64 (56) <0.001
Grade 2 54 (70) 49 (42)
 Low Grade 5 (7) 2 (2)  
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validation of the prognostic markers for prediction of progression
Tumor DNA was analyzed for methylation of GATA2, TBX2, TBX3 and ZIC4. Methylation analysis 
failed in 41/768 (5%), i.e. GATA2 n=0, TBX2 n=20, TBX3 n=14 and ZIC4 n=7. The efficacy of 
each gene was determined by calculating the area under the receiver-operating curve. The area 
under the curve for GATA2 was 0.803, TBX2 0.644, TBX3 0.785 and ZIC4 0.692. A methylation 
percentage cut-off was selected with the best combination of sensitivity and specificity for each 
individual marker (Figure 2.1). Cut-off values, sensitivity and specificity are given in table 2.3.
To determine the predictive value of the methylation markers for developing progression over 
time, Log-rank analysis was performed based on a follow-up period of ten years. 66/77 (86%) of 
the progressors developed disease progression within ten years of follow-up. Figure 2.2 shows the 
resulting survival graphs for grade and the four methylation markers. Patients with a G1 tumor or 
low methylation of TBX2, TBX3, GATA2 and ZIC4 had a significantly better progression-free sur-
vival, p<0.001 (Figure 2.2). In order to calculate the combined effect of the methylation markers for 
predicting progression over time, multivariate Cox-regression analysis with backward elimination 
was performed. This analysis based on TBX2, TBX3, GATA2 and ZIC4 in combination with grade 
showed the clear independent prognostic ability of TBX3 for the risk of progression within ten years 
of follow-up time (Table 2.4, multivariate analysis step #1). After removing GATA2 as predictor from 
Figure 2.1 Boxplots indicating the range of gene methylation % regarding the progression status: progressors 
(P) and non-progressors (NP). The horizontal line indicates the cut-off.
Table 2.3: Methylation marker performance for predicting disease progression
Methylation marker Cut-off sensitivity n specificity n auC
TBX3 3.4% 71% 51/72 76% 80/106 0.785
TBX2 5.0% 63% 46/73 66% 66/99 0.644
ZIC4 37% 70% 53/76 64% 70/109 0.692
GATA2 28% 78% 60/77 75% 86/115 0.803
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the model TBX3 and TBX2 appeared the best predictors (multivariate analysis step #2). Based on 
the methylation status of TBX2 and TBX3, a new molecular grading system was defined. Patients 
were assigned to the high molecular grade group in case both markers were positive. The inter-
mediate grade group group included patients with one marker positive. The low molecular grade 
group consisted of patients with none of the markers positive. Disease progression occurred in 
32/43 (74%) of the patients in the high molecular grade group and in 20/49 (40%) patients of the 
intermediate molecular grade group. In comparison, only 9/73 (12%) patients in the low molecular 
grade group showed disease progression. The majority of patients developed progression within 5 
years of follow-up: 27/43 (63%) of the patients from the high molecular grade group compared to 
14/49 (29%) of the intermediate grade group and 6/73 (8%) of the low molecular grade group. 
Log-rank analysis showed significantly better progression-free survival in patients assigned to the 
low molecular grade group compared to patients at the intermediate molecular grade group and 
the high molecular grade group. Furthermore, patients in the intermediate grade group showed 
better progression-free survival than patients in the high molecular grade group (low molecular 
grade vs. intermediate molecular grade p = 0.04, low molecular grade group vs. high molecular 
grade p <0.001, intermediate molecular grade vs. high molecular grade p < 0.001) (Figure 2.3).
Figure 2.2 Kaplan-Meijer curves showing the time to progression of patients with primary TaG1/G2 BC, accord-
ing to the grade (A) given at time of diagnosis and according to the methylation status of GATA2 (B), TBX2 (C), 
TBX3 (D) and ZIC4 (E) in the primary tumor. A: G1 vs. G2 p<0.001, G1 vs. LG p<0.001 and G2 vs. LG p=0.355. 
B-E: patients with low methylation status showed better progression-free survival compared to patients with 
high methylation status (p<0.001).
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Table 2.4: Univariate and multivariate progression-free survival analysis
variable
univariate analysis Multivariate step #1 Multivariate step #2
No of pts events p-value hr 95% CI p-value hr 95% CI p-value
Grade G1 82 14 <0.001 1.824 0.957 - 3.474 0.068 1.882 0.988 - 3.586 0.054
G2 103 48
TBX2
< 5.0% 
methylated 103 23 <0.001 1.656 0.922 - 2.975 0.091 1.873 1.069 - 3.283 0.028
≥ 5.0% 
methylated 69 41
TBX3
< 3.4% 
methylated 101 15 <0.001 3.522 1.788 - 6.936 <0.001 4.087 2.149 - 7.772 <0.001
≥ 3.4% 
methylated 77 47
ZIC4
< 37% 
methylated 93 19 <0.001 1.786 0.985 - 3.237 0.056 1.873 1.038 - 3.379 0.037
≥ 37% 
methylated 92 46
GATA2
< 28% 
methylated 103 15 <0.001 1.605 0.802 - 3.213 0.181 - - -
 
≥ 28% 
methylated 89 51        
Figure 2.3 Patients stratified according to methylation status of TBX2 and TBX3 into three molecular grade 
groups: Low molecular grade (lmG) both markers negative, intermediate-molecular (imG) one marker positive 
and high molecular grade (hmG) both markers positive. A follow-up time of maximum ten years was selected.
Supplementary figure 2.1 Kaplan-Meijer curves showing the time to progression of patients with primary TaG1/
G2 bladder cancer, according to the pathological reassessment (A) Revised grade by WHO1973 (B) Revised grade by 
WHO2004.
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reevaluation of the pathological review
All cases were reviewed by an expert uropathologist. Seventeen were not available. This reevalu-
ation was not completely unbiased because the pathologist was aware that the series comprised 
many tumors that had progressed. Reassessment of the histological slides revealed a dissimilarity 
of 12% (21/175) in staging and of 54% (95/175) in revised grading by the WHO1973 system. 
80/175 (45%) tumors were upgraded and 8% (15/175) of the tumors were downgraded. 
Furthermore, tumors of the progressors were higher graded and staged compared to the group 
of non-progressors, p<0.001 (table 2.5). Revised grade by the WHO2004-system showed more 
high-grade tumors in the progressor-group (p<0.001).
Log-rank analysis based on the revised WHO1973 grade revealed better progression-free survival 
in G1 vs. G2 and G2 vs. G3 (Supplementary Figure 2.1 A: G1 vs G2 p=0.026, G1 vs G3 p<0.001 and 
G2 vs. G3 p<0.001). WHO2004 grading also showed a worse progression-free survival for patients 
with a high-grade tumor compared to patients with a low grade or PUNLMP tumor (Supplementary 
Fig 2.1B: HG vs. LG <0.001, LG vs. PUNLMP p=0.534, and HG vs PUNLMP p=0.035). Next, we per-
formed multivariate Cox regression analyses with backward elimination to compare revised grade 
with the molecular markers. These results are depicted in the supplementary tables 2.1 and 2.2. 
Compared to both grading systems TBX3 and TBX2 remained the best predictors for progression.
Table 2.5: Tumor characteristics after reassessment of histological slides
reassessment
Progressors Non-progressors
p-value
n=77 n=98
n (%) n (%)
stage
Papilloma 2 (3) 1 (1)
Ta 56 (73) 95 (97) <0.001
T1 17 (22) 2 (2)
T2 1 (1) -
Tis 1 (1) -
revised grade by WhO 1973*
Papilloma 2 (3) 1 (1) <0.001
G1 3 (4) 21 (22)
G2 45 (59) 66 (67)
G3 26 (34) 10 (10)
revised grade by WhO 2004*
Papilloma 2 (3) 1 (1) <0.001
PUNLMP 2 (3) 8 (8)
Low Grade 20 (26) 57 (58)
 High Grade 52 (68) 32 (33)  
* Without Tis n=1
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DIsCussION
Although most important predictors for disease progression in patients with non-muscle invasive 
bladder cancer are stage, grade and carcinoma in situ18, patients with primary low stage and low 
grade bladder cancer still have a 1-6% chance of disease progression according the European 
Association of Urology guidelines.3 In order to safely reduce the number of cystoscopies in pa-
tients with low grade non-muscle invasive bladder cancer, risk prediction is necessary. Up to now, 
no sensitive markers are available to predict progression in this specific patient group. Recently, 
Kandimalla et al. proved the prognostic ability of the methylation markers TBX2, TBX3, GATA2 
and ZIC4 using fresh frozen tumor tissue.16 In this more extensive validation these markers again 
proved to be highly sensitive for prediction of progression in low-grade pTa disease. Patients 
with low methylation percentages of TBX2, TBX3, GATA2 and ZIC4 showed better progression-
free survival in univariate Log-rank analysis. Multivariate Cox-regression analysis showed an 
independent increased risk for progression in patients with high methylation ratios of TBX2, 
TBX3 and ZIC4. New molecular grading based on the methylation status of TBX2 and TBX3 into 
three risk groups resulted in accurate prediction of progression risk, with better progression-free 
survival in patients in the low risk group and intermediate risk group. In addition, this validation 
was carried out on DNA isolated from formalin-fixed paraffin embedded tissue.
The four investigated genes, TBX2, TBX3, GATA2 and ZIC4, encode transcription factors 
that are important in the regulation of developmental processes and gene expression is more 
frequent in non-muscle invasive bladder cancer compared to muscle invasive disease.19, 20 This 
could be linked to our results in which aggressive tumors that progressed to muscle-invasive 
bladder cancer showed more methylation than the non-progressive tumors. Furthermore, the 
most significant markers, TBX2 and TBX3, downregulate the p53-pathway by inhibiting the 
expression of the ARF and CIP1 gene.21 Mutation of the p53 gene is a common phenomenon in 
muscle invasive bladder cancer. Methylation of TBX2 or TBX3 could be a different way to inhibit 
the p53-pathway. Therefore, we propose that methylation of TBX2 and TBX3 characterizes the 
more aggressive non-muscle invasive bladder cancer, which are more similar to the muscle-
invasive bladder cancer.
Multiple studies previously reported the prognostic ability of methylation markers based on 
DNA isolated from formalin-fixed paraffin-embedded tissue.22 Friedrich et al found that methyla-
tion of TIMP3 was associated with a better progression-free survival in patients with pT1 and pTa 
tumors.23 Yan et al showed that methylation of RUNX3 in combination with G3 increased the 
chance of disease progression.24 According to Yates et al. methylation of E-cadherin, TNFRSF25, 
EDNRB, RASSF1A and APC were significantly associated with progressive disease.15 Yet, these 
studies all used a mixture of pT1 and pTa tumors. Our study specifically focused on patients 
with low-grade pTa disease. These patients have the lowest chance of developing progression 
and therefore, adjustment of the surveillance protocol will be most beneficial in this particular 
patient group.
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The progression scores as recommended in the European Association of Urology guidelines 
are currently calculated according to the European Organisation of Research and Treatment of 
Cancer risk scores developed by Sylvester et al.3 The pathological review plays an important 
role in this prediction model. However, this pathological assessment highly depends on the 
experience of the pathologist and suffers from high interobserver and intraobserver variation.8, 25 
Upgrading and upstaging could increase the 5-year progression risk up to 45% according to 
the European Organisation of Research and Treatment of Cancer risk calculator. This empha-
sizes the importance of accurate pathological assessment. This study again proved the high 
interobserver variation with significant more high grade tumors among the progressors after 
pathological reassessment. Yet, it should be emphasized that the pathological review could be 
biased. Although, the slides were blinded, the pathologist was aware of the fact that there was 
a high percentage of aggressive tumors in this study. Therefore, we decided to use the original 
pathological grade as inclusion criteria, since this is the diagnosis on which further treatment 
was based. Patient outcome is a result of this original review and the treatment choices made.
The use of molecular markers could facilitate the pathologist’s estimation of tumor aggres-
siveness. A previous study by van Rhijn et al investigated the additional value of molecular 
markers to the pathological assessment. Molecular grading based on the combination of FGFR3 
mutation status and MIB1 expression resulted in better risk prediction compared to conventional 
pathological grade.26 The addition of the methylation markers to FGFR3 and MIB1 might further 
increase the predictive accuracy. The methylation analysis is an easy test and could be performed 
in a standard laboratory. Furthermore, the SnapShot method proved to be highly reproducible.27
A limitation of this study is the retrospective design. Due to the low incidence of progres-
sion in low grade Ta disease a prospective study design is difficult to establish. Therefore, the 
distribution of patients is not representative for the clinical practice, since the actual percentage 
of patients with low-grade non-muscle invasive bladder cancer and disease progression will 
be much lower in the clinical setting. However, the predictive risk ability of the methylation 
markers still holds after a second validation and therefore, we believe that these results could 
be translated to the clinic.
CONClusIONs
This study represents an independent validation of pTa-prognostic markers in a large set of 
patients. These markers proved again to be accurate risk predictors for progression in patients 
with primary low-grade pTa bladder cancer. New molecular grading based on the methylation 
status of TBX2 and TBX3 resulted in sensitive risk prediction for progression. Determining DNA 
methylation is a highly reproducible method as we showed previously.27 Hence these markers 
present a valuable tool for assessing risk of progression in patients presenting with TaG1/G2 
tumors.
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suPPleMeNtary fIles
Supplementary table 2.1: multivariate progression-free survival analysis based on the methytlation markers 
and re-grade WHO1973
Multivariate analysis step #1 Multivariate analysis step #2 Multivariate analysis step #3
variable hr 95% CI p-value hr 95% CI p-value hr 95% CI p-value
Revised Grade 
WHO 1973
1.335 0.857-2.081 0.202 1.357 0.873-2.112 0.175 - - -
TBX2 1.616 0.923-2.829 0.093 1.748 1.013-3.019 0.045 1.823 1.061-3.130 0.030
TBX3 3.662 1.909-7.028 <0.001 4.247 2.294-7.861 <0.001 4.638 2.543-8.460 <0.001
ZIC4 1.683 0.942-3.010 0.079 1.651 0.992-2.957 0.092 1.812 1.029-3.193 0.040
GATA2 1.513 0.792-2.894 0.210 - - - - - -
          
Supplementary table 2.2: multivariate progression-free survival analysis based on the methytlation markers 
and re-grade WHO2004
Multivariate analysis step #1 Multivariate analysis step #1 Multivariate analysis step #3
variable hr 95% CI p-value hr 95% CI p-value hr 95% CI p-value
Revised Grade 
WHO 2004
1.891 1.155-3.096 0.011 1.961 1.205-3.191 0.007 2.126 1.322-3.419 0.002
TBX2 1.789 1.023-3.129 0.041 1.889 1.095-3.258 0.022 1.936 1.121-3.344 0.018
TBX3 3.840 2.013-7.324 <0.001 4.232 2.301-7.780 <0.001 4.439 2.420-8.148 <0,001
ZIC4 1.483 0.824-2.670 0.189 1.458 0.811-2.622 0.208 - - -
GATA2 1.327 0.690-2.552 0.396 - - - - - -
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aBstraCt
Objective | To investigate TERT mutation frequency, spectrum, association with expression and 
clinical outcome, and potential for detection of recurrences in urine in patients with urothelial 
bladder cancer.
Material and methods | A set of 111 UBCs of different stages was used to assess TERT pro-
moter mutations by Sanger sequencing and TERT messenger RNA (mRNA) expression by reverse 
transcription-quantitative polymerase chain reaction. The two most frequent mutations were 
investigated, using a SNaPshot assay, in an independent set of 184 non–muscle-invasive and 
173 muscle-invasive UBC (median follow-up: 53 mo and 21 mo, respectively). Voided urine 
from patients with suspicion of incident UBC (n = 174), or under surveillance after diagnosis of 
non–muscle-invasive UBC (n = 194), was tested using a SNaPshot assay. The outcome measure-
ments were: Association of mutation status with age, sex, tobacco, stage, grade, fibroblast 
growth factor receptor 3 (FGFR3) mutation, progression-free survival, disease-specific survival, 
and overall survival.
results | In the two series, 78 of 111 (70%) and 283 of 357 (79%) tumors harbored TERT 
mutations, C228T being the most frequent substitution (83% for both series). TERT mutations 
were not associated with clinical or pathologic parameters, but were more frequent among 
FGFR3 mutant tumors (p = 0.0002). There was no association between TERT mutations and 
mRNA expression (p = 0.3). Mutations were not associated with clinical outcome. In urine, TERT 
mutations had 90% specificity in subjects with hematuria but no bladder tumor, and 73% in 
recurrence-free UBC patients. The sensitivity was 62% in incident and 42% in recurrent UBC. A 
limitation of the study is its retrospective nature.
Conclusions | Somatic TERT promoter mutations are an early, highly prevalent genetic event in 
UBC and are not associated with TERT mRNA levels or disease outcomes. A SNaPshot assay in 
urine may help to detect UBC recurrences.
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INtrODuCtION
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathologic, and genetic levels. 
Approximately 75% of newly diagnosed tumors are non–muscle invasive (Ta, Tis, and T1); most 
of them recur and 15–20% progress to invade muscle. The remaining 25% of patients pres-
ent with muscle-invasive tumors and have a 5-yr survival of <50%.1-3 Fibroblast growth factor 
receptor 3 (FGFR3) is the most commonly mutated gene in UBC, with an overall frequency of 
60%.4-6 Mutations in Harvey rat sarcoma viral oncogene homolog (HRAS), neuroblastoma RAS 
viral (v-ras) oncogene homolog (NRAS), Kirsten rat sarcoma viral oncogene homolog (KRAS), 
and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) are less 
frequent.6, 7 FGFR3 mutations are associated with stage and grade and are very common in pTa 
and grade 1/2 tumors. This makes FGFR3 mutation analysis in voided urine a useful tool for 
diagnosing recurrent disease after a primary non–muscle-invasive bladder cancer (NMIBC).8, 9
Telomerase increases telomere length at chromosome ends. This activity is crucial for prolifer-
ating cells: Without telomerase, chromosomes are shortened every cell-division cycle, leading to 
replicative senescence and genomic instability.10, 11 Telomerase is active in stem cells but becomes 
downregulated in differentiated cells in somatic tissues. By contrast, it becomes reactivated in 
many tumors. Somatic hotspot mutations in the promoter of the gene coding for telomerase 
reverse transcriptase (TERT) catalytic subunit have recently been described in 71% of sporadic 
melanomas; germline mutations have also been reported in a melanoma kindred.12, 13 The so-
matic mutations were mutually exclusive C-to-T transitions at nucleotides 1,295,228 (C228T) 
and 1,295,250 (C250T). These are the first hotspot somatic mutations reported in a gene 
promoter in human cancers and have been proposed to enhance TERT expression through the 
creation of novel binding sites for E-twenty-six (ETS)/ELK transcription factors.12, 13 Nevertheless, 
direct proof for this mechanism is absent. Interestingly, Huang et al. reported the C228T muta-
tion in three of three UBC cell lines13 and, in a survey of different tumor types, TERT promoter 
mutations were also found in UBC, hepatocarcinoma, glioblastoma, oligodendroglioma, and 
myxoid liposarcomas, but not in breast, colorectal, and prostate cancers.14 However, the number 
of bladder tumors analyzed was small and clinical or pathologic information was not available.14 
In this chapter, we investigate the frequency of TERT promoter mutations in two large series of 
UBC. In the first one, lacking outcome information, we assessed the relationship between TERT 
mutations and TERT messenger RNA (mRNA) expression; in the second, with patient follow-up, 
we assessed the relationship between mutations and outcome. Finally, we explored whether 
mutation detection in urine may be used to identify tumor recurrence.
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MaterIal aND MethODs
Patient characteristics
A set of 111 patients with associated frozen tumor samples came from the Spanish Bladder 
Cancer/EPICURO Study15, 16 and from the Integrated Study of Bladder Cancer (ISBLAC). Clinical 
and sociodemographic information was retrieved from hospital records through a structured 
questionnaire. Subjects were defined as former smokers if they quit smoking ≥1 yr before the 
date of interview. A second set of 357 patients, with associated formalin-fixed paraffin embed-
Table 3.1: Characteristics of patients whose tumor samples were studied
Characteristic Variable
spain (n=111)
the 
Netherlands, 
NMIBC (n=184)
the 
Netherlands, 
MIBC (n=173)
no. (%) no. (%) no. (%)
age, yr, median 76 70 71
sex Female 13 (12) 46 (25) 28 (16)
Male 98 (88) 138 (75) 145 (84)
stage pTa + pTis 63 (57) 107 (58) –
pT1 28 (25) 77 (42) –
pT2 13 (12) – 72 (42)
pT3 3 (3) – 75 (43)
pT4 3 (3) – 26 (15)
Grade G1 27 (24) 14 (8) 1 (1)
G2 28 (25) 101 (55) 13 (7.5)
G3 56 (51) 69 (37) 159 (92)
follow-up, mo, median – 53 21
end point Progression to MIBC – 90 (49) –
Local or distant progression to MIBC – – 78 (45)
Died of disease – – 65 (37)
Died of other causes – – 36 (21)
Alive at follow-up – – 37 (21)
Lost to follow-up – – 35 (20)
TERT status MT 78 (70) 147 (80) 136 (79)
WT 33 (30) 37 (20) 37 (21)
tert mutations * C228T 65 (83) 121 (82) 113 (83)
C228A 1 (1.5) 3 (2) 3 (2)
CC242/243TT 2 (2.5) NA NA
 C250T 10 (13) 23 (16) 20 (15)
MT = mutant; NMIBC = non–muscle-invasive bladder cancer; TERT = telomerase reverse transcriptase; WT = wild type.
* The C242T mutation was not assessable with the SNaPshot assay.
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ded (FFPE) tumor samples and follow-up information, came from the Erasmus Medical Center 
and other hospitals in the Netherlands. This cohort comprises 184 patients with primary NMIBC 
selected to contain a 50:50 distribution of cases with or without progression; the latter was 
defined by the development of MIBC. It also comprises 173 patients who have undergone a 
cystectomy for primary MIBC, stage pT2-4. Cause of death for patients in the MIBC cohort was 
determined from hospital records and/or direct contact with general practitioners. Staging and 
grading were performed according to the TNM 2002 classification and the three-grade 1973 
World Health Organization classification. To confirm staging/grading and ensure uniformity 
of classification criteria, expert pathologists reviewed diagnostic slides from all tumor blocks. 
Table 3.1 shows the characteristics of patients whose tumor samples were studied.
For the urine study, samples were obtained from a consecutive, prospectively sampled col-
lection of urine specimens from two centers (Hospital del Mar, Barcelona, Spain; and Erasmus 
MC, Rotterdam, Netherlands) participating in the European Community Seventh Framework 
Table 3.2: Characteristics of tumors and patients used for urine diagnostic assays
Characteristic Variable
the Netherlands spain
no. (%) no. (%)
Patients with primary tumor diagnosis Patients, no. 45 90
stage pTa 39 (87) 53 (59)
pTis 3 (3)
pT1 5 (11) 21 (23)
pT2-4 1 (2) 13 (15)
Grade G1 17 (38) 27 (30)
G2 26 (58) 17 (19)
 G3 2 (4) 46 (51)
Patients under surveillance after NMIBC diagnosis* Patients, no. 118 76
With relapsing tumors
  stage pTa 78 (90) 40 (71)
pTis - 2 (4)
pT1 2 (2) 7 (12)
pT2-4 5 (6) 4 (6)
pTx 2 (2) 3 (7)
  Grade G1 25 (29) 23 (35)
G2 52 (60) 13 (23)
G3 8 (9) 19 (32)
Gx 2 (2) 1 (10)
recurrence-free
Patients, no./urine, 
no. samples, no.
65/232 20/20
NMIBC = non–muscle-invasive bladder cancer.
* Relapsing tumors include both recurrences and progression detected in patients with initial diagnosis of NMIBC.
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program–funded “Prediction of bladder cancer disease course using risk scores that combine 
molecular and clinical risk factors” (UROMOL) study (EU-7FP UROMOL #201663). Samples were 
obtained prior to cystoscopy at the time when a primary UBC was diagnosed (n = 135), or from 
patients lacking a prior history of UBC who presented with hematuria for diagnostic work-up 
and lacked visible bladder tumors at cystoscopy (n = 39). Additional samples (n = 395) were 
obtained during surveillance for relapsed disease (recurrence or progression) in 194 patients 
with NMIBC. Primary tumor or recurrence was defined by the presence of a histologically proven 
tumor. Table 3.2 shows the characteristics of patients included in the urine study. All patients 
provided written informed consent. The ethics committees of the participating institutions ap-
proved all studies. Samples from the Netherlands were obtained according to the Federation 
of Dutch Medical Scientific Societies’ Code for Proper Secondary Use of Human Tissues in the 
Netherlands (http://www.federa.org/).
Cell lines
UBC cell lines (Supplementary Table 3.1) were cultured under standard conditions and used for 
DNA extraction when at 70–80% confluence. All cultures were Mycoplasma free; their identity 
was tested by analysis of known genetic mutations.
DNa isolation and mutation analyses
Tumor cell-containing regions were macrodissected from frozen blocks or FFPE sections after 
examination of hematoxylin and eosin–stained sections. For MIBC cases, DNA was isolated 
from tumor obtained at the time of cystectomy or, in case of pT0, of incident transurethral 
resection. Tumor DNA and leukocyte DNA were extracted using the Qiagen kit for blood and 
tissue, according to manufacturer’s instructions (Qiagen GmbH, Hilden, Germany). Sanger 
sequencing of polymerase chain reaction (PCR) products was used to identify all possible muta-
tions in the first set of patients (Fig. 1A). A 163-base pair (bp) PCR product encompassing 
the proximal TERT promoter was amplified (primers: CAGCGCTGCCTGAAACTC [forward] and 
GTCCTGCCCCTTCACCTT [reverse]); for some samples, a broader 488-bp region of the pro-
moter was amplified (primers: AGCACCTCGCGGTAGTGG [forward], GGCCGATTCGACCTCTCT 
[reverse]). PCR conditions can be provided on request to the authors. FGFR3 mutation assays 
were performed as described.8 For the TERT mutational analysis in the second patient group, we 
designed a SNaPshot assay (Invitrogen Corp, Carlsbad, CA, USA) through a PCR (155 bp) cover-
ing the two most frequent mutations identified (primers: AGCGCTGCCTGAAACTCG [forward], 
CCCTTCACCTTCCAGCTC [reverse]), similar to the previously designed FGFR3 mutation assay.8 
The PCR was followed by a single-nucleotide extension using probes annealing to the amplicon 
adjacent to the mutation site. Probe sequences were: T23GGCTGGGAGGGCCCGGA for muta-
tion 1,295,228 (C228T/A) and T39CTGGGCCGGGGACCCGG for 1,295,250 (C250T) at 1 μM 
and 1.5 μM, respectively (ABI PRISM SNaPshot Multiplex Kit; Applied Biosystems, Foster City, 
CA, USA). The products were analyzed (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems, 
Foster City, CA, USA) with the label indicating the presence or absence of a mutation. Genescan 
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Figure 3.1 Somatic telomerase reverse transcriptase (TERT) promoter mutations in urothelial bladder cancer 
(UBC). (A) The C228T and C242T/C243T mutations are detected in tumor DNA but not in leukocyte DNA 
(Sanger sequencing). (B) Mutation assay for the indicated nucleotides in the promoter of the TERT gene. Upper 
panel: Control sample with wild-type peaks for positions C228T and C250T (from left to right). The lower panels 
show mutant samples and the nature of the mutation has been indicated. Note that the assay detects the muta-
tions from the complementary strand, hence the mutations are indicated as G228A, G228T, and G250A. (C) 
Distribution of TERT promoter mutations in UBC according to T and G. Tumors are categorized in three groups: 
low-risk non–muscle-invasive bladder cancer (NMIBC) (TaG1/G2) (Low R), high-risk NMIBC (TaG3, T1G2/G3) 
(High R), and MIBC (>T2) for Spain (Sanger sequencing) and the Netherlands (SNaPshot; Applied Biosystems, 
Foster City, CA, USA). Absolute numbers of cases are given for each mutation and group. (D) TERT messenger 
RNA levels in bladder tumors assessed by reverse transcriptase-quantitative polymerase chain reaction (n = 60); 
results show the comparison of wild type versus mutant tumors and the comparison of the three tumor groups 
according to T and G. *** p ≤ 0.001. WT = wild type; MT = mutant type.
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Analysis Software v.3.7 (Applied Biosystems, Foster City, CA, USA) was used for data analysis 
(Fig. 1B). For urine DNA extraction and mutation analysis, cell pellets were washed twice with 
phosphate-buffered saline, after thawing, by centrifugation for 5 min at 6000 rpm (3000 g). 
DNA was extracted using the QiAamp Mini and Blood mini kit (Qiagen NV, Venlo, Netherlands) 
according to the manufacturer’s protocol. TERT mutational analysis was performed using the 
SNaPshot assay. Reverse transcriptase-quantitative PCR (RT-qPCR) was used to assess TERT RNA 
expression.
statistical and bioinformatics analyses
The Predictive Analytics Software v.19 (IBM Corp., Armonk, NY, USA) was used. Statistical dif-
ferences were considered significant if p < 0.05. The chi-square and Fisher exact tests were 
used to determine the relationships between different variables. Statistical differences between 
groups were assessed using a nonparametric Wilcoxon test, as appropriate. The log-rank test 
was used for survival analysis. In the NMIBC group, all outcomes other than progression appear 
as censored in the Kaplan-Meier curve. Bioinformatics analysis of the TERT promoter sequence 
is detailed in the Supplement.
results
tert promoter mutations in bladder cancer
We first analyzed the occurrence of mutations in UBC cell lines and tumors using Sanger se-
quencing of PCR products. Of 32 lines analyzed, 4 were wild type and 28 (87%) harbored the 
C228T (n = 25) or C250T (n = 3) mutations (Supplementary Table 3.1). The somatic nature of 
these mutations could not be evaluated due to lack of germline DNA.
Among the 111 UBCs from Spain, covering the full spectrum of the localized disease, 78 
were mutated (70%) (Table 3.1). The most common mutation was C228T (n = 65), followed by 
C250T (n = 10); two additional rare mutations were C242T/C243T (n = 2) and C228A (n = 1). 
All mutations were mutually exclusive; their somatic nature was confirmed in 10 cases (Fig. 1A). 
The C250T mutation was significantly less common in UBC than in melanoma (p = 0.00003); the 
C228T/C229T mutation reported in melanoma was not found in UBC. TERT mutations were not 
associated with age, sex, or smoking. The frequency of TERT mutations was similar in low-risk 
NMIBC (TaG1 and TaG2; 33 of 45 [73%]), high-risk NMIBC (TaG3, Tis, T1G2, T1G3; 34 of 46 
[74%]), and in MIBC (10 of 19 [53%]) (p = 0.192) (Fig. 1C) and in newly diagnosed versus 
recurrent tumors (p = 0.716). TERT mutations were significantly more frequent among FGFR3 
mutant tumors (43 of 49 vs 29 of 54; p = 0.0002).
We analyzed the two most frequent TERT mutations in an independent set of tumors from 
the Netherlands using a specifically designed SNaPshot assay; mutations were found to be 
mutually exclusive. A high mutation rate was confirmed in both NMIBC (147 of 184 [80%]) and 
MIBC (136 of 173 [79%]) (Fig. 1C). To assess heterogeneity, we analyzed TERT mutations using 
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the SNaPshot assay in multiple (median: 4; range: 2–5) regions of nine NMIBCs. We observed 
general consistency among the regions, suggesting a low level of intraindividual heterogeneity 
(Supplementary Table 3.2). These findings place TERT mutations as the most common genetic 
alteration in UBC6, 7 and as an early event in urothelial carcinogenesis.
TERT mutations have been proposed to generate novel transcription factor binding sites lead-
ing to increased TERT expression.12, 13 Mining the DNA-binding factor database JASPAR, we 
performed a comparative analysis of the wild-type and mutant sequences and found that the 
C228A mutation newly reported in this paper was also associated with an increased probability 
of binding to ELK1 (a member of the ETS oncogene family) and v-ets avian erythroblastosis virus 
E26 oncogene homolog 1 (ETS1), as the previously reported mutations. The analysis revealed 
additional transcription factors that could contribute to TERT overexpression as well some that 
showed mutation selectivity, such as v-rel avian reticuloendotheliosis viral oncogene homolog 
(REL) for C242T/C243T or GATA bind protein 2 (GATA2) for C228A (Supplementary Table 3.3). 
To assess the relationship between TERT mutations and mRNA levels, we analyzed 60 primary 
UBC samples using RT-qPCR. TERT mRNA levels were higher in TERT mutant tumors, but the 
difference was not statistically significant (Wilcoxon test p = 0.3). TERT mRNA levels were signifi-
cantly higher in high-risk NMIBC and in MIBC than in low-risk NMIBC (Wilcoxon test p = 0.001) 
(Fig. 3.1D).
tert mutations and patient outcome
The set of tumors from the Netherlands was used to assess tumor prognostic value. Of 184 
patients with NMIBC, 90 (49%) experienced progression to MIBC (Table 3.1). There was no 
relationship between progression-free survival and the presence of mutations (log-rank test 
p = 0.984) (Supplementary Fig. 1). In the group of 173 patients with MIBC, 78 (45%) patients 
had local or distant progression and TERT mutation status was not associated with progression-
free survival (log-rank test p = 0.160). Furthermore, 101 (58%) patients died during follow-up, 
including 65 (37%) who died of bladder cancer (Table 3.1). Overall- and cancer-specific survival 
were not related to TERT mutations (log-rank tests p = 0.987 and p = 0.834) (Supplementary 
Fig. 3.1). Among patients with MIBC, 25 received adjuvant chemotherapy with curative intent; 
TERT mutations were not predictive for survival in this subgroup or the group without chemo-
therapy.
tert mutation detection in exfoliated cells in urine
Patients with NMIBC require continued follow-up due to frequent tumor recurrences. We as-
sessed whether TERT mutations can be detected in exfoliated tumor cells in voided urine and 
compared the findings with FGFR3 mutations (Table 3.3). Of 39 urine samples from patients 
with hematuria and in whom no bladder tumor was visible at cystoscopy (17 of 39 [44%] 
female; median age: 54 yr), 4 were positive for TERT mutations, resulting in a specificity of 90%. 
None of these four patients developed a UBC or another tumor in the subsequent >3.5 yr. In 
urine samples obtained before resection of a primary bladder tumor, the sensitivity of incident 
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tumor detection was 36% (46 of 128) for FGFR3, 62% (73 of 118) for TERT, and 70% (73 of 
105) for TERT and FGFR3 combined (FGFR3 vs. TERT, p < 0.0001). We then tested 395 urine 
samples prospectively collected from 194 patients under surveillance after a primary NMIBC 
diagnosis. Sensitivity of detection of relapsing (recurrence or progression) UBC developing after 
a primary NMIBC was 19% (24 of 124) for FGFR3, 42% (48 of 113) for TERT, and 50% (52 of 
103) for both combined (FGFR3 vs. TERT, p = 0.0001). In the recurrence-free urine samples, a 
TERT mutation was detected in 58 of 218 cases, corresponding to a specificity of 73%, whereas 
the specificity for FGFR3 mutation was 90% (FGFR3 vs. TERT, p < 0.0001).
DIsCussION
TERT promoter hotspot mutations constitute a new type of somatic genetic alterations in cancer. 
A recent survey in a wide range of tumors indicated a selective mutational pattern associated 
with tumor histology and tissue of origin.14 It has been proposed that mutations occur more 
commonly in tumors derived from tissues with low proliferation rates.12-14 Based on the analysis 
of 21 UBCs, a high mutation rate was proposed, but there was no clinical or pathologic informa-
tion on these patients.
In this paper, we provide definitive evidence on the occurrence of TERT promoter mutations 
in UBC. First, we show a high mutation rate (70%), which was replicated in an independent 
series (79%) using different assays, thus making TERT the most frequently mutated gene in UBC. 
Table 3.3: Sensitivity and specificity of urine diagnostic assays
variable
the 
Netherlands, 
no./total (%)
spain, 
no./total 
(%)
Netherlands 
and spain, 
no./total (%)
Netherlands and spain,
p value
Primary tumors, 
sensitivity
FGFR3 17/42 (40) 29/86 (34) 46/128 (36) –
TERT 21/37 (57) 52/81 (64) 73/118 (62) FGFR3 vs TERT, p < 0.0001
TERT + FGFR3 20/28 (71) 53/77 (69) 73/105 (70)
TERT vs TERT + FGFR3, 
p = 0.23
recurrent tumors, 
sensitivity
FGFR3 15/68 (22) 9/56 (16) 24/124 (19) –
TERT 18/63 (29) 30/50 (60) 48/113 (42) FGFR3 vs TERT, p = 0.0001
TERT + FGFR3 21/53 (40) 31/50 (62) 52/103 (50)
TERT vs TERT + FGFR3, 
p = 0.238
recurrence-free fu 
urine
FGFR3 208/232 (90) 19/20 (95) 227/252 (90) –
samples, specificity TERT 149/200 (75) 11/18 (61) 160/218 (73) FGFR3 vs TERT, p < 0.0001
 TERT + FGFR3 131/183 (72) 11/18 (61) 142/201 (71)
TERT vs TERT + FGFR3, 
p = 0.529
FGFR3 = fibroblast growth factor receptor 3; FU = follow-up; TERT = telomerase reverse transcriptase.
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Second, we show a similar mutation frequency across stages and grades, strongly suggesting 
that TERT mutations participate in the two major genetic pathways involved in UBC. Third, we 
show a distinct mutational spectrum in comparison with melanoma with a dominance of the 
C228T mutation. Finally, we show a lack of association with progression in NMIBC or with the 
development of local or distant metastases in MIBC.
The high frequency of hotspot mutations renders TERT a very attractive target for diagnosis 
of bladder tumors, both primary and recurrent, using body fluids such as urine or blood. We 
show that tumor cell detection in urine is feasible, with a sensitivity of 62% at initial diagnosis 
and 42% at recurrence. For urine diagnostics during surveillance, the patients were not stratified 
for mutation status of the primary tumor; we expect that when this is performed, sensitivity of 
detection of recurrent UBC will increase. Accordingly, TERT mutation was assayed concomitantly 
in tumor tissue and urine in 31 cases: TERT was concordant in 26 cases (19 mutated, 7 wild 
type), one tumor harbored a C242T mutation not assessable by the SNaPshot assay, and four 
mutations were detected in urine but not in tumor samples. We show that TERT mutation detec-
tion has a higher sensitivity than FGFR3 mutation for tumor cell detection in urine, and assays 
of both TERT and FGFR3 mutations might have improved sensitivity, though the difference was 
not statistically significant in our study. By contrast, TERT mutations may have a lower specificity 
than FGFR3 mutations, as four mutations were detected in 39 urine samples from patients 
without cancer and in 58 of 218 of patients in clinical remission. In this group, we cannot 
distinguish reduced specificity from higher lead-time bias in detection of tumor relapse. Larger, 
well-designed, prospective studies are required to establish the clinical usefulness of mutation 
detection in urine. As previous reports have proposed TERT expression or activity assessment in 
urine as a tool to detect recurrence, it will be of high interest to compare TERT mutation with 
them and with other candidate biomarkers in future studies.17, 18
Several observations support the notion that TERT somatic mutations are an early event in 
urothelial carcinogenesis, including their occurrence in a small fraction of subjects without UBC, 
their presence in tumors of both the papillary and invasive pathways, and the low level of 
intraindividual heterogeneity when multiple tumor regions were analyzed. UBC cell lines are also 
very frequently mutated, and we noticed that most of the mutant ones lacked the wild-type 
allele. These observations also suggest that mutant cells may display a growth advantage over 
wild-type cells.
The mechanisms through which TERT promoter mutations contribute to UBC and other tu-
mors remain to be determined. One possibility is that the acquisition of new, putative transcrip-
tion binding sites leads to altered regulation of gene expression, as previously proposed, and 
also suggested by our bioinformatics analysis using the DNA-binding factor database JASPAR. 
However, we failed to find a significant association between TERT mutation and expression. This 
could be explained by alternative mechanisms of TERT upregulation in wild-type tumors, also 
leading to TERT overexpression, or by the participation of TERT mutations in additional biologic 
processes.
58 Chapter 3
Given its reverse transcriptase activity, telomerase is a potential therapeutic target. Recent 
developments suggest that azidothymidine (AZT), an inhibitor of HIV reverse transcriptase, also 
inhibits telomerase. Hence, it is conceivable that AZT or other telomerase inhibitors may sup-
press the growth of UBC overexpressing the enzyme.19
One of the limitations of our work is the retrospective nature of the cohorts used for the 
outcome analysis, even though our results do not make positive claims. Another is the lack 
of comparison for urine-based diagnostic assays between TERT mutation, cytology, and other 
biomarkers. However, the high frequency of these mutations in urine reported herein provides 
evidence for future prospective and comparative studies. Overall, the novelty of TERT mutation 
in UBC is strengthened by the independent analysis that we performed in two different centers.
CONClusIONs
Mutations in the promoter of the TERT gene are the most frequent somatic mutations in tumors 
of the urinary bladder. Mutations occur with similar frequency, regardless of stage or grade, 
and are not associated with clinical outcome. TERT mutation assays may be used for tumor cell 
detection in urine and TERT may be a therapeutic target.
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suPPleMeNtary fIles
reverse transcriptase quantitative polymerase chain reaction (PCr)
RNA was extracted using Trizol. Following DNAse treatment (DNAfree, Ambion; Invitrogen Corp, 
Carlsbad, CA, USA), complementary DNA was reverse transcribed (Taqman Reverse Transcription 
Reagents kit; Applied Biosystems, Foster City, CA, USA); 20 ng RNA equivalent was used for PCR 
with specific primers (AAGCATGCCAAGCTCTCG [forward], ATCAGCCAGTGCAGGAACTT [re-
verse]) in the presence of SYBR GreenER (Invitrogen Corp, Carlsbad, CA, USA) using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). All analyses were done in 
duplicate. A melting-curve analysis was performed to control for product quality and specificity. 
Levels of each transcript were normalized to individual hypoxanthine phosphoribosyltransferase 
1 (HPRT) expression using the ΔΔCt method.
Bioinformatics analysis
The JASPAR CORE database1 contains a curated, nonredundant set of profiles derived from 
published collections of experimentally defined transcription factor binding sites for eukaryotes. 
We scanned telomerase reverse transcriptase (TERT) mutations in a sequence of 20 nucleotides 
for the presence of the profiles included in the JASPAR CORE Vertebrata using the SCAN tool 
in JASPAR database Web server.2 Relative profile scores increasing 0.05 point after including 
the mutation, when compared with the reference sequence, were predicted to have higher 
probability of binding. Scores decreasing 0.05 point were predicted to have lower probability 
of binding.
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Supplementary Table 3.1: Results of telomerase reverse transcriptase (TERT) promoter mutational analysis in 
bladder cancer cell lines
Name TERT promoter Mutation status
92-1 1,295,228 G>A Homozygous
96-1 1,295,228 G>A Heterozygous
97-18 1,295,228 G>A Homozygous
97-24 1,295,228 G>A Homozygous
CRL-2742 1,295,228 G>A Homozygous
HT1197 1,295,228 G>A Homozygous
HU456 wt
JON wt
KK47 wt
LGWO 1 G600 wt
MG-HU-3 1,295,228 G>A Homozygous
MG-HU-4 1,295,250 G>A Heterozygous
PSI 1,295,228 G>A Homozygous
RT112 1,295,228 G>A Heterozygous
RT4 1,295,228 G>A Homozygous
SCaBER 1,295,228 G>A Homozygous
SW1710 1,295,228 G>A Homozygous
SW780 1,295,228 G>A Homozygous
SW800 1,295,228 G>A Homozygous
T24 1,295,228 G>A Homozygous
TCC-SUP 1,295,228 G>A Homozygous
UM-UC-10 1,295,228 G>A Homozygous
UM-UC-11 1,295,250 G>A Homozygous
UM-UC-13 1,295,228 G>A Homozygous
UM-UC-14 1,295,228 G>A Heterozygous
UM-UC-15 1,295,228 G>A Heterozygous
UM-UC-18 1,295,228 G>A Homozygous
UM-UC-2 1,295,228 G>A Homozygous
UM-UC-5 1,295,228 G>A Homozygous
UM-UC-7 1,295,228 G>A Heterozygous
UM-UC-9 1,295,250 G>A Homozygous
VM-CUB-1 1,295,228 G>A Homozygous
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Supplementary Table 3.2: Telomerase reverse transcriptase (TERT) mutations assessed in distinct regions of 
non–muscle-invasive bladder cancer (NMIBC)
Case NMIBC Fragment TERT promoter
IS_11453 #1 1,295,250 G>A
#2 1,295,250 G>A
#3 1,295,250 G>A
#4 1,295,250 G>A
#5 1,295,228 G>A
IS_11545 #1 1,295,228 G>A
#2 1,295,250 G>A
#3 wt
#4 1,295,228 G>A
IS_11656 #1 wt
#2 wt
IS_11801 #1 1,295,250 G>A
#2 1,295,250 G>A
#3 1,295,250 G>A
#4 1,295,250 G>A
IS_11818 #1 1,295,228 G>A
#2 1,295,228 G>A
#3 1,295,228 G>A
#4 1,295,228 G>A
IS_11825 #1 1,295,228 G>A
#2 wt
#3 1,295,228 G>A
IS_11832 #1 wt
#2 wt
#3 wt
#4 wt
IS_11834 #1 1,295,228 G>A
#2 1,295,228 G>A
#3 wt
IS_11837 #1 wt
#2 wt
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Supplementary Table 3.3: Bioinformatic analyses of sequences around the hotspot mutations using JASPAR
Genomic 
coordinate
>chr5:1295218-
1295238
>chr5:1295218-
1295238
>chr5:1295218-
1295238
Sequence
gggcccggagggg 
gctgggc
gggcccggaaggg 
gctgggc
gggcccggatggg 
gctgggc
G228G G228a * G228t *
Model ID Model name Relative score Relative score Relative score Start End Strand
MA0098.1 ETS1 0.82 1.00 0.98 6 11 -1
MA0028.1 ELK1 0.81 0.94 0.85 2 11 1
MA0062.2 GABPA 0.81 0.93 0.82 5 15 1
MA0145.1 Tcfcp2l1 0.90 0.91 0.95 5 18 -1
MA0003.1 TFAP2A 0.98 0.89 0.87 3 11 1
MA0079.2 SP1 0.94 0.87 0.87 10 19 -1
MA0144.1 Stat3 0.72 0.82 0.71 2 11 1
MA0136.1 ELF5 0.68 0.81 0.78 5 13 -1
MA0076.1 ELK4 0.70 0.81 0.76 4 12 1
MA0103.1 ZEB1 0.65 0.81 0.62 9 14 -1
MA0156.1 FEV 0.67 0.81 0.71 5 12 1
MA0081.1 SPIB 0.64 0.80 0.68 4 10 1
MA0057.1 MZF1_5-13 0.84 0.80 0.81 7 16 1
MA0116.1 Zfp423 0.79 0.80 0.72 1 15 1
MA0163.1 PLAG1 0.81 0.77 0.77 14 1
MA0056.1 MZF1_1-4 0.78 0.76 0.81 10 15 1
MA0095.1 YY1 0.69 0.69 0.90 8 13 -1
MA0036.1 GATA2 0.68 0.68 0.96 7 11 1
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Genomic 
coordinate >chr5:1295232-1295252 >chr5:1295232-1295252
Sequence ctgggccggggacccgggag ctgggccggaaacccgggag
GG242GG GG242aa
Model ID Model name Relative score Relative score Start End Strand
MA0098.1 ETS1 0.63 1.00 7 12 -1
MA0028.1 ELK1 0.84 0.98 11 20 1
MA0062.2 GABPA 0.63 0.87 6 16 1
MA0101.1 REL 0.62 0.87 8 17 -1
MA0003.1 TFAP2A 0.89 0.86 5 13 1
MA0076.1 ELK4 0.63 0.86 5 13 1
MA0133.1 BRCA1 0.60 0.83 9 15 1
MA0107.1 RELA 0.64 0.82 8 17 -1
MA0156.1 FEV 0.54 0.81 6 13 1
MA0081.1 SPIB 0.48 0.80 5 11 1
MA0039.2 Klf4 0.82 0.74 2 11 1
MA0146.1 Zfx 0.82 0.74 2 15 -1
MA0079.2 SP1 0.84 0.70 2 11 -1
MA0039.2 Klf4 0.82 0.67 3 12 1
MA0056.1 MZF1_1-4 0.97 0.59 7 12 1
Genomic 
coordinate
>chr5:1295240-
1295260
>chr5:1295240-
1295260
Sequence gggacccgggaggggtcggg gggacccggaaggggtcggg
G250G G250a
Model ID Model name Relative score Relative score Start End Strand
MA0098.1 ETS1 0.82 1.00 7 12 -1
MA0028.1 ELK1 0.84 0.96 3 12 1
MA0062.2 GABPA 0.80 0.92 6 16 1
MA0155.1 INSM1 0.77 0.83 7 18 1
MA0136.1 ELF5 0.68 0.81 6 14 -1
MA0076.1 ELK4 0.69 0.81 5 13 1
MA0103.1 ZEB1 0.71 0.81 10 15 -1
MA0156.1 FEV 0.67 0.81 6 13 1
MA0081.1 SPIB 0.64 0.80 5 11 1
MA0057.1 MZF1_5-13 0.84 0.79 9 18 1
MA0079.2 SP1 0.82 0.77 6 15 -1
MA0039.2 Klf4 0.85 0.73 7 16 1
* Situations in which increased binding to a specific transcription factor is predicted in the mutated sequence are 
screened in dark grey. Situations in which reduced binding is predicted are screened in light grey.
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Supplementary figure 3.1 Actuarial survival curves according to telomerase reverse transcriptase (TERT) mu-
tation: progression-free survivals in non–muscle-invasive bladder cancer (NMIBC) and MIBC, and overall and 
cancer-specific survival in MIBC. Cum = cumulative.
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aBstraCt
Objective | To develop a Methylation-Specific Multiplex Ligation-dependent Probe Amplification 
(MS-MLPA) assay for the detection of non-muscle invasive bladder cancer (NMIBC) recurrences 
in voided urine.
Material and methods | Genes frequently methylated in NMIBC tumors (n=37) were selected 
to develop a BC-specific MS-MLPA assay and genes methylated in urine from non-BC patients 
(n=46) and blood from BC patients (n=29) were excluded. A four-gene panel with the highest 
predictive value was selected from the initial assay. This four-gene panel was tested and vali-
dated on urine of patients with a histologically proven recurrence (n=68 test set; n=49 validation 
set) and urine samples from non-BC patients (n=91 test set) and urines from recurrence-free 
BC (rec-free BC) patients (n=60). A model was developed to predict the probability of having 
a recurrence based on methylation of the four-gene panel and a cut-off probability with the 
highest sensitivity and specificity was determined. Outcome of the model was validated on BC 
urine samples (n=65) and on urine samples from rec-free BC patients (n=29).
results | The BC MS-MLPA assay consisted of 23 methylation probes. The selected four-gene 
panel included: APC, 2x hTERT, and EDNRB. This panel reached an area under the ROC curve 
(AUC) of 0.82 (test set) and AUC: 0.69 (validation set). Sensitivity and specificity for the detec-
tion of a concomitant tumor were 63.3% and 58.3% respectively (test set) and 72.3% and 
55.2%, respectively (validation set).
Conclusions | We have developed a methylation detection assay specifically for the detection 
of recurrences of NMIBC patients on voided urine. The findings are promising and improvement 
of this test could eventually contribute to a more individualized patient friendly surveillance.
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INtrODuCtION
Bladder cancer (BC) is the most prevalent type of urothelial cell carcinoma and is associated with 
the highest costs in patient surveillance compared to other types of cancer.1 This is mainly caused 
by the high recurrence rate of non-muscle invasive bladder cancer (NMIBC), which necessitates 
life-long cystoscopic follow-up and frequent trans-urethral resections (TUR).2-4 Today, cystoscopy 
remains the golden standard for surveillance of NMIBC patients, but this is a costly and time-
consuming procedure with a sensitivity ranging from 68-83% and causing physical discomfort 
to the patient.5-8 During follow-up, cytology is used in addition to cystoscopy, however the 
sensitivity of cytology is specifically insufficient for the detection of low stage and grade tumors, 
whereby its accuracy is influenced by the pathologist’s experience.9-14 Many urinary biomarkers 
have been identified to reduce the number of cystoscopies and BC-associated costs, hereby 
improving patient quality of life and patient care. Most available biomarkers have a low sensitiv-
ity for the detection of NMIBC recurrences, hence the clinical applicability of these markers 
remains limited. Together, these findings emphasize the need for identification of new urinary 
biomarkers for the follow-up of NMIBC patients.
Recently, the role of epigenetic changes in BC has become more apparent. Epigenetic changes 
are defined as changes in gene expression that are heritable through cell division, without as-
sociated DNA sequence alterations. Previous studies demonstrated the role of aberrant DNA 
promoter hypermethylation, leading to transcriptional silencing of tumor suppressor genes.15-17 
Hypermethylation in BC has been associated with age, smoking status, gender, tumor location, 
stage, recurrence rate and progression.18-22 In addition to detection of methylation in tumor 
tissue, aberrant methylation has also been detected in voided urine of BC patients and appears 
to be more sensitive than urine cytology.23-30
Current urinary biomarkers are mostly tested and validated on primary tumors, which are 
large in size and thus easier to detect in urine than in recurrent tumors. In addition to this, 
muscle-invasive (MI) tumors are used to validate markers for the detection of recurrent bladder 
tumors. MI tumors are also larger in size, are high grade with more genetic aberrations and shed 
more tumor cells than NMI tumors. Thus, they are easier to detect by urine-based assays, not 
reflecting the true sensitivity of the assay for the detection of NMIBC recurrences. Therefore, we 
designed a Methylation-Specific Multiplex Ligation-dependent Probe Amplification (MS-MLPA) 
assay for the detection of genes specifically methylated in recurrences of NMIBC patients. We 
selected a smaller gene panel from the BC MS-MLPA assay and developed a logistic regression 
model to predict the recurrence probability based on genes methylated in urinary tumor cells. 
Lastly, we determined the sensitivity and specificity of the selected gene panel on an indepen-
dent test and validation cohort.
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MaterIal aND MethODs
The study design consisted of a four step process to develop the MS-MLPA specifically for the 
detection of NMIBC recurrent tumors (Figure 4.1, Table 4.1). The Medical Ethical Committee of 
the Erasmus MC approved the study (MEC 168.922/1998/55) and written informed consent was 
obtained from all patients.
study population
step 1. Recurrent tumors from patients included with a primary NMI bladder tumor were 
selected (n=37) for methylation analysis. As a control group, urine from patients with benign 
urological disorders other than BC (non-BC) (n=46) was collected prior to cystoscopy at the 
Erasmus MC Urology outpatient department and stored at 4ºC. All patients with a history of 
urinary tract malignancies (bladder, upper urinary tract, prostate and kidney) were excluded. 
Patients with benign prostate hyperplasia, which is age related and often diagnosed in elderly 
men, were included in the control group. The reason for inclusion is the concurrent presentation 
with bladder cancer, also developing in elderly men. Samples were checked for leucocytes, 
erythrocytes and nitrite (Bayer, multistix 10 SG). Additionally, 29 blood samples from BC patients 
were included in the study.
Figure 4.1 Four-step process to select genes that are specifically methylated in NMIBC recurrences, select a 
smaller gene panel, validate this gene panel and develop a prediction model for the detection of BC recurrences 
in voided urine. Non-BC: non-bladder cancer patients; rec-free BC; recurrence-free BC patients; Pre-TUR: urine 
collected 1 day before transurethral resection of tumor
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step 2. Urine samples collected one day before TUR of the recurrent tumor (pre-TUR urine) 
(n=68) were selected for analysis. After TUR, stage and grade of the recurrent tumor were 
confirmed by an expert uro-pathologist. Control urine samples from non-BC patients (n=91) 
were drawn from the Dutch bladder cancer screening study.
step 3. Urine samples from BC patients collected during follow up (n=109) were used for 
analysis. From this group 49 patients had a histologically proven recurrence at the time of 
urine collection. The other 60 urines were from BC patients who were recurrence-free at the 
time of urine collection.
step 4. Urine samples from an independent set of BC patients (n=94) were used to validate 
the developed logistic regression model. From this group 65 urines were from patients with 
a histologically proven recurrent tumor at the time of urine collection. The other 29 urine 
samples were from BC patients who were recurrence-free at the time of urine collection.
DNa isolation from patient material
Fresh tumor tissue: Tumor tissue was collected at a TUR at Erasmus Medical Center, Rotterdam. 
Part of the tissue was used for DNA isolation and the other part was used for a histological 
report. Muscle-invasive tumors and carcinoma in situ were excluded from analysis. Fresh tumor 
samples for DNA isolation were stored at -80°C until DNA isolation. DNA was extracted using 
the Qiagen Dneasy blood and tissue kit (Qiagen, GmbH, Hilden Germany) according to the 
manufacturer’s protocol and analyzed with the MS-MLPA assay.
Urine: Freshly voided urine samples (10-100ml) were centrifuged for 10 minutes’ at 3000 
rpm. Cell pellets were washed twice with 10ml of Phosphate-buffered saline, followed by cen-
trifugation for 10 minutes’ at 3000 rpm. Pellets were resuspended in 1ml of Phosphate-buffered 
Table 4.1: Patient and tumor characteristics
Characteristics
age (years) tumor stage, n(%) tumor grade, n(%)
N
Mean  
(se, range) N ta t1 t2 tis G0 G1 G2 G3
step 1
Tumor 37 69 (15, 26-86) 37 36 (97) 1(3) - - - 14 (38) 23 (62) -
Non-BC urine 46 54 (14, 26-74)
Blood 29 59 (10, 40-80)
step 2
BC- urine 68 65 (11, 35-85) 68 61(90) 7 (10) - - - 14 (31) 52 (77) 3 (4)
Non-BC urine 91 62 (6, 51-73)
step 3
Follow-up urine 109 63 (12, 20-82) 49 38 (78) 9 (18) - 2(4) - 15 (31) 22 (45) 12 (24)
step 4
Follow-up urine 94 64 (11, 42-86) 65 58 (89) 6 (9) 1 (2) - 3 (5) 25 (38) 29 (45) 8 (12)
Non-BC urine = urine from patients without BC; BC urine = urine from patients with concomittant BC; Follow-up 
urine = urine collected from patients with BC during follow-up with and without recurrence
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saline, transferred to an eppendorf vial and centrifuged for 5 minutes’ at 6000 rpm (3000xg). 
Supernatant was discarded and the cell pellet was stored at -20ºC until DNA isolation. DNA 
was extracted using the QiAamp Mini and Blood mini kit (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s protocol.
Blood: Freshly extracted blood samples were stored at -20°C until DNA isolation. DNA was 
extracted using the QIAamp DNA blood mini kit (Qiagen, GmbH, Hilden Germany) according to 
the manufacturer’s protocol.
Methylation-specific multiplex ligation probe amplification assay
50 ng of fresh tumor tissue or urine-derived genomic DNA was used and MS-MLPA assays 
were performed as described by van Schouten et al31. Briefly, the MS-MLPA technique (MRC 
Holland) is based on DNA sample denaturation followed by hybridization of probes directed to 
one specific CpG site that contains a restriction site for the methylation sensitive endonuclease 
HhaI enzyme. Following probe hybridization and ligation unmethylated hybrids are digested 
by HhaI and will not be exponentially amplified by PCR, leading to the absence of a signal 
when analyzed by capillary electrophoresis. In contrast, methylated hybrids are prevented from 
being digested by HhaI and ligated probes will generate a signal after amplification by PCR. The 
MS-MLPA contains 18 reference probes that do not contain a HhaI restriction site, and thus are 
not sensitive to HhaI digestion.
MRC kit-001 contains probes for 26 tumor suppressor genes with 15 reference probes and 
kit-002 contains 27 probes for tumor suppressor genes with 14 reference probes. Kit-001 and 
002 contain probes for the same genes, but the probes recognize a different CpG-site.
statistical analyses
Statistical analysis for probe selection of the BC MS-MLPA kit was performed using the Statistical 
Package for Social Sciences 11.5 (SPSS Inc, Chicago) and R statistical Software (R Foundation 
for Statistical Computing, Vienna). The probes were selected with the LASSO (least absolute 
shrinkage and selection operator) method. This method combines selection and estimation by 
shrinking coefficients, some effectively to zero. The purpose of using the LASSO method was 
to prevent overfitting, i.e. probes being selected by coincidence. Consecutively the probes with 
non-zero coefficients in the LASSO were combined into a logistic regression model to determine 
their combined area under the curve.
results
step 1. Construction of the BC Ms-MlPa
In order to select genes for a bladder cancer specific MS-MLPA assay, recurrent NMIBC tumors 
(n=37) were analyzed with the commercially available MS-MLPA kit 001 and 002 and methyl-
ated genes were selected to develop a BC specific MS-MLPA (Figure 4.1, Step 1). Urine samples 
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of non-BC patients (n=46) and blood samples from NMIBC patients (n=29) were selected as 
controls. Patient and tumor characteristics are depicted in Table 4.1 (Step 1). Methylation of 
TIMP3 (p=0.022), APC (p=0.004), RARB (p=0.022), DAPK (p=0.022), and ESR1 (p=0.001) from 
kit-001 was significantly higher in BC tumor tissue compared to urine of non-BC patients. 
Methylation of TP53 (p=0.034), MGMT (p=0.031), PAX5 (p<0.0001), CDH13 (p<0.0001), TP73 
(p=0.039), WT1 (p<0.0001), ESR1 (p<0.0001), MSH6 (p=0.005), RARB (p=0.005), and CD44 
(p=0.039) from kit-002 was significantly higher in BC tumor tissue compared to urine of non-BC 
patients. Interestingly, RASSF1A (kit-001) was methylated in 53% of the non-BC urine samples. 
Genes methylated in urine from non-BC patients and genes methylated in blood were excluded. 
The selection of genes for the BC MS-MLPA was based on above findings with the addition of 6 
Table 4.2: Bladder cancer probe mix
length (nt) Gene Partial sequence with hhaI site
64-70-76-82 DNA quantity control fragments
88-92-96 Denaturation, hybridization and ligation control fragments
124 TRAF4 TGCCAAGGTGAGTCCACACTGCCAGGA-
AGAAGCCCAAGCACAGTCTGTTGCCCTTGGA
130 BCL2 TGTGAGATGTCCAGCCAGCTGCACCTG-
ACGCCCTTCACCGCGCGGGGACGCTTTGCCA
136 PTEN GCTCTTTCATTTTTAGGGCAAACGAGCCGAGT-
TACCGGGGAAGCGAGAGGTGGGGCGCTGCAAG
142 TIMP3 TCCAGCGCCGAGGCAGCCTCGC-TGCGCCCCATCCCGTCCCGCCGGGCACTCGG
148 APC GGCTGGGTGTGGGCGCACGT-GACCGACATGTGGCTGTATTGGTGCAGCCCGCCAG
GGT
154 TERT CGCAGCGCGGGGACCCGGCGGCTT-TCCGCGCGCTGGTGGCCCAGTGCCTGGT
160 TERT TCTGTGTCCTGCCTGAAGGAGCTGGT-
GGCCCGAGTGCTGCAGAGGCTGTGCGAGCGCG
172 WIF1 TCTGTCTAAACGGGAACAGCCCTGGCT-GAGGGAGCTGCAGCGCAGCAGAGTATCTG
ACGGCGCC
178 CCM2 CTGGAATTGTCTCGCCATTTAAACGAGTAT-TCCTAAAAGGTGAAAAGAGTAGAGATAAG
AAAGCCCATGAGAAGGT
193 RARB CCGCCGGCTTGTGCGCTCGCT-GCCTGCCTCTCTGGCTGTCTGCTTTTGCAGGGCTGCT
202 MLH3 GCGACCTTGTTCTTCCTTTCCTTCCGA-GAGCTCGAGCAGAGAGGACTGTGATGAGAC
AGGATAACAG
211 TGFBR1 GGCGTTACAGTGTTTCTGCCACCTCT-GTACAAAAGACAATTTTACTTGTGTGACAGATG
GGCTCTGCTTT
220 COL2A1 GCCTCTTCCTTCTACACAGGGTCCTT-CTGGAGACCAAGGTGCTTCTGGTCCTGCTGGT
CCTTCT
229 PAH CAGTGCCCTGGTTCCCAAGAA-CCATTCAAGAGCTGGACAGATTTGCCAATCAGATTC
TCAG
238 CDKN2A CTGGATCGGCCTCCGACCGTAAC-TATTCGGTGCGTTGGGCAGCGCCCCCGCCTCCA
GCAGC
247 PTCH GTGGACAGCTGGGAGGAAATGCTGAA-TAAGGCTGAGGTTGGTCATGGTTACATGGA
CCGCCCCT
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Table 4.2: Bladder cancer probe mix (continued)
length (nt) Gene Partial sequence with hhaI site
259 CDKN2A CCAGGGGCACCAGAGGCAGTAACCATG-
CCCGCATAGATGCCGCGGAAGGTCCCTCAGA
265 SLC2A1 CTCTGGTCCCTCTCAGTGGCCATCTTTTCT-GTTGGGGGCATGATTGGCTCCTTCTCTGTG
GGCCTTTTCGTTAACC
283 BCL2 GTGAAGCGGTCCCGTGGATAGAGA-TTCATGCCTGTGCCCGCGCGTGTGTGCGCGCG
TG
292 PTEN CACCGGAGCGGGCGCAGGAGA-GGCCTGCGGGGTGCGTCCCACTCACAGGGAT
301 ESR1 GCTCGCGTGTCGGCGGGACAT-GCGCTGCGTCGCCTCTAACCTCGGGCTGTGCTCTTT
TTCC
310 DBC1 CTGGAGGTTTGTTGAGCTCCTCTACT-TCCTGTTTATATGGGGCCGTATCTCAGTGCAGC
CC
319 TIMP3 CATCGTGCTCCTGGGCAGCTGGA-GCCTGGGGGACTGGGGCGCCGAGGCGTGCACA
328 KRIT1 TGGTCTAGGAGCTCCAGACTACTCAAAAAT-CCAAATACCTAAACAGGAAAAATGGCAG
AGAAGCATGAGCAGT
337 CDH1 CTATGAAGGAAGCGGTTCCGAAGCTGCTA-GTCTGAGCTCCCTGAACTCCTCAGAGTC
AGACAAAGACCAGGAC
346 TNFRSF25 CTGAAGGCGGAACCACGACGGGCA-GAGAGCACGGAGCCGGGAAGCCCCTGGGC
GCCCG
355 TGFBR1 GAGAATGTTGGTATGCCAATGGAGCA-GCTAGGCTTACAGCATTGCGGATTAAGAAAA
CATTATCGCA
364 DBC1 TCACTTCCTGACCATCGGAAGCATCCA-
TCAGCACTGGGGCAATGACTGGGACCTGCAGA
375 ESR1 CCAGCCCGCCGTGTACAACTACCCCG-
AGGGCGCCGCCTACGAGTTCAACGCCGCGGC
382 PTCH GATAAGAGCTCCGGGGGGATTCTTCA-TGCACCAGTGTTTAGGGTACGTGCTTCCTAAG
TAAATCCAAACATTG
391 CDKN2A GCTCTTCCGCCAGCACCGGAGGAA-GAAAGAGGAGGGGCTGGCTGGTCACCAGAG
GGTG
400 TIMP3 CCAGCGCTATATCACTCGGCCGCCCA-GGCAGCGGCGCAGAGCGGGCAGCAGGCAG
409 EDNRB CCAAGTTTCCCACTGGCGCGCAA-ACTTGAGTTACTTTTGAGCGTGGATACTGGCGAA
GAGGCTG
418 TERT CCAGAGTTTCAGGCAGCGCTGCGTCCT-
GCTGCGCACGTGGGAAGCCCTGGCCCCGGCC
427 APAF1 CCATTCATGCTTGTTTTGTTTTGGATTTTAGTAAGGACA-GTCCTGTGTGAAGGTGGAGTA
CCACAGAGGCCAGTTGTTTTTG
436 CDH13 GTTCTGTGCGTTCTCCTGTCCCAG-GTAGGGAAGAGGGGCTGCCGGGCGCGCTCTG
445 DBC1 GCAGTCACTCCTCTACTGTAATGAGAATGGGTT-TTGGGGAACCTTCCTGGAGAGCCAG
CGGAGCTGCGTG
454 APC CTCAGCTGTGTAATCCGCTGGATGCGGACC-
AGGGCGCTCCCCATTCCCGTCGGGAGCCCGC
463 WIF1 CCTGCAAATAGAGCGAGAACAGAAGAGCGGGA-
AGGGCTGGCGCGAGCGAGGTGCGAGCGAGGAG
472 CDH1 CTGAGGAGCGGAGCGGCCTGGAA-GCCTCGCGCGCTCCGGACCCCCCAGTGATGG
GAGT
481 RARB CCACATGTGCTTTTTCTGGAGTGGAAAAATACATA-AGTTATAAGGAATTTAACAGACAG
AAAGGCGCACAGAGGAATTT
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genes methylated in BC patients selected from the literature18, 19, 25, 28, 32. Due to space restraints 
selected genes from kit-001 were: TIMP3, APC, RARB, PTEN, and CDH13. ESR1 was selected from 
kit-002. Genes selected from the literature included BCL2, HTERT, TNFRSF25, EDNRB, CDH1 and 
WIF1. An overview of the final BC MS-MLPA containing 23 methylation probes is demonstrated 
in Table 4.2. It should be noted that the BC MS-MLPA assay contains multiple probes for BCl2, 
PTEN, TIMP3, APC, TERT, WIF1, RARB, ESR1 and CDH1. Next, we analyzed the same available 
tumors and control non-BC urine samples with the newly developed BC MS-MLPA to validate 
the selection of probes. Results from the analyzed non-BC urine samples (n=40) and NMIBC 
tumor samples (n=34) are displayed in Table 4.3 Significantly higher methylation of tumor tissue 
was reached for TERT_b (p<0.0001), ESR1_a (p<0.0001), EDNRB (p<0.0001), TERT_c (p=0.001) 
and CDH13 (p<0.0001). Methylation of TNFRSF25 was significantly higher in the non-BC control 
group. In summary the newly designed BC custom MS-MLPA contains gene probes specifically 
methylated in tumor tissue of NMIBC patients.
Table 4.3: Methylation frequencies for BC Ms-MLPA custom kit
Genes
urine non-BC (n=40) tumor tissue (n=34)
p- valueM %M  M %M  
BCl2_a 5 12,5 13 38,2 0,01
PteN_a 0 0 1 2,9 0,459
tIMP3_a 0 0 1 2,9 0,459
aPC_a 0 0 6 17,6 0,007
tert_a 0 0 6 17,6 0,007
tert_b* 0 0 10 29,4 <0.0001
WIf1_a 0 0 2 5,9 0,208
rarB_a 0 0 5 14,7 0,017
CDkN2a 0 0 1 2,9 0,459
BCl2_b 0 0 1 2,9 0,459
PteN_b 0 0 1 2,9 0,459
esr1_a* 0 0 27 79,4 <0.0001
tIMP3_b 0 0 1 2,9 0,459
tNfrsf25 35 87,5 31 91,2 0,719
esr1_b 0 0 2 5,9 0,208
tIMP3_c 0 0 1 2,9 0,459
eDNrB* 4 10 23 67,6 <0.0001
tert_c* 0 0 8 23,5 0,001
CDh13* 0 0 9 26,5 <0.0001
aPC_b 0 0 6 17,6 0,007
WIf1_b 5 12,5 14 41,2 0,005
CDh1 0 0 1 2,9 0,459
rarB_b 1 2,5  3 8,6  0,328
*Statistical significant methylated genes. Chi-square test (Bonferroni correction α=0,002)
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step 2. a four-gene panel for the detection of recurrences
We aimed at selecting a smaller gene panel to improve the utility of the developed BC MS-
MLPA. (Figure 4.1, Step 2). To this end, the LASSO-method was used to select a combination 
of methylated gene probes with the highest predictive value, based on a dataset containing 
68 pre-TUR urine samples versus urine samples from non-BC patients (n=91). The gene probes 
APC_a, TERT_a, TERT_b and EDNRB were identified by the LASSO approach as discriminating 
between tumor and control and were combined into the final gene panel. This panel reached an 
AUC under the ROC curve of 0.82 (Figure 4.2A).
step 3. recurrence risk probability increases with stage and grade
The selected gene panel was validated on an independent dataset of 49 pre-TUR urines and 60 
control urines of recurrence-free BC patients. The AUC for the gene panel reached 0.69 in this 
validation (Figure 2B). Next, we developed a logistic regression model, based on methylation of 
the gene panel, to predict the probability of a recurrence: (APC_a *0.097) + (Tert_a *0.507) + 
(Tert_b * 0.218) + (EDNRB *0.501) + -2.480. Raw methylation outcomes were used as input 
in the logistic regression model to predict the recurrence probability, without converting results 
to a dichotomized variable. This was done to prevent loss of any data. A probability cut-off 
point (0.34), with the most optimal sensitivity and specificity, was selected to indicate whether 
a test outcome was considered positive (detected recurrence) or negative (missed recurrence) 
(Figure 4.3A). This resulted in a sensitivity and specificity of 31/49 (63.3%) and 35/69 (58.3%), 
respectively (Table 4.4). All high grade tumors i.e. T1, grade 3 and carcinoma in situ, were 
detected and most were associated with a high recurrence risk probability. Missed tumors were 
of low risk potential, namely TaG1-2.
Figure 4.2 ROC and AUC of the four-gene panel. (A) ROC of gene panel: APC a , TERT a , TERT b and EDNRB 
for the test set (AUC 0.82) and (B) validation set (0.69).
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step 4. Methylation-based probability, a promising tool for the detection of 
high risk tumors
Finally, we validated the selected cut-off probability of 0.34 on an independent set of 65 pre-
TUR urine samples and 29 urine samples from recurrence-free BC patients. The sensitivity and 
specificity were 47/65 (72.3%) and 16/29 (55.2%), respectively (Table 4.4). High risk tumors 
were detected in 91% (10/11). Mostly pTaG1-2 tumors were missed, together with one pT1G2 
tumor was missed (Figure 4.3B).
Figure 4.3 Probability plot for the detection of a recurrent tumour in voided urine. Probability plot based on 
the four-gene panel. X-axis depicts stage and grade of the resected recurrences. Y-axis depicts the predicted 
recurrence probability based on the developed logistic regression model. Test outcome was considered positive 
(detected recurrence) based on the probability outcome > 0.34 and negative (missed recurrence) < 0.34. Each 
dot represents a urine sample.
Table 4.4: Sensitivity and specificity of the four-gene panel in the test and validation set of urine samples
      test set
validation 
set
sensitivity rate of gene panel, methylated (>0.34)/ total (%)
All cancer 31/49 (63) 47/65 (72)
Ta 20/38 (53) 41/58 (71)
T1 9/9 (100) 5/6 (83)
Tis 2/2 (100) 1/1 (100)
Low grade 19/37 (51) 39/57 (68)
High grade 12/12 (100) 8/8 (100)
specificity rate of gene panel, not methylated (<0.34)/total (%)
 Recurrence-free patients without BC  35/60 (58) 16/29 (55)
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DIsCussION
Promoter methylation is a frequent finding in bladder tumors and previous research has indi-
cated the possibility of methylation detection in urine. Since methylation has been associated 
with bladder tumor stage, grade, recurrence and progression detection of methylated tumor 
cells shed in urine might be a promising tool during the follow-up of NMIBC patients.18 We 
developed an MS-MLPA assay specifically for the detection of NMIBC recurrences and selected 
a smaller panel of four probes from the original MS-MLPA to improve utility of the assay. Next, 
we developed a logistic regression model based on this panel to determine the probability of 
having a recurrence and found that the model was able to predict recurrent tumors and that the 
recurrence risk increased with tumor stage and grade.
Since voided urine does not contain many cells and there is a limited availability of clinical 
samples for molecular analyses, newly developed tests should be able to detect a low number 
of tumor cells and require small amounts of input DNA. The BC MS-MLPA assay is a sensitive 
method for detecting tumor cells and requires only 50ng of urinary DNA input.31 The assay is 
based on a multiplex PCR to investigate the methylation status of up to 23 genes in one assay, 
hereby enabling simultaneous analysis of multiple patient samples without an increase in associ-
ated costs and the use of large amounts of DNA. Futhermore, the assay does not require bisulfite 
conversion, which is known to cause DNA breakage and thus might affect the sensitivity of a test.
The sensitivity for detection of recurrences in the test and validation set were 63% and 72% 
respectively. Interestingly, all high-grade recurrences (including one T2G3) were detected in the 
test and validation set and mostly associated with a high risk probability. Most of the undetected 
tumors were low risk TaG1-2. Only one pT1G2 was missed. Thus, the methylation detection 
assay is able to detect recurrent and progressing tumors. Compared to previous studies the 
sensitivity of this assay is relatively low.25, 27, 28, 33 Friedrich et al. reported a sensitivity of 78% for 
the detection of methylation in urine samples associated with a primary tumor collected before 
radical cystectomy (22/37 ≥pT2).25 Although size was not recorded in their manuscript, primary 
tumors and tumors selected for radical cystectomy are often large in size, have a higher grade 
and more genetic aberrations than recurrences. Accordingly, Catto et al. demonstrated that 
methylation levels increase with advanced tumor stage, possibly leading to an easier detection of 
these tumors.18 Dulaimi et al. reported a sensitivity of 87% for their gene panel (APC, RASSF1A, 
p14 (ARF). Although they did not record whether primary or recurrent samples were used 28/45 
tumors were classified as muscle-invasive.27 In the same line, recently Renard et al. developed a 
two-gene panel (TWIST1 and NID2) to identify tumors in voided urine samples of 466 primary 
bladder cancer patients (sensitivity 90%; specificity 93%). Notably, most studies use urine from 
patients without bladder cancer as a control group, but we believe that this does not reflect the 
true clinical practice where patients with a history of BC do not have the same risk probability of 
developing a recurrent tumor compared to control patients without a history of bladder cancer. 
The selection of our gene panel was based on recurrent NMIBC tumors and the test was vali-
dated on a subset of urines from BC patients with no recurrence at the time of urine collection.
MS-MLPA for recurrence detection in urine 83
4
Recurrent tumors (mainly TaG1-2, and one T1G2) were not detected in 32% of the cases 
(18/49+18/65) by the methylation assay. Possibly, tumor cells were absent at the time of urine 
collection or the number of urinary tumor cells was below the detection threshold of the assay. 
We show in a recent study that this might partly be solved by regular urine sampling (manuscript 
submitted). Secondly, we also demonstrated that not all tumors are methylated, hence stratifica-
tion according to methylation status of the primary tumor could improve the sensitivity of the 
test (unpublished data).
“False” positive urines were detected in 33% (25/56+13/60) of cases (Table 4.4). Firstly, BC 
appears to arise from a field of change that affects not only macroscopically visible tumors, 
but also the area surrounding the tumor.34 It might be possible that even though no tumor is 
detected cystoscopically, urothelial cells in the surrounding area of the resected tumor contain 
epigenetically changed cells. Secondly, multiple studies showed residual tumor in 35-81% at 
the same site of the initial resection at the first follow-up cystoscopy or at deep resection of the 
tumor base.35-37 Thirdly, it is known that cystoscopy does not detect all tumors and recent studies 
show that the sensitivity of detection of NMIBC by the currently used white light cystoscopy 
varies between 68-83%. These studies also demonstrate that blue light fluorescence cystoscopy 
has superior sensitivity and studies on micro-satellite analysis demonstrate an increased sensitiv-
ity of cystoscopy when the urologist was aware of a positive test outcome.5-7, 38
Most biomarkers have a chosen cut-off point to distinguish positive (detected) from negative 
(missed) test results. However, dichotomizing markers before adding them to a statistical model 
generally leads to loss of data, resulting in reduced accuracy of the developed test. We designed 
a logistic regression model, based on raw methylation input data, to predict the probability of 
a recurrent tumor. A cut-off probability of 0.34 was selected for having the highest sensitivity 
and specificity.
Limitations of this study are the absence of tumor material for the test and validation subsets. 
Possibly, methylation was absent in the tumor, which might affect the sensitivity of the assay. 
Furthermore, our assay contains 23 probes, which might influence the efficiency of probe hy-
bridization. Therefore, we selected a gene panel and our next aim is to develop a BC MS-MLPA, 
containing only the selected gene probes.
CONClusIONs
This is the first study to develop a methylation assay specific for the detection of NMIBC recur-
rent tumors in voided urine. These patients have small recurrences that require development 
of highly sensitive tests. Although at this time the sensitivity and specificity of the test are not 
sufficient for clinical implementation, our findings are promising and improvement of this test 
might eventually contribute to a more individualized patient-friendly surveillance. Additionally it 
would be of interest to perform functional studies to determine whether promoter methylation 
of the selected panel is related to gene silencing.
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aBstraCt
Objective | To determine a combination of markers with optimal sensitivity for detection of 
recurrences in voided urine after resection of a primary low-grade non-muscle invasive bladder 
tumor (NMIBC).
Material and methods | Patients with NMIBC G1/G2 (n=136) were included at trans-urethral 
resection of the primary tumor. At least three follow-up urine samples were required for patient 
selection. DNA was extracted from the primary tumor and cell pellets of the subsequently col-
lected urine samples. FGFR3, PIK3CA and RAS mutation analysis, micro-satellite analysis (MA) 
and methylation analysis (MS-MLPA) were performed on the tissue and urine DNA samples.
results | We obtained 716 urine samples. The 136 patients experienced 552 recurrences during 
a median follow-up of three years. Sensitivity for detection of a recurrent tumor varied between 
66% and 68% for the molecular tests after stratification of the patients based on tumor DNA 
analysis. A combination of markers increased sensitivity but reduced the number of patients 
eligible for a certain test combination. Combination of urine cytology with FGFR3 analysis, 
without stratification for FGFR3 status of the primary tumor, increased sensitivity from 56% to 
76%.
Conclusions | A combination of markers increases the percentage of patients eligible for urine-
based follow-up and increases the sensitivity of recurrence detection. Addition of FGFR3 analysis 
to urine cytology could be valuable for the non-invasive follow-up of NMIBC patients.
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INtrODuCtION
Cystoscopy is the gold standard for the follow-up of non-muscle invasive bladder cancer (NMIBC) 
patients and the cystoscopy frequency is determined by the recurrence and progression risk 
according to EAU guidelines.1 However, cystoscopy is a time-consuming procedure that causes 
physical discomfort for patients and the sensitivity has been estimated to vary from 68-83%.2, 3
After resection, up to 70% of patients with NMIBC develop one or multiple recurrences. 
Hence, patients have frequent trans-urethral resections of the tumor (TUR) and together with 
the abundant cystoscopies this makes bladder cancer one of the most expensive tumor types.4, 5 
In addition to cystoscopy, urine cytology is performed, but its sensitivity for the detection of 
low-grade tumors is low.6 Nevertheless, cytology is still used as a reference in the absence of 
highly sensitive urinary biomarkers. Up to now, multiple studies have been performed, usually 
investigating one type of urinary maker. Various markers proved to be more sensitive than cytol-
ogy, however none of the single type of markers reached a sensitivity high enough to safely 
reduce the number of cystoscopies. A major problem with many studies that test biomarkers 
for urine diagnosis is that the investigated urine samples are often derived from patients with 
primary tumors, which are mostly larger than recurrent tumors and are also of higher grade. 
This results in high sensitivities and subsequently the marker sensitivity drops considerably when 
tested on urine samples derived from patients with a recurrent tumor.7 Patients that are eligible 
for urine-based surveillance will typically present with NMIBC of G1 or G2. The risk of progres-
sion in these patients is low; however the risk of multiple recurrences is high.
Previous studies have demonstrated the role of hypermethylation, leading to transcriptional 
silencing of tumor suppressor genes and aberrant methylation has been detected in voided urine 
of patients with BC, which appears to be more sensitive than urine cytology.8-13 Recently, we 
have developed a methylation assay, i.e. bladder cancer specific multiplex ligation-dependent 
probe amplification (MS-MLPA) assay. This methylation assay is specifically developed for the 
detection of NMIBC recurrences in voided urine.14 The use of micro-satellite analysis (MA) for 
the detection of loss-of-heterozygosity (LOH) in voided urine samples is also reported in multiple 
studies.15-17 Van der Aa et al. demonstrated that the positive predictive value of MA was higher 
in patients without mutations in the fibroblast growth factor receptor-3 (FGFR3).15 Mutations in 
FGFR3, leading to constitutive activation of the RAS-MAPK pathway, have been found in 70% 
of NMI bladder tumors and are associated with overall favorable prognosis.18, 19 RAS mutations 
(KRAS, HRAS, NRAS) have been found in 13% of bladder tumors of all stages and grades, 
being mutually exclusive with FGFR3 mutations.20 Previous research demonstrated PIK3CA 
mutations in 13-27% of the bladder tumors, whereas PIK3CA mutations mostly co-occurred 
with FGFR3 mutations.21 Recently, we showed that urinary FGFR3 mutation analysis in patients 
with a primary FGFR3 mutant (MT) tumor is a suitable assay for the detection of recurrences.22 
Additionally, we found that 88% of the low-grade NMIBC patients harbored a mutation in one 
of the mentioned oncogenes, making these patients eligible for urine-based surveillance by 
mutation detection assay.23
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The FGFR3, RAS, PIK3CA and MS-MLPA assays are multiplex assays that can either detect 
a mutation or a methylated gene. Hence, they represent a single assay. It is not possible to 
multiplex the MA, making this assay more labor intensive. Further developments like next-
generation sequencing would facilitate the combination of assays. Therefore, it is worthwhile to 
test whether a combination of assays would be better than a single.
The objective of this study was to determine a combination of markers with optimal sensitivity 
in order to detect recurrences in voided urine. Therefore, we used mutation analysis of FGFR3, 
PIK3CA, HRAS, KRAS, NRAS, in combination with methylation-specific MLPA and MA assays to 
increase the percentage of patients that could be monitored by urine analysis. The results were 
compared to urine cytology in a large retrospective longitudinal cohort. This study was part of 
the European FP7 UROMOL project.
MaterIal aND MethODs
Patient material
A total of 716 voided urine samples from 136 patients with NMIBC (Ta/T1, G1/2)24 were col-
lected at the Department of Urology at Aarhus University Hospital at trans-urethral resection of 
the primary tumor. Patients with a history of carcinoma in situ were excluded from participation. 
10-50 mL urine was collected at regular follow-up visits. Urine specimens were collected imme-
diately before cystoscopy; cells were sedimented by centrifugation, and frozen at -80°C. Tumor 
biopsies were stored at -80°C immediately following resection of the tumor. A cystoscopic 
examination coincided with urine collection for molecular analysis. The availability of at least 3 
follow-up urine samples, were a prerequisite for study inclusion. Recurrence was defined as a 
histologically proven tumor. Progression was defined as progression to muscle-invasive disease. 
Informed written consent was obtained from all patients, and research protocols were approved 
by the Central Denmark Region Committees on Biomedical Research Ethics.
DNa isolation and molecular analyses
DNA from tumor biopsies was extracted using Qiagen Dneasy blood and tissue kit (Qiagen, 
GmbH, Hilden Germany). DNA was extracted from urine cell pellets using the QiAamp Mini and 
Blood mini kit (Qiagen GmbH, Hilden, Germany).
Mutation analysis for FGFR3, PIK3CA, RAS was performed as described previously.22, 23, 25 LOH 
was detected by micro-satellite analysis using primers for 12 polymorphic micro-satellite markers 
localised on chromosomes 8, 9, 10, 11 and 17 (van Tilborg et al., submitted). The MS-MLPA 
was used for the detection of methylation as described by Nygren et al,26 This MS-MLPA was 
specifically developed for the detection of bladder cancer recurrences14. All details of primers, 
probes and conditions are given in Supplementary File 5.1.
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statistical analysis
The Predictive Analytics Software 17 (SPSS Inc, Chicago, Illinois, USA) was used for data analysis. 
Statistical differences were considered significant if p <0.05. The Chi-square and Fisher’s exact 
test were used to determine the relationships between different variables.
results
Patient and tumor characteristics
Patients with primary NMIBC G1 or G2 (n=136) were included for molecular analyses. Patients with 
G3 primary tumors were excluded because of their high risk of progression. Included patients had 
a total of 552 recurrences during a median follow-up of three years. Patient and primary tumor 
characteristics are depicted in Table 5.1. Four patients had progression to muscle-invasive disease. 
From 93/136 patients, there was DNA available from the primary tumor and from 22/136 patients, 
there was DNA available from the tumor at first visit. Tumors were analyzed for mutations in FGFR3, 
PIK3CA, RAS (HRAS, KRAS, NRAS) and the presence of LOH and methylation. FGFR3 mutations 
were detected in 68% (78/115), PIK3CA 18% (20/111) and RAS 9% (10/110). PIK3CA and FGFR3 
mutations co-occurred in 16/20 (80%) cases, whereas FGFR3 and RAS mutation were overall mutu-
ally exclusive, since only one patient harbored both mutations. Combined, 79% (91/115) of the 
patients had a mutation either in FGFR3, PIK3CA or RAS (Figure 5.1). LOH was detected in 63% 
(72/114) and methylation in 98% (88/90) of the patients. FGFR3 mutations or LOH were detected in 
81% of the primary tumors. During follow-up, 552 histologically proven recurrences were detected. 
These included mainly stage Ta (92%), G1/2 (82%) and solitary tumors (67%) (Table 5.2). Overall, 
recurrent tumors in patients with FGFR3 mutant primary tumor were of lower stage (Figure 5.2a, 
p=0.001) and lower grade (Figure 5.2b, p=0.003) when compared to recurrent tumors from pa-
tients with an FGFR3 wild-type primary tumor. No upper tract recurrences were detected.
Figure 5.1 Mutation status of 115 incident tumors. 79% harboured an activating mutation in at least one of 
the tested oncogenes and 21% had no mutation.
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Table 5.1: Clinical and molecular characteristics of 136 patients and primary tumors 
n (%) n (%)
Gender FGFR3
Male 90 (66) Wild-type 37 (32)
Female 46 (34) Mutant 78 (68)
PIK3CA
Smoking Wild-type 91 (82)
No 47 (35) Mutant 20 (18)
Yes 70 (51) RAS
Unknown 19 (14) Wild-type 100 (91)
Mutant 10 (9)
Stage FGFR3 + PIK3CA
Ta 120 (88) Mutant 16 (14)
T1 16 (12) FGFR3 + RAS
Mutant 1 (0.9)
Grade FGFR3 + PIK3CA + RAS
G1 34 (25) Mutant 1 (0.9)
G2 102 (75) FGFR3, PIK3CA or RAS
Wild-type 24 (21)
Multiplicity Mutant 91 (79)
Solitary 104 (76) LOH
Multiple 32 (24) No 42 (37)
Yes 72 (63)
Tumor Size* FGFR3 or LOH
<3 cm 97 (71) No 22 (19)
>3 cm 38 (28) Yes 93 (81)
Unknown 1(1) Methylation
No 2 (2)
Progression Yes 88 (98)
No 132 (97) FGFR3 or Methylation
Yes 4 (3) No 1 (1)
  Yes 88 (99)
* In case of multiplicity, tumor size was determined by largest tumor
LOH = Loss of Heterozygosity
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Table 5.2: Clinical characteristics of 552 recurrent tumors
n (%)
Stage
Ta 506 (92)
T1 30 (5)
T2-T4 9 (2)
Tx 7 (1)
Grade
G0 17 (3)
G1 155 (28)
G2 298 (54)
G3 63 (11)
Gx 19 (3)
Multiplicity*
Solitary 434 (79)
Multiple 118 (21)
Tumor size
<3 523 (96)
>3 17 (3)
 unknown 7 (1)
* In case of multiplicity, tumor size was determined by largest tumo
Figure 5.2 Stage (A) and grade (B) of 482 recurrent tumors. Patients were stratified by FGFR3 mutation 
status of incident tumor. Sixpatients with Tx and 16 with Gx were not included in analysis. WT= wild-type, 
MT = mutant.
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test performance of all single and combination of urine tests for the detection 
of recurrent tumors
Based on the molecular characteristics of the primary tumors, a combination of FGFR3 mutation 
analysis with other mutation assays, MA or MS-MLPA increased the percentage of patients suit-
able for urine-based follow-up. 99% of all urine samples could be analyzed for FGFR3 mutations. 
Due to the limited amount of DNA in some of the urine samples, only 70% could be analyzed for 
LOH and 63% for methylation. In 20% of all urine samples there was DNA left for the analysis 
of RAS and PIK3CA mutations. For each single and combination of assays the sensitivity for the 
Figure 5.3 Sensitivity and specificity of all single and combined tests with (A) and without (B) patient stratifica-
tion based on the molecular status of the primary tumor
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detection of a recurrent tumor in voided urine was determined. Patients were stratified accord-
ing to the molecular status of the primary tumor and analyses were done for each subgroup. 
Calculation of the sensitivity for PIK3CA or RAS mutation analysis in recurrent tumors separately 
was omitted because of the low numbers of urine samples available for analysis. For MA, we 
also calculated the sensitivity when using only the five markers for loss on chromosome 9. 
Sensitivity of all single and combined tests is shown in Figure 3a. The sensitivity for the detection 
of recurrences in patients with an FGFR3 mutant primary tumor (stratified) was 66%. Add-
ing PIK3CA and RAS assays to FGFR3 mutation analysis increased the sensitivity for recurrence 
detection from 66% to 71%. However, only a limited amount of samples could be analyzed for 
PIK3CA and RAS mutations. The combination of FGFR3/MA had the highest sensitivity (82%) for 
the detection of recurrences. For this combination, patients were stratified based on an FGFR3 
mutation in their primary tumor and/or LOH in the primary tumor. This analysis was possible 
for 81% of the patients. The analysis with 12 different MA markers requires a high amount of 
DNA; therefore we also calculated the sensitivity for the detection of recurrent tumors using only 
the five markers for loss on chromosome 9. The sensitivity of MA was now 64% compared to 
67% for analysis with all 12 markers. Combined with FGFR3 analysis the sensitivity increased to 
76%. For the combination of FGFR3/cytology patients were not stratified based on their primary 
tumor, this combination reached a sensitivity of 76%. Overall the specificity for all single and 
combined tests was low ranging from 34% (FGFR3/MA) to 66% (FGFR3 unstratified).
Molecular analyses are superior to urine cytology for the detection of low 
stage and low grade recurrences
The overall sensitivity of all single and combined molecular tests for the detection of recurrent 
tumors was higher than the sensitivity of urine cytology alone (Figure 5.3). Combining urine 
cytology with FGFR3 analysis improved the sensitivity from 56% to 76%. Table 5.3 shows the 
Table 5.3: Test sensitivity stratified and not stratified by molecular status of primary tumor
Detected stage/total (% sensitivity) Detected Grade/total (% sensitivity)
Ta T1 T2-4 Tx G0 G1 G2 G3 Gx
Stratified:
FGFR3 164/253 (65) 8/9 (89) 4/4 (100) 1/1 (100) 7/12 (58) 52/80 (65) 97/143 (68) 18/23 (78) 3/9 (33)
MA 92/139 (66) 4/6 (67) 6/7 (86) - 3/5 (60) 31/47 (66) 56/82 (68) 11/16 (69) 1/2 (50)
Methylation 122/180 (68) 8/9 (89) 1/2 (50) 0/1 (0) 1/5 (20) 29/51 (57) 79/107 (74) 18/22 (82) 4/7 (57)
FGFR3/MA 137/163 (84) 2/2 (100) 3/4 (75) - 6/6 (100) 46/54 (85) 79/91 (87) 6/12 (50) 5/6 (83)
FGFR3/methylation 153/204 (75) 6/9 (66) 3/4 (75) 2/2 (100) 8/9 (89) 53/70 (76) 79/110 (72) 19/24 (79) 5/6 (83)
Not stratified:
FGFR3 186/381 (49) 10/19 (53) 4/5 (80) 1/3 (33) 8/16 (50) 60/117 (51) 109/219 (50) 21/42 (50) 3/14 (21)
Cytology 185/344 (54) 16/19 (84) 6/8 (75) 4/6 (67) 6/13 (46) 33/99 (33) 127/203 (63) 37/45 (82) 8/17 (47)
FGFR3/cytology 208/279 (75) 12/13 (92) 5/5 (100) 2/3 (67) 9/13 (69) 52/79 (66) 130/162 (80) 30/33 (91) 6/13 (46)
FGFR3/MA 155/195 (79) 5/6 (83) 3/4 (75) 2/2 (100) 7/7 (100) 50/63 (79) 91/113 (81) 10/16 (63) 7/8 (88)
FGFR3/methylation 189/249 (76) 7/12 (58) 4/5 (80) 2/2 (100) 9/10 (90) 66/86 (77) 98/133 (74) 24/33 (73) 5/6 (83)
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sensitivities for all tests stratified according to stage and grade. The sensitivity for the detection 
of high stage and high grade tumors was similar in both the combined molecular tests and urine 
cytology. However in the case of low stage and low grade tumors, both single and combined 
molecular tests displayed higher sensitivity when compared to urine cytology. Adding FGFR3 
analysis to urine cytology improved the sensitivity for the detection of low stage and low grade 
tumors i.e. Ta 54% to 75%, G1 33% to 66%.
DIsCussION
In this study, we investigated whether molecular analyses could play a role in the surveillance 
of patients presenting with G1-2 NMIBC. Activating point mutations in FGFR3, PIK3CA and 
RAS, LOH and methylation have been found in bladder tumors of all stages and grades. These 
genetic and epigenetic alterations could be used for early recurrence detection in voided urine, 
possibly reducing the number of cystoscopies, resulting in a less invasive follow-up. Molecular 
characterization of the primary tumor could be used to stratify patients for an appropriate 
follow-up schedule according to the recurrence and progression risk of that specific molecular 
profile. In this study, FGFR3, PIK3CA, RAS mutation detection, MA and MS-MLPA were evaluated 
for the detection of bladder cancer recurrences in voided urine.
The sensitivity of FGFR3 analysis (66%) for concomitant recurrence detection in urine of 
patients with an FGFR3 MT primary tumor was comparable to previous reports.22 That not all 
recurrent tumors are detected is mainly the result of the number of tumor cells being below 
the analytical sensitivity of the assays. In a previous study we showed that sensitivity of the 
FGFR3 assay for tumors larger than 1.5 cm was 100% and 75% for tumor smaller than 1.5 cm. 
Analyzing more than one urine sample could increase the sensitivity27. A combination of FGFR3 
analysis with other molecular tests improved the sensitivity. A total of 79% of the tumors were 
mutant for FGFR3, PIK3CA and/or RAS. Although, we could only analyze a limited number of 
samples for this combination; the combined sensitivity of the three mutation assays was 71%. 
The optimal combination for recurrence detection was FGFR3/MA based on stratification of 
the primary tumor for the presence of FGFR3 mutations and/or LOH. Without stratification of 
patients based on molecular status of the primary tumor, the combination of FGFR3/cytology 
reached a sensitivity of 76%. Cytology is known to have a low sensitivity for G1 (7%-38%) and 
G2 (18%-46%) tumors.28 Hence, the combination of cytology with the FGFR3 mutation assay, 
which is more directed towards low grade/stage tumors, for surveillance is an attractive idea.
Overall the specificity of all single and combined tests was low. In principle, the specificity 
of FGFR3 and other mutation assays is 100% since these mutations do not occur in sufficient 
amounts in non-bladder cancer controls.29 The low specificity of molecular tests in cohorts under 
surveillance for recurrent bladder cancer could partly be explained by the so called anticipatory 
effect of the urine analysis, i.e. the urine test identifies a recurrence earlier than cystoscopy.22 
For example in 85% (46/54) of the patients in this study with a ‘false positive’ FGFR3 analysis, 
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a recurrent tumor was detected within 12 months. In addition, cystoscopy misses tumors since 
the currently used white light cystoscopy has been estimated to have a sensitivity between 
68%-83%.2, 3
Clinical implementation of a molecular test is not only dependent on the performance of the 
marker, but also dependent on the costs, specifically since bladder cancer is an expensive cancer. 
Mutation analysis is cheap with consumables under $10 per sample, including DNA isolation, 
and the tests can be performed in a standard laboratory. Additionally, the tests require only 
5ng of DNA. Based on our finding in this retrospective study, 99% of the urine samples would 
contain sufficient DNA to perform the FGFR3, PIK3CA and RAS mutation assays. Although MA 
by itself is cheap, the test requires 12 individual PCR reactions per sample and the analysis of 
the results is laborious and would need automation before being implemented in routine clinical 
practice. Moreover, a substantial percentage of urine samples will not yield sufficient DNA to 
perform MA. However the amount of markers could be reduced by using only the five markers 
for chromosome 9. The markers in the MS-MLPA kit have a high predictive value. Unfortunately, 
in our hands the test appeared not to be a suitable technology for introduction into clinical 
practice. The reason for this is that in many cases the PCR step failed and no product was 
apparent on the sequencer.
Strengths of the study include the analysis of a substantial number of primary tumors together 
with at least three follow-up urine samples per patient. Only a limited number of urine samples 
could be analyzed for PIK3CA and RAS mutations, because the study had already started when 
these assays were under construction. The findings presented here need to be validated in a 
large prospective study, which is currently being done in the European FP7 UROMOL project.
CONClusIONs
This is the first study to develop an optimal combination of urine-based tests in order to increase 
the sensitivity of recurrence detection. All tests had a higher sensitivity for low stage and grade 
disease compared to urine cytology. Therefore, a combination of molecular tests or a combina-
tion of the FGFR3 assay with cytology represents promising possibilities for the follow-up of low 
grade NMIBC patients. These findings will be validated in a large prospective multicenter study 
of the European FP7 UROMOL project.
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suPPleMeNtary fIles
sNaPshot mutation analysis
Mutation analysis of FGFR3, PIK3CA and RAS was performed as described by van Oers et al1. 
A multiplex PCR was performed in a volume of 15μl, containing 1x PCR buffer, 1.5mM MgCl2 , 
0.5 units Taq DNA polymerase (Promega, Madison, WI), 0.17mM deoxynucleotide triphosphates 
(Roche, Basel, Switzerland) 5% Glycerol (Fluka, Buchs SG, Switzerland) and 5ng of DNA and 1 
μl of PCR primer mix (final concentrations of primers are depicted in supplementary table 5.1). 
The PCR conditions were as follows: 5 minutes at 95°C followed by 35 cycles at 95°C for 45 sec-
onds, 55°C for 45 seconds, and 72°C for 45 seconds. The PCR was completed with 10 minutes 
at 72°C. Next products were treated with 3 units of shrimp alkaline phosphatase and 2 units 
of Exonuclease I (SAP and ExoI, Amserham Biosciences, Uppsala, Sweden). After the remov-
ing of the excess primers and deoxynucleotide triphosphates, PCR-products were analyzed for 
mutations by using the ABI PRISM SnaPshot Multiplex kit (Applied Biosystems, Foster City, CA) 
according to manufacturer’s protocol. The SNaPshot method is based on dideoxy single-base 
extension of unlabeled oligonucleotide primers. For each mutation a primer annealing adjacent 
to the potentially mutant nucleotide was developed. The different in length of poly(dT)-tail at-
tached to the 5’-end enabled the simultaneous detection of the different primers. The multiplex 
SNaPshot reaction was performed in a volume of 10μl, containing 1μl PCR product, 2.5μl Ready 
Reaction mix, 1x sequencing buffer, and 1μl SNaPshot Primer mix (final primer concentrations 
are depicted in supplementary table 5.2). The cycling scheme consisted of 35 cycles of 10 
seconds at 96 °C and 40 seconds at 58.5°C. In the final step 1μl shrimp alkaline phosphatase 
was added. Products were analyzed using an automatic sequencer (ABI 3130, Genetic Analyzer, 
Applied Biosystems).
Microsatellite analysis
Microsatellite analysis (MA) was performed as described by van Tilborg et al (submitted, 2012). 
Shortly, PCR of 12 different microsatellite markers was performed with separate primer pairs of 
which 1 oligonucleotide was labelled at the 5-end with fluorescent dyes 6-FAM (Invitrogen, the 
Netherlands). Primer sequences are depicted in supplementary table 5.3. PCR was carried out 
in a total volume of 15μl, consisting of 5x GoTaq PCR buffer, 2.5 mM MgCl2 (Promega) 0.2 mM 
dNTP’s (Boehringer), and 5 units GoTaq DNA polymerase. For each marker a DNA input of 5ng 
was required. The following cycling conditions were used: 95°C for 5 minutes followed by 28 
cycles at 95°C for 45 seconds, 55°C at 45 seconds and 72°C for 45 seconds and the final step 10 
minutes at 72°C. Next DNA fragments were analyzed using an automatic sequencer (ABI 3130, 
Genetic Analyzer, Applied Biosystems). All samples were analyzed in duplicate. We applied a 
lower limit for peak heights of 700 to exclude possible preferential amplification of one of the 
two alleles due to insufficient input DNA. All reactions with off-scale signals were diluted and 
rerun. A result was only taken into account when at least four MA markers in a sample were 
informative.
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Based on findings from a previous study (Tilborg et al, submitted) cut-off values for each 
marker were set to 95% specificity based on urine samples from healthy individuals. The upper 
and lower cut-off values are depicted in supplementary table 5.4. The mean peak ratio per 
sample was calculated.
Bladder Cancer specific Ms-MlPa
DNA amplicons were prepared for hybridization according to MS-MLPA protocol, originally 
described by Nygren et al2. MLPA reagents were obtained from MRC-Holland, Amsterdam, the 
Netherlands (KIT-ME014). Probe sequences are depicted in supplementary table 5.5. Briefly, 50-
150ng of genomic DNA was denatured for 10 minutes at 98°C. 1.5μl SALSA MLPA-buffer and 
1.5μl probe mix were added and the mixture was incubated for 1 minute at 95°C, followed by a 
16-hours incubation at 60°C. This incubation allowed the probes to bind to their respective tar-
gets. After hybridization a mix of 10μl water and 3μl Ligase-buffer A was added to each sample, 
resulting in a total volume of 20μl. 10μl of this volume was then transferred to an adjacent well 
to ensure duplicate analysis. The 96-wells plate was incubated for 1 minute at 49°C followed by 
the addition of Ligase-65 Mix. This mix contained 1.5μl Ligase-65 buffer B, 8.25μl water, 0.25μl 
Ligase enzyme and 0.5μl HhaI enzyme (Promega R6441, 10 units/μl). Simultaneous ligation and 
digestion was then performed by incubation for 30 minutes at 49°C, followed by a 98°C ligase 
inactivation treatment of 5 minutes. Finally 5μl of ligation product was added to a PCR mixture, 
consisting of 1μl SALSA PCR-primers, 1μl SALSA Enzyme Dilution buffer, 2μl SALSA PCR buffer, 
15.75μl water, and 0.25μl SALSA polymerase. Ligation products were amplified by PCR for 35 
cycles: 30 seconds 95°C; 30 seconds 60°C; 60 seconds 72°C. The PCR was completed with 20 
minutes incubation at 72°C. Products were analyzed using an automatic sequencer (ABI 3130, 
Genetic Analyzer, Applied Biosystems).
A combination of probes was selected using the least absolute shrinkage and selection opera-
tor (LASSO) method. Probes with non-zero coefficients in the LASSO were combined into a gene 
panel. This gene panel was used in a logistic regression model to determine the probability 
for having a recurrence based on methylation of this selected gene panel: (APC_a * 0.097) + 
(TERT_a * 0.507) + (TERT_b * 0.218) + (EDNRB * 0.501) – 2.480. A probability threshold of 0.34 
was selected to indicate whether a test outcome was considered positive or negative3.
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Supplementary table 5.1: Primer sequences mutation analysis
fGfr3 PCr Primermix
Primer sequence (5’->3’)
Product size 
(bp)
Concentration 
in PCr mix (μM)
FGFR3 RI Fw AGTGGCGGTGGTGGTGAGGGAG 115 1.2
FGFR3 RI Rev GCACCGCCGTCTGGTTGG 1.2
FGFR3 RII Fw CAACGCCCATCTCTTTGCAG 138 0.7
FGFR3 RII Rev AGGCGGCAGAGCGTCACAG 0.7
FGFR3 RIII Fw GACCGAGGACAACGTGATG 160 0.7
FGFR3 RIII Rev GTGTGGGAAGGCGGTGTTG 0.7
Pan-ras PCr Primermix
Primer sequence (5’->3’)
Product size 
(bp)
Concentration 
in PCr mix (μM)
HRAS exon1 Fw CAGGAGACCCTGTAGGAGG 139 0.6
HRAS exon1 Rev TCGTCCACAAAATGGTTCTG 0.6
HRAS exon2 Fw GGAGACGTGCCTGTTGGA 140 0.3
HRAS exon2 Rev GGTGGATGTCCTCAAAAGAC 0.3
KRAS exon1 Fw GGCCTGCTGAAAATGACTG 163 0.3
KRAS exon1 Rev GGTCCTGCACCAGTAATATG 0.3
KRAS exon2 Fw CCAGACTGTGTTTCTCCCTT 155 0.3
KRAS exon2 Rev CACAAAGAAAGCCCTCCCCA 0.3
NRAS exon1 Fw GGTGTGAAATGACTGAGTAC 128 0.3
NRAS exon1 Rev GGGCCTCACCTCTATGGTG 0.3
NRAS exon2 Fw GGTGAAACCTGTTTGTTGGA 103 0.3
NRAS exon2 Rev ATACACAGAGGAAGCCTTCG 0.3
PIk3Ca/Nras PCr Primermix
Primer sequence (5’->3’)
Product size 
(bp)
Concentration 
in PCr mix (μM)
PIK3CA ex9-Fw AGTAACAGACTAGCTAGAGA 139 1
PIK3CA ex9-Rev ATTTTAGCACTTACCTGTGAC 1
PIK3CA ex20-Fw GACCCTAGCCTTAGATAAAAC 109 0.7
PIK3CA ex20-Rev GTGGAAGATCCAATCCATTT 0.7
NRAS ex.2 Fw GGTGTGAAATGACTGAGTAC 128 0.3
NRAS ex.2 Rev GGGCCTCACCTCTATGGTG 0.3
NRAS ex.3 Fw GGTGAAACCTGTTTGTTGGA 103 0.5
NRAS ex.3 Rev ATACACAGAGGAAGCCTTCG 0.5
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Supplementary Table 5.2: Probe sequences mutation analysis
fGfr3 Probe mix
Probe sequence (5’-> 3’)
size 
(bp) strand Wt Mt μM*
S373C T19 GAGGATGCCTGCATACACAC 39 sense t a 0.4
K652M/T T20 CACAACCTCGACTACTACAAGA 42 sense a t/C 0.7
G372C T29 GGTGGAGGCTGACGAGGCG 48 sense G t 0.2
A393E T34 CCTGTTCATCCTGGTGGTGG 54 sense C a 0.7
R248C T46 CGTCATCTGCCCCCACAGAG 66 sense C t 0.4
Y375C T43 ACGAGGCGGGCAGTGTGT 61 sense a G 0.6
S249C T36TCTGCCCCCACAGAGCGCT 55 sense C G 0.8
K652Q/E T50 GCACAACCTCGACTACTACAAG 72 antisense a C/G 0.3
G382R T56 GAACAGGAAGAAGCCCACACC 76 antisense C t 0.4
ras set 1 Probe mix
Probe sequence (5’-> 3’)
size 
(bp) strand Wt Mt μM*
HRAS pos.34 T17 CTGGTGGTGGTGGGCGCC 35 sense G C/t/a 0.5
HRAS pos.182 T18 GCATGGCGCTGTACTCCTCC 38 antisense t G/C/a 0.15
KRAS pos.34 T25 GGCACTCTTGCCTACGCCAC 45 antisense C G/a/t 0.5
HRAS pos.35 T31 CGCACTCTTGCCCACACCG 50 antisense C G/a/t 0.7
NRAS pos.182 T33 GACATACTGGATACAGCTGGAC 55 sense a G/C/t 0.5
KRAS pos.181 T41 CTCATTGCACTGTACTCCTCTT 63 antisense G t/C 0.2
HRAS pos.181 T46 CATCCTGGATACCGCCGGC 65 sense C a/G 0.7
KRAS pos.35 T49 AACTTGTGGTAGTTGGAGCTG 70 sense G C/t/a 0.2
HRAS pos 37 T55 CAGCGCACTCTTGCCCACAC 75 antisense C G/a/t 0.7
NRAS pos.34 T62 CTGGTGGTGGTTGGAGCA 80 sense G C/t/a 0.2
PIk3Ca/Nras Probe mix
Probe sequence (5’-> 3’)
size 
(bp) strand Wt Mt μM*
E542K T17 ACACGAGATCCTCTCTCT 35 sense G a 0.15
E545G T21 CCTCTCTCTGAAATCACTG 40 sense a G 0.5
E545K T25 ATCCTCTCTCTGAAATCACT 45 sense G a 0.3
H1047R T30 GAAACAAATGAATGATGCAC 50 sense a G 0.3
NRAS pos.34 T34 GTGCGCTTTTCCCAACACCAC 55 antisense C G/a/t 0.5
NRAS pos.35 T41 CTGGTGGTGGTTGGAGCAG 60 sense G C/a/t 0.3
NRAS pos.37 T46 GGTGGTGGTTGGAGCAGGT 65 sense G C/a/t 0.1
NRAS pos.38 T49 GTCAGTGCGCTTTTCCCAACA 70 antisense C G/a/t 0.5
NRAS pos.180 T54 GGACATACTGGATACAGCTGG 75 sense a t 0.3
NRAS pos.181 T58 CTCATGGCACTGTACTCTTCTT 80 antisense G C/t 0.2
NRAS pos.182 T63 GACATACTGGATACAGCTGGAC 85 sense a C/G/t 0.2
NRAS pos.183 T68 CTCTCATGGCACTGTACTCTTC 90 antisense t a/G/C 0.7
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Supplementary table 5.3: primer sequences microsatellite markers
Marker size locus het f/r sequence
D8S1109 143-167 8p 0.88 F
R
TCAGAATTGCTCATAGTGCAAGA
ACTGTCTTGGTACATTTGTTTACCC
D8S1125 221-233 8p 0.69 F
R
CCCCCTAAAATTTAGCTCCA
TATGCCTAGCCCTCCTTTCT
D8S1130 128-148 8p 0.94 F
R
GAAGATTTGGCTCTGTTGGA
TGTCTTACTGCTATAGCTYYCATAA
D9S252 152-176 9q 0.75 F
R
CAAATTTGGCCTTGAACCAT
AGCCCAGATATCCCCAAGTT
D9S299 178-198 9q 0.70 F
R
AAGTGTTGCATCAGAGCCTC
AGTGTGAACATTATTTCATTCTGG
D9S304 135-175 9q 0.86 F
R
GTGCACCTCTACACCCAGAC
TGTGCCCACACACATCTATC
D9S752 178-201 9q 0.73 F
R
CAGAGGTTGCAGTGAGCTA
GCAAAGTCAGGCCATTATAC
D9S1118 141-177 9q 0.79 F
R
CAGGATATTATGTGATGGAATCC
CTGCTGACTCCAAAAATATGC
D11S1981 134-178 11p 0.85 F
R
AATTCCTTTACTCCAGAAAGG
CAGATTTCTGCTTTCCCAGA
D11S1999 109-137 11p 0.78 F
R
TACATGGCAGCAGGCATATA
GAGATAAACAAGATTGCTAGATAGGC
D17S969 111-132 17q 0.73 F
R
ATCTAATCTGTCATTCATCTATTCA
AACTGCAGTGCTGCATCATA
G10693 174-194 17p 0.94 F
R
ACATACAGCACAGGCCAAAT
CCAGTCTTCCGTCACTATGC
* Concentration in reaction
Supplementary table 5.4: Lower en upper cut-off values microsatellite markers
Marker 95% interval
D8S1109 0.93-1.29
D8S1125 0.85-1.19
D8S1130 1.00-1.40
D9S252 0.97-1.23
D9S299 0.95-1.27
D9S304 0.86-1.33
D9S752 0.92-1.31
D9S1118 0.97-1.42
D11S1981 0.93-1.39
D11S1999 0.93-1.45
D17S969 0.95-1.33
G10693 1.00-1.29
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Supplementary table 5.5: Probe sequences MS-MLPA kit ME014
124 TRAF4 TGCCAAGGTGAGTCCACACTGCCAGGA-AGAAGCCCAAGCACAGTCTGTTGCCCTTGGA
130 BCL2 TGTGAGATGTCCAGCCAGCTGCACCTG-ACGCCCTTCACCGCGCGGGGACGCTTTGCCA
136 PTEN GCTCTTTCATTTTTAGGGCAAACGAGCCGAGT-
TACCGGGGAAGCGAGAGGTGGGGCGCTGCAAG
142 TIMP3 TCCAGCGCCGAGGCAGCCTCGC-TGCGCCCCATCCCGTCCCGCCGGGCACTCGG
148 APC GGCTGGGTGTGGGCGCACGT-GACCGACATGTGGCTGTATTGGTGCAGCCCGCCAGGGT
154 TERT CGCAGCGCGGGGACCCGGCGGCTT-TCCGCGCGCTGGTGGCCCAGTGCCTGGT
160 TERT TCTGTGTCCTGCCTGAAGGAGCTGGT-GGCCCGAGTGCTGCAGAGGCTGTGCGAGCGCG
172 WIF1 TCTGTCTAAACGGGAACAGCCCTGGCT-GAGGGAGCTGCAGCGCAGCAGAGTATCTGACGG
CGCC
178 CCM2 CTGGAATTGTCTCGCCATTTAAACGAGTAT-TCCTAAAAGGTGAAAAGAGTAGAGATAAGAAAG
CCCATGAGAAGGT
193 RARB CCGCCGGCTTGTGCGCTCGCT-GCCTGCCTCTCTGGCTGTCTGCTTTTGCAGGGCTGCT
202 MLH3 GCGACCTTGTTCTTCCTTTCCTTCCGA-GAGCTCGAGCAGAGAGGACTGTGATGAGACAGGA
TAACAG
211 TGFBR1 GGCGTTACAGTGTTTCTGCCACCTCT-GTACAAAAGACAATTTTACTTGTGTGACAGATGGGCT
CTGCTTT
220 COL2A1 GCCTCTTCCTTCTACACAGGGTCCTT-CTGGAGACCAAGGTGCTTCTGGTCCTGCTGGTCCTTCT
229 PAH CAGTGCCCTGGTTCCCAAGAA-CCATTCAAGAGCTGGACAGATTTGCCAATCAGATTCTCAG
238 CDKN2A CTGGATCGGCCTCCGACCGTAAC-TATTCGGTGCGTTGGGCAGCGCCCCCGCCTCCAGCAGC
247 PTCH GTGGACAGCTGGGAGGAAATGCTGAA-TAAGGCTGAGGTTGGTCATGGTTACATGGACCGC
CCCT
259 CDKN2A CCAGGGGCACCAGAGGCAGTAACCATG-CCCGCATAGATGCCGCGGAAGGTCCCTCAGA
265 SLC2A1 CTCTGGTCCCTCTCAGTGGCCATCTTTTCT-GTTGGGGGCATGATTGGCTCCTTCTCTGTGGGCC
TTTTCGTTAACC
283 BCL2 GTGAAGCGGTCCCGTGGATAGAGA-TTCATGCCTGTGCCCGCGCGTGTGTGCGCGCGTG
292 PTEN CACCGGAGCGGGCGCAGGAGA-GGCCTGCGGGGTGCGTCCCACTCACAGGGAT
301 ESR1 GCTCGCGTGTCGGCGGGACAT-GCGCTGCGTCGCCTCTAACCTCGGGCTGTGCTCTTTTTCC
310 DBC1 CTGGAGGTTTGTTGAGCTCCTCTACT-TCCTGTTTATATGGGGCCGTATCTCAGTGCAGCCC
319 TIMP3 CATCGTGCTCCTGGGCAGCTGGA-GCCTGGGGGACTGGGGCGCCGAGGCGTGCACA
328 KRIT1 TGGTCTAGGAGCTCCAGACTACTCAAAAAT-CCAAATACCTAAACAGGAAAAATGGCAGAGAA
GCATGAGCAGT
337 CDH1 CTATGAAGGAAGCGGTTCCGAAGCTGCTA-GTCTGAGCTCCCTGAACTCCTCAGAGTCAGAC
AAAGACCAGGAC
346 TNFRSF25 CTGAAGGCGGAACCACGACGGGCA-GAGAGCACGGAGCCGGGAAGCCCCTGGGCGCCCG
355 TGFBR1 GAGAATGTTGGTATGCCAATGGAGCA-GCTAGGCTTACAGCATTGCGGATTAAGAAAACATTA
TCGCA
364 DBC1 TCACTTCCTGACCATCGGAAGCATCCA-TCAGCACTGGGGCAATGACTGGGACCTGCAGA
375 ESR1 CCAGCCCGCCGTGTACAACTACCCCG-AGGGCGCCGCCTACGAGTTCAACGCCGCGGC
382 PTCH GATAAGAGCTCCGGGGGGATTCTTCA-TGCACCAGTGTTTAGGGTACGTGCTTCCTAAGTAAAT
CCAAACATTG
391 CDKN2A GCTCTTCCGCCAGCACCGGAGGAA-GAAAGAGGAGGGGCTGGCTGGTCACCAGAGGGTG
400 TIMP3 CCAGCGCTATATCACTCGGCCGCCCA-GGCAGCGGCGCAGAGCGGGCAGCAGGCAG
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Supplementary table 5.5: Probe sequences MS-MLPA kit ME014 (continued)
409 EDNRB CCAAGTTTCCCACTGGCGCGCAA-ACTTGAGTTACTTTTGAGCGTGGATACTGGCGAAGAGG
CTG
418 TERT CCAGAGTTTCAGGCAGCGCTGCGTCCT-GCTGCGCACGTGGGAAGCCCTGGCCCCGGCC
427 APAF1 CCATTCATGCTTGTTTTGTTTTGGATTTTAGTAAGGACA-GTCCTGTGTGAAGGTGGAGTACCACA
GAGGCCAGTTGTTTTTG
436 CDH13 GTTCTGTGCGTTCTCCTGTCCCAG-GTAGGGAAGAGGGGCTGCCGGGCGCGCTCTG
445 DBC1 GCAGTCACTCCTCTACTGTAATGAGAATGGGTT-TTGGGGAACCTTCCTGGAGAGCCAGCGGA
GCTGCGTG
454 APC CTCAGCTGTGTAATCCGCTGGATGCGGACC-AGGGCGCTCCCCATTCCCGTCGGGAGCCCGC
463 WIF1 CCTGCAAATAGAGCGAGAACAGAAGAGCGGGA-
AGGGCTGGCGCGAGCGAGGTGCGAGCGAGGAG
472 CDH1 CTGAGGAGCGGAGCGGCCTGGAA-GCCTCGCGCGCTCCGGACCCCCCAGTGATGGGAGT
481 RARB CCACATGTGCTTTTTCTGGAGTGGAAAAATACATA-AGTTATAAGGAATTTAACAGACAGAAAGG
CGCACAGAGGAATTT
The Hha1 sites are marked in grey.
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aBstraCt
Objective | Non-muscle invasive bladder cancer (NMIBC) accounts for 75-85% of all bladder 
cancer (BC). Recurrence develop in up to 70% and hence patients are followed with cystoscopy 
which has a sensitivity around 70%. A sensitive urine test would allow a reduction of these 
invasive endoscopic examinations. The aim of this study is to investigate the effect of combina-
tion of three urine assays for the detection of recurrent disease during the follow-up of patients 
with primary NMIBC.
Material and methods | This large prospective study comprised 1109 patients from four large 
European hospitals. Patients presenting with an initial tumor or in follow-up for BC were included 
from 2007 to 2012. Urine samples (n=2711) were collected prior to cystoscopy during regular 
follow-up visits. Marker performance was calculated for detection of concomitant recurrence. 
Anticipatory effect of urine analysis was visualized by Kaplan-Meijer curves.
results | The combination of FGFR3, TERT and OTX urine analysis detected 57% of the recurrent 
tumors from patients with primary low-grade NMIBC. Sensitivity was 83% for recurrences that 
were grade 3 and/or ≥pT1 in this group. Sensitivity for recurrence detection in patients with 
primary high-grade disease was 72%. In addition, 76% of the positive urine samples were 
followed by a recurrence within 5 years. Most high stage recurrences were identified within 1 
year after a positive urine sample. A limitation was the relatively small amount of urine samples 
that could be analyzed for TERT analysis.
Conclusions | The combination of assays increased recurrence detection in primary NMIBC 
patients and most aggressive tumors were identified. Furthermore, we observed that a positive 
urine assay was frequently followed by a recurrence. This study supports the value of urine 
analysis as an alternative for cystoscopies in patients with LG-NMIBC and as a valuable addition 
to the surveillance of patients presenting with HG tumors.
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INtrODuCtION
Around 75%-85% of all patients presenting with bladder cancer will have non-muscle invasive 
disease (NMIBC).1 Although the overall prognosis of NMIBC is favorable, these tumors tend 
to recur, with a 5-years recurrence rate ranging from 31-78%. Furthermore, there is a 1-17% 
chance of progression to muscle invasive disease, which is associated with a worse prognosis.1 
Since the high recurrence rate and the risk of disease progression, patients with NMIBC will be 
followed extensively by cystoscopy as defined by the guidelines of the European Association of 
Urology.2 Cystoscopy is the gold standard for the detection of recurrent disease. Yet, the detec-
tion rate of white light cystoscopy is not optimal, with an estimated sensitivity varying between 
46% and 80%.3 Moreover, the procedure is expensive and invasive and causes discomfort.4 In 
addition to cystoscopy, cytology is still frequently used, even though the additional value for the 
detection of low-grade tumors is poor.5, 6
Many studies have been performed searching for sensitive urine markers to detect NMIBC. 
Currently, none of the newly investigated markers are thought to be sufficiently sensitive to 
adjust the follow-up protocol. In addition, in many studies markers were tested on a mixture of 
urine samples derived from patients with an initial tumor and patients presenting with recurrent 
disease. Primary tumors are mostly larger in size and less differentiated than the recurrent tumor, 
causing more spilling of tumor cells, resulting in high marker sensitivity. When testing the marker 
in patients under surveillance sensitivity drop significantly.7 Likewise, high-grade tumors are 
more likely to shed tumor cells compared to low-grade tumors and therefore the sensitivity will 
be much higher when investigating both low grade and high-grade tumors together compared 
to low-grade tumors alone.
We previously showed that the sensitivity of recurrence detection can be improved by combin-
ing several urine assays.8 In this study we investigated three urine assays that showed their ability 
of recurrence detection in previous studies i.e. the FGFR3 mutation assay, the TERT mutation 
assay, and the OTX1 methylation assay. FGFR3 mutations are present in approximately 70% of 
all NMIBC. Since these mutations are tumor specific, FGFR3 mutation analysis proved to be an 
excellent marker for urine follow-up in patients with a primary FGFR3 mutant tumor.8-10 We 
recently showed that 70-80% of BCs harboured a TERT mutation and TERT mutation analysis 
in urine reached a sensitivity of 42% for recurrence detection.11 The combination of FGFR3 
and TERT urine analysis improved the sensitivity to 50%. A methylation assay was recently 
developed by Kandimalla et al and contained probes for CpG-islands of three different genes, 
i.e. ONECUT2, OTX1 and OSR1. This urinary assay reached a sensitivity of 74% for recurrence 
detection. OTX1 was the best performing marker with a sensitivity of 65%.12
All three assays were studied in small patients series. This is the first study on urinary bio-
markers involving a large prospective European patient cohort. The objective was to improve 
recurrence detection by combining the three promising assays, with the main focus on patients 
in follow-up for primary low-grade NMIBC. Furthermore, we aimed to elucidate the longitudinal 
effect of urine analysis.
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MaterIal aND MethODs
Patient and tissue collection
Between January 2007 and July 2012, patients treated for primary or recurrent bladder cancer 
were included from four different European hospitals i.e. Aarhus University Hospital, Aarhus, 
Denmark, Academic Hospital, Uppsala, Sweden, Centro Nacional de Investigaciones Oncológicas 
(CNIO) Madrid, Spain, and Erasmus Medical Centre, Rotterdam, The Netherlands. Patients from 
the Netherlands were checked in the opting-out system and tumor tissue and urine samples were 
used according according to the code of secondary use of human tissue (www.federa.nl). In-
formed written consent was obtained from all patients of the other hospitals. Research protocols 
were approved by the institutional review boards or ethical committees in all involved countries.
Urine samples were collected prior to cystoscopy during regular follow-up visits. Cells were 
sedimented by centrifugation within 12 hours after collection and frozen at -80ºC until further 
processing. Tumor biopsies were collected in TissueTEK O.C.T and immediately frozen at -80ºC. 
All tumors were histologically proven. A tumor found within 14 days after urine collection was 
defined as a concomitant tumor. Urine samples taken within 35 days after the previous urine 
sample were labeled as double and censured for data analysis. We distinguished a group of low-
grade NMIBC (LG-NMIBC) that included patients with primary grade 1, grade 2, PUNLMP and 
low-grade BC and a group of high-grade NMIBC (HG-NMIBC) including patients with primary 
grade 3 and high-grade disease.
DNa Isolation and Molecular analyses
DNA from urine cell pellets was extracted by using the QIAamp mini and Blood kit (Qiagen, 
Venlo, The Netherlands) according to manufacturer’s protocol and tumor DNA was extracted by 
using the DNeasy® Blood and Tissue Kit. The FGFR3 mutation analysis, TERT mutation analysis 
and methylation analysis were performed as described previously.9, 12-15. More details about 
experiment conditions, primer and probe sequences are given in the supplementary data.
Although we initially used five methylation markers we soon decided that this was unrealistic 
given the low amount of DNA available in many urine samples. Considering the results of Kandi-
malla et al, we decided to use only the marker for OTX1.12 Based on our recent finding of TERT 
mutations in BC, we then assayed the samples with sufficient DNA left for the TERT mutation.11 
90% of the urine samples yielded more than 25ng DNA, which is required to perform all three 
assays.
Data analysis
GeneMarker Software version 1.7 (SoftGenetics, State College) was used for the analysis of the 
SnaPshot data. Methylation percentage was calculated by dividing the height of the methylated 
peak by the sum of the height of the methylated and unmethylated peak multiplied by 100. Only 
methylation of OTX1 was used for further data analysis. The determined cut-off value of 13.44 
for the methylation percentage of OTX1 allowed 20% false positives in the recurrent NMIBC 
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patients (80% specificity). TERT and FGFR3 analysis were considered positive in case a mutant 
peak was present. For analysis of the combined marker sensitivity, a urine sample was marked 
positive when all assays were performed and at least one of the tested markers was positive.
T-test was used to calculate the difference in means and Chi-square test was used to com-
pare sample distribution. KM-curves were used the present the anticipatory effect of the urine 
analysis. All statistical analyses were performed using the Statistical Package for Social Sciences 
version 22 (SPSS, Chicago).
results
Patients and urine samples
Between January 2007 and July 2012 a total of 2711 urine samples were collected from 1109 
patients, comprising 858 (77%) males and 251 (23%) females. Patient and tumor characteristics 
are depicted in table 6.1. Sixty-five percent (720/1109) initially presented with LG-NMIBC. As 
Table 6.1: Clinical and tumor characteristics of 977 patients included with primary NMIBC.
 Denmark 
(n=519)
Netherlands 
(n=231)
sweden 
(n=103)
spain 
(n=124)
total 
(n=977)
Median age at primary tumor (yrs) 65 65 69 70 66
Median fuP (yrs) 6,3 5,1 5,2 0,0 5,1
Gender Male 393 (74%) 181 (78%) 78 (76%) 114 (92%) 766 (78%)
Female 126 (26%) 50 (22%) 25 (24%) 10 (8%) 211 (22%)
stage primary tumor Ta 394 (76%) 175 (76%) 67 (65%) 91 (73%) 727 (74%)
T1 125 (24%) 51 (22%) 34 (33%) 28 (23%) 238 (24%)
Tis - 5 (2%) 2 (2%) 5 (4%) 12 (1%)
Missing - - -
Grade primary tumor G0 8 (2%) - - 8 (1%)
G1 82 (16%) 69 (30%) 26 (25%) 50 (40%) 227 (23%)
G2 282 (54%) 119 (52%) 47 (44%) 28 (23%) 476 (49%)
G3 139 (27%) 38 (16%) 25 (24%) 40 (32%) 242 (25%)
G4 2 - 1 - 3
PUNLMP - 1 - - 1
LG 5 (1%) - 1 1 (1%) 7 (1%)
HG - - 1 - 1
CIS - 5 (2%) 2 (2%) 5 (4%) 12 (1%)
# concomitant recurrences LG- NMIBC 251 101 81 18 451
HG-NMIBC 79 17 24 7 127
# urines FUP - LGNMIBC 1029 477 182 18 1706
Primary - LGNMIBC 71 64 28 61 224
FUP - HGNMIBC 352 56 70 7 485
 Primary - HGNMIBC 20 16 7 38 81
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shown in fi gure 6.1, we collected a total of 1930 urine samples from these patients. 23% 
(257/1109) of the patients were included with primary HG-NMIBC, with a total of 566 urine 
samples collected. Cytology data was available in 42% (1144/2713).
the diagnostic value of a combination of urine markers in the follow-up of 
NMIBC patients
HTERT mutation analysis reached highest sensitivity of 45% (147/324) for recurrence detection 
in patients with primary low-grade NMIBC, compared to 27% (107/403) for FGFR3 mutation 
analysis and 38% (143/373/365) for OTX1 methylation analysis. Urine cytology detected only 
18% (21/114) of all recurrent tumors. Specifi city for all three individual tests was relatively high: 
FGFR3 91% (1011/1113), OTX1 81% (800/993) and HTERT 70% (543/777). Combination of 
the three assays increased recurrence detection to 57% (163/285) with a specifi city of 59% 
(392/668). All numbers are shown in Figure 6.2a. Most tumors missed by the combination of 
three assays were low stage and low grade i.e. 45% of the Ta tumors and 49% and 43% of 
grade 1 and 2 tumors (Table 6.2). On the other hand, most aggressive tumors were detected by 
urine analysis with the three-assay combination, i.e. 88% of the T1, 77% of the T2-4 tumors 
and 83% of the grade 3 tumors.
Analysis of urine samples collected during follow-up visits from patients with primary high-
grade NMIBC (HG-NMIBC) revealed a higher rate of tumor detection for all markers and combi-
nation of markers, with the exception of FGFR3, refl ecting the low percentage of mutations in 
Figure 6.1 Number of included patients and corresponding urine samples
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these tumors.13 The 3-assay combination identified 72% (70/97) of all recurrences (Figure 6.2b). 
Again sensitivity increased with higher stage and grade of the recurrences (Table 6.3).
In order to get a realistic view of marker sensitivity we stratified patients based on the mo-
lecular analysis of tumor DNA. There was tumor DNA available in 342 NMIBC patients: 239 
LG-NMIBC and 103 HG-NMIBC. FGFR3 and TERT mutations were found in 69% and 77% of 
LG-NMIBC and in 26% and 58% of HG-NMIBC, respectively. 88% of the LG-NMIBC and 67% 
of the HG-NMIBC was mutant for either FGFR3 or TERT. OTX methylation was observed in 
93% of LG-NMIBC and 91% of HG-NMIBC. A total of 176 tumors were analyzed for all three 
assays of which 4 (2%) tumors did not harbor any alteration, 29 (16%) had one mutation or 
methylation, two aberrations were found in 71 (41%) tumors and all three were present in 
72 (41%). Stratification was based on the molecular status of the analyzed tumor, assuming 
that the molecular make-up of the recurrent tumors was similar. This resulted in an improve-
ment of sensitivity for all markers. In 44% (52/117) of the LG-NMIBC patients with a FGFR3 
mutant tumor, the recurrence was detected by FGFR3 urine analysis (Figure 6.2a). Likewise, 45% 
Figure 6.2 Marker performance for recurrence detection in patients with primary (A) low-grade and (B) high-
grade NMIBC: unstratified and stratified. F=FGFR3 analysis, T=TERT analysis, O=OTX1 analysis, C=cytology.
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(72/160) of the recurrences were detected by OTX1 methylation analysis in patients with tumor 
methylation of the OTX1 gene. Stratification based on the molecular status of the tumor was 
most beneficial in patients with primary LG-NMIBC and a TERT mutation. In these patients the 
rate of recurrence detection by HTERT urine analysis increased from 46 to 68%. Stratification 
based on all three markers slightly increased the sensitivity for recurrence detection in patients 
Table 6.2a: Tumor stage of detected and missed recurrences from patients with primary low-grade NMIBC by 
the combination of FGFR3, TERT, and OTX1 analysis.
 ta t1 t2-4 tx ptis total
all negative 102 2 3 12 3 122
 44,9% 12,5% 23,1% 50,0% 60,0% 42,8%
≥1 positive 125 14 10 12 2 163
 55,1% 87,5% 76,9% 50,0% 40,0% 57,2%
total 227 16 13 24 5 285
Table 6.2b: Tumor grade of detected and missed recurrences from patients with primary low-grade NMIBC 
by the combination of FGFR3, TERT, and OTX1 analysis.
 G1 G2 G3 Gx PUNLMP LG HG CIS Total
all negative 32 23 3 11 8 35 7 3 122
 49,2% 42,6% 16,7% 44,0% 72,7% 37,2% 50,0% 75,0% 42,8%
≥1 positive 33 31 15 14 3 59 7 1 163
 50,8% 57,4% 83,3% 56,0% 27,3% 62,8% 50,0% 25,0% 57,2%
total 65 54 18 25 11 94 14 4 285
Table 6.3a: Tumor stage of detected and missed recurrences from patients with primary high-grade NMIBC by 
the combination of FGFR3, TERT, and OTX1 analysis.
 ta t1 t2-4 tx ptis total
all negative 12 7 4 3 1 27
 30,8% 31,8% 28,6% 30,0% 8,3% 27,8%
≥1 positive 27 15 10 7 11 70
 69,2% 68,2% 71,4% 70,0% 91,7% 72,2%
total 39 22 14 10 12 97
Table 6.3b: Tumor grade of detected and missed recurrences from patients with primary high-grade NMIBC 
by the combination of FGFR3, TERT, and OTX1 analysis.
 G1 G2 G3 Gx PUNLMP LG HG CIS Total
all negative 1 2 4 0 6 9 4 1 27
 20,0% 22,2% 17,4% 0,0% 50,0% 52,9% 22,2% 8,3% 27,8%
≥1 positive 4 7 19 1 6 8 14 11 70
 80,0% 77,8% 82,6% 100,0% 50,0% 47,1% 77,8% 91,7% 72,2%
total 5 9 23 1 12 17 18 12 97
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with primary LG-NMIBC from 57% to 62%. This was to be expected because one of the three 
markers is altered in 98% of the tumors. Similar stratification results were found in patients with 
a primary HG-NMIBC (Figure 6.2b). We conclude that stratification increases sensitivity for the 
individual markers but not much for the combination (Figure 6.2).
Next, we investigated whether there was a difference in marker performance between males 
and females. Interestingly, a significantly higher sensitivity for all (combination of) markers was 
observed in male compared to female LG-NMIBC patients, except for OTX (p=0.168). The 3-as-
say combination detected 63% of the recurrences from the male patients, compared to 44% of 
the recurrent tumors from the female patients (p=0.003) (Figure 6.3a). A possible explanation 
for these findings is the presence of more normal cells, such as vaginal cells, in urine from 
women. To support this hypothesis, we analyzed urine DNA yield as a surrogate for the number 
of cells and we indeed found significantly higher DNA concentrations in urine samples from 
female patients compared to male patients (15.5ng/μl vs. 11.4ng/μl, p<0.001). Differences 
in marker performance between males and females were less pronounced in the HG-NMIBC 
patients (Figure 6.3b) and although urine from females yielded more DNA, this difference in 
DNA concentration was not significant (19.35ng/μl vs. 15.25ng/μl, p=0.083).
Figure 6.3 Marker performance for recurrence detection in patients with primary (A) low-grade and (B) high-
grade NMIBC: Male vs. Female. F=FGFR3 analysis, T=TERT analysis, O=OTX1 analysis.
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In total 318 urine samples collected at first diagnosis were available for analysis. This included 
230 samples associated with a primary LG-NMIBC and 87 samples with a HG-NMIBC. For all 
three assays, the sensitivity for detection of a primary HG-NMIBC or LG-NMIBC was much higher 
compared to the sensitivity for recurrence detection. The combination of three assays detected 
81% (113/140) of all primary LG-NMIBC and 94% (61/65) of the primary HG-NMIBC. Again, 
detection rate increased with higher stage and grade of the primary tumor (supplementary 
table 6.4 and 6.5).
Overall, relatively high false-positives rates were observed for concomitant recurrence detec-
tion. We believe this is partly due to the anticipatory effect of urine analysis, meaning that the 
urinary assay detects the tumor before it is visible by cystoscopy. To show this effect, every 
first positive follow-up urine sample of a patient was selected and plotted against time to next 
recurrence. Importantly, 86% of the FGFR3-positive urine samples were followed by a recur-
rence within 5 years (Figure 6.4a). Likewise, in 78% of the urines samples positive for the TERT 
mutation a recurrence occurred within a period of 5 years and in 76% of the urine samples 
positive for the 3-assay combination (Figure 6.4b and 6.4c). Subsequently, we investigated how 
recurrences of different stages were detected in time after a positive urine test. Interestingly, 
high stage recurrences were mostly identified within the first year after urine analysis, whereas 
stage Ta recurrences were continuing to be observed for a long time after a positive urine test. 
These findings underline the additional value of urinary markers for earlier detection of high-risk 
tumors.
Figure 6.4 Positive urine samples followed by recurrence over time: 86% of all FGFR3 positive samples(A), 78% 
of all TERT positive samples (B), and 76% of all urine samples positive for FGFR3 mutation and/or TERT mutation 
and/or OTX methylation (C) were followed by recurrence within 5 years.
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DIsCussION
In this study we evaluated the performance of three assays for the detection of recurrent BC 
in voided urine, i.e. FGFR3 mutation analysis, TERT mutation analysis and the OTX methylation 
assay, especially in patients with primary low-grade disease. Previously, these assays proved to be 
sensitive for the detection of recurrent bladder tumors in smaller patient series.9, 15, 16 This is the 
first study on urine analysis involving a large multicenter prospective European patient cohort.
All assays were superior to urine cytology for recurrence detection in patients with primary 
LG-NMIBC. Combination of the three assays improved the recurrence detection rate to 57%. 
Overall, most of the aggressive recurrences in patients with a primary LG-NMIBC were detected 
by this combination with a sensitivity of 77% for MI recurrences, and 83% for G3. Remarkably, 
we found higher marker performance in male patients with primary LG-NMIBC compared to fe-
male patients, suggesting the disturbing influence of the high amount of benign cells in female 
urine. This difference was not observed in the HG-NMIBC patients. This could be due to the 
higher amount of tumor cells shed into urine in the high-grade tumors, leading to less disturbing 
influence of the benign cells. Furthermore, we showed that almost all positive urine samples 
were followed by a recurrence over time and all high-stage recurrence were identified within 1 
year of follow-up. We believe that this is a very important finding, since it could contribute to 
earlier detection of aggressive tumors.
FGFR3 mutation analysis after stratification based on the mutation status of analyzed tumor 
resulted in lower marker sensitivity compared to previous studies.9, 17 This could be caused by the 
larger prospective patient population with a higher amount of LG-NMIBC recurrences. Overall 
sensitivity of 46% for the combination of FGFR3 and TERT mutation analysis for the detection of 
recurrences in primary LG-NMIBC patients was similar to previously reported data.15 Previously, 
Kandimalla et al reported a sensitivity of 65% for the OTX methylation analysis with a specificity 
of 90%.16 The negative controls included in that study were collected from healthy men. In our 
study, all samples were derived from patients with a history of bladder cancer. We observed 
that, in patients of the current study that already had bladder cancer, a higher background of 
methylation was measured. Therefore, we decided to use a higher cut-off for the methylation 
ratio of OTX allowing 20% false-positives. Subsequently, this resulted in a lower sensitivity than 
reported previously. The three-assay combination was significantly better for the detection of 
recurrences in patients with primary HG-NMIBC compared to patients with primary LG-NMIBC 
(sensitivity 72% vs. 57%, p=0.009). Likewise, higher detection rates were observed in urine 
samples collected prior the resection of the initial tumor compared to follow-up urine samples. 
This again emphasizes the difficulties in the development of a sensitive urine test for the detec-
tion of low-grade recurrences. As previously mentioned, these tumors are mostly smaller in size 
compared to the original primary tumor. Small tumor size together with low tumor grade will 
result in a reduced shedding of tumor cells. Therefore, the amount of tumor DNA is often below 
the analytical threshold leading to false-negative test outcomes. Multiple urine testing could 
minimize this problem as shown in a previous study.18
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Overall, specificity of the combination of three assays was relatively low. Several reasons could 
be given for the high false-positive rate of urine analyses. First, often not realized, the diagnostic 
ability of the cystoscopy is not flawless. Up to 29% of the Ta tumors and 25% of the T1 tumors 
are missed by white-light cystoscopy.3 Therefore, in several patients with ‘false-positive’ urine 
samples there could have been a tumor present, yet it was missed by cystoscopy. Secondly, posi-
tive urine assays are often followed by a positive cystoscopy later in time, the so-called anticipa-
tory effect. The specificity of FGFR3 mutation analysis is generally considered to be 100%, since 
these mutations are only found in sufficient amounts in tumor cells.19 We showed that 86% of 
the FGFR3 positive urine samples were followed by a recurrence within 5 years. Likewise, we 
found that 76% of the urine samples positive for the 3-assay combination were associated with 
a recurrence within 5 years. Thirdly, small recurrences are often coagulated without collecting 
tissue for pathological examine. Since we defined recurrence as a histologically proven tumor, 
we did not include these coagulated recurrences in the data analysis. Finally, a small proportion 
of recurrences will appear as upper urinary tract tumor that are be missed by cystoscopy. This 
data was not available in this study. in the data analysis.
Strengths of the study include the multicenter prospective character and the analysis of a 
substantial number of follow-up urine samples, including multiple samples per patient. One of 
the limitations was the low number of urine samples that could be analyzed for TERT mutations, 
since the study had already started when this assay was under construction.
CONClusIONs
This is the first study on urine analysis in mainly LG-NMIBC patients including a large prospec-
tive European multicenter patient cohort. We showed that a combination of urinary assays 
increased sensitivity for recurrence detection in low-risk patients and assume that sensitivity 
will further increase by testing of multiple urine samples per patient. The combination detected 
most concomitant aggressive tumors. Furthermore, we observed that a positive urine assay was 
almost always followed by a recurrence. This study supports the value of urine analysis as an 
alternative for cystoscopies in patients with LG-NMIBC and as a valuable addition to the surveil-
lance of patients presenting with HG tumors. Next step in investigating the role of urine analyses 
in the follow-up of NMIBC patients would be a randomized control trial, which is currently in 
progress. As future perspective, we advocate a urine first-strategy, meaning that the analysis of 
urine samples will reduce the number of cystoscopies, since only a positive urine test will be fol-
lowed by cystoscopy. This will be mostly relevant for patients with low-risk Ta-tumors, especially 
because the sensitivity of cystoscopy is relatively low for the detection of these Ta-tumors.
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suPPleMeNtary fIles
fGfr3 mutation analysis
The FGFR3 analysis was performed as described previously by van Oers et al.1 The FGFR3 assay 
consists of a multiplex PCR comprising the three regions with most frequent mutations, i.e. Exon 
7 (R248C and S249C), exon 10 (G372C, S737C, Y375C, G382R and A393E) and 15 (K652M, 
K652T, K652E K652Q). Primers sequences are depicted in supplementary table 6.1a. PCR was 
carried out in 15μl containing 5ng of DNA, 1x GO-Taq PCR buffer (Promega), 1.5mmol/l MgCl2, 
0.17mmol/l deoxynucleotide triphosphates (Roche), 1.0 unit Taq polymerase (Promega), 5% 
Glycerol (Fluka), 18 pmol of exon 7 primers and 10 pmol of exon 10 and 15 primers. PCR 
Cycling started at 95°C for 3 minutes followed by 40 cycles at 95°C for 15 seconds, 55°C for 15 
seconds and 72°C for 2 seconds. Next, samples stayed at 72°C for 10 minutes. The PCR product 
was treated with 3 units of shrimp alkaline phosphatase (Amersham bioscience) and 2 units of 
exonuclease-! (Amersham bioscience) and incubated for 60 minutes at 37°C followed by 15 
minutes at 72°C, in order to remove the overload of primers and deoxynucleotide triphosphates. 
This was followed by a single-nucleotide probe extension assay using the SNaPshot Multiplex 
kit (Applied Biosystems) in combination with probes that anneal directly next to investigating 
mutation site. Different lengths of T-tail were attached to the probes at their 5’ end allowing 
separation of the products based on size. Probe sequences and concentrations are given in 
supplementary table 6.1b. The SNaPshot reaction was carried out in a total volume of 10μl 
comprising 1μl of PCR product, 2.5μl of the SNaPshot ready mix, 2μl of the 5x sequence buffer, 
and 1μl of the probemix. Thermal cycling conditions were 35 cycles of 10 seconds at 96°C, 
followed by 40 seconds at 58.5°C. As final step the SNaPshot product was treated with 1 
unit of shrimp alkaline phosphatase to remove the excess of dideoxynucleotide triphosphates 
(ddNTPs). The final product was separated on an automatic sequencer (ABI PRISM 3130 XL 
Genetic Analyzer, Applied Biosystems) with the fluorescent label on the incorporated ddNTP 
indicating the absence or presence of a mutation.
tert mutation analysis
The TERT mutation analysis was performed as described previously by Allory et al.2 and is 
similar to the FGFR3 mutation analysis. The PCR covered the two most frequent mutation sites 
(G228A/T and G250A). Primer and probe sequences are given in supplementary table 6.2. All 
experimental conditions were equal to the FGFR3 analysis.
Methylation analysis
Methylation analysis, also known as the Bisulphite Specific-SnaPhot, was done as described by 
Kandimalla et al.3 The assay includes bisulphite conversion of the genomic DNA (EZ DNA meth-
ylation gold kit, Zymo Research Corp). The following steps are similar to the mutation analyses 
and involve amplification of the region with the CpG island from the gene of interest and single 
nucleotide probe extension using the SNaPshot Multiplex kit. Primer and probe sequences are 
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given in supplementary table 6.3. The fluorescent label on the incorporated ddNTP indicated the 
presence or absence of a methylation of the investigated CpG.
Supplementary table 6.1a: primer sequences and conditions FGFR3 mutation analysis
Primer sequence (5’->3’) Product size (bp) pmol per reaction
FGFR3 RI Fw AGTGGCGGTGGTGGTGAGGGAG 115 18
FGFR3 RI Rev GCACCGCCGTCTGGTTGG 18
FGFR3 RII Fw CAACGCCCATGTCTTTGCAG 138 10
FGFR3 RII Rev AGGCGGCAGAGCGTCACAG 10
FGFR3 RIII Fw GACCGAGGACAACGTGATG 160 10
FGFR3 RIII Rev GTGTGGGAAGGCGGTGTTG  10
Supplementary table 6.1b: probe sequences and conditions FGFR3 mutation analysis
Probe sequence (5’-> 3’) size (bp) strand Wt Mt
pmol per 
reaction
S373C T19 GAGGATGCCTGCATACACAC 39 sense t a 2
K652M/T T20 CACAACCTCGACTACTACAAGA 42 sense a t/C 7
G372C T29 GGTGGAGGCTGACGAGGCG 48 sense G t 2
A393E T34 CCTGTTCATCCTGGTGGTGG 54 sense C a 10
R248C T46 CGTCATCTGCCCCCACAGAG 66 sense C t 8
Y375C T43 ACGAGGCGGGCAGTGTGT 61 sense a G 10
S249C T36TCTGCCCCCACAGAGCGCT 55 sense C G 4
K652Q/E T50 GCACAACCTCGACTACTACAAG 72 antisense a C/G 3
G382R T56 GAACAGGAAGAAGCCCACACC 76 antisense C t 6
Supplementary table 6.2a: primer sequences and conditions hTERT mutation analysis
Primer sequence (5’->3’) Product size (bp) pmol per reaction
hTERT Fw AGCGCTGCCTGAAACTCG 155 10
hTERT Rev CCCTTCACCTTCCAGCTC  10
Supplementary table 6.2b: probe sequences hTERT mutation analysis
Probe sequence (5’->3’) size (bp) strand Wt Mt
pmol per 
reaction
hTERT 1295228 T20 GGCTGGGAGGGCCCGGA 37 sense G a/t 10
hTERT 1295242 T27 GGAGGGGGCTGGGCCGG 44 sense G a 5
hTERT 1295250 T39 CTGGGCCGGGGACCCGG 56 sense G a 15
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Supplementary table 6.3: primer sequences and conditions OTX methylation analysis
Primer/probe
sequence (5’->3’)
Product size 
(bp) Meth unmeth
pmol per 
reaction
OTX1 Fw TTTTGAGAGGTATAGAGAGGGGTAGT 172 10
OTX1 Rv CCCCTAACAAACCCAAATCTC
SNaPshot probe OTX1 TTTATTTGTGGTTTTTTAGGTT 23 C t 5
Supplementary table 6.4: Tumor stage of detected and missed primary tumors from patients with primary 
low-grade NMIBC by the combination of FGFR3, TERT, and OTX1 analysis.
 ta t1 total
all negative 25 2 27
 19,8% 14,3% 19,3%
at least 1 positive 101 12 113
 80,2% 85,7% 80,7%
total 126 14 140
Supplementary table 6.5: Tumor stage of detected and missed primary tumors from patients with primary 
high-grade NMIBC by the combination of FGFR3, TERT, and OTX1 analysis.
 ta t1 tis total
all negative 2 2 0 4
 9,5% 4,9% 0,0% 6,2%
at least 1 positive 19 39 3 61
 90,5% 95,1% 100,0% 93,8%
total 21 41 3 65
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aBstraCt
Objective | Patients presenting with painless hematuria form a large part of the urological 
patient population. In many cases, especially in younger patients, the cause of hematuria is 
harmless. Nonetheless, hematuria could be a symptom of malignant disease and hence most 
patients will be subject to cystoscopy. In this study, we aimed to develop a prediction model 
based on methylation markers in combination with clinical variables, in order to stratify patients 
with high risk for bladder cancer.
Material and methods | A total of 169 patients presenting with painless hematuria were 
included. 54 patients were diagnosed with bladder cancer. In the remaining 115 patients, the 
cause of hematuria was non-malignant. Urine samples were collected prior to cystoscopy. Urine 
DNA was analyzed for methylation of OSR1, SIM2, OTX1, MEIS1 and ONECUT2. Methylation 
percentages were calculated and were combined with clinical variables into a logistic regression 
model.
results | Logistic regression analysis based on the five methylation markers, age, gender and 
type of hematuria resulted in an area under the curve (AUC) of 0.88 and an optimism corrected 
AUC of 0.84 after internal validation by bootstrapping. Using a cut-off value of 0.307 allowed 
stratification of patients in a low-risk and high-risk group, resulting in a sensitivity of 82% 
(44/54) and a specificity of 82% (94/115). Most aggressive tumors were found in patients in 
the high-risk group. The addition of cytology to the prediction model, improved the AUC from 
0.88 to 0.89, with a sensitivity and specificity of 85% (39/46) and 87% (80/92), retrospectively.
Conclusions | This newly developed prediction model could be a helpful tool in risk stratification 
of patients presenting with painless hematuria. Accurate risk prediction might result in less 
extensive examination of low risk patients and thereby, reducing patient burden and costs. 
Further validation in a large prospective patient cohort is necessary to prove the true clinical 
value of this model.
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INtrODuCtION
Hematuria is one of the most common symptoms in urological practice, as up to 20% of all 
urological visits are for hematuria1. Hematuria in the adult population can have different causes, 
e.g. urinary tract infections, urolithiasis, benign prostate enlargement (BPH), and urologic 
malignancies. A urological cancer is found in approximately 5% of patients presenting with 
microscopic hematuria and in around 20% of patients with macroscopic hematuria2,3. However, 
in up to 60% of the patients no source of bleeding is found. Thus, most important in the 
evaluation of hematuria is the discrimination between a malignant and non-malignant cause. 
As a consequence, patients will be subject to an extensive examination, including cystoscopy, 
cytology and imaging of the upper urinary tract. The sensitivity of cystoscopy for the detection 
of bladder cancer (BC) is high, ranging from 68-83%4,5. Yet, it is an invasive procedure, causing 
pain and discomfort. Cytology has a high specificity, but a poor sensitivity especially for the 
detection of low-grade BC. Therefore cytology is only used in combination with cystoscopy.
The use of molecular markers in the assessment of hematuria could be of importance in 
order to reduce costs and to avoid invasive diagnostic procedures. However, none of the current 
investigated markers have a high enough sensitivity and specificity to accurately distinguish 
between malignant and non-malignant causes.
Recently, we developed a combination of methylation markers for urine-based follow-up of 
bladder cancer patients. The sensitivity of the combination of markers was 74% for the detec-
tion of bladder cancer recurrences6. The aim of the current study is to investigate whether these 
markers could also be used to predict the risk of urothelial cell carcinoma (UCC) in patients 
presenting with painless microscopic and macroscopic hematuria.
MaterIal aND MethODs
Patients and urine samples
In this study, urine samples were included from patients presenting with painless microscopic 
or macroscopic hematuria. All urine samples were retrieved from a sample bank. This sample 
bank contained urine samples that were prospectively collected prior to cystoscopy between 
January 2007 and July 2012 at the Urology outpatient departments of Erasmus MC, Rotterdam 
and Aarhus University Hospital, Denmark. There were 54 urine samples available from which the 
cause of hematuria was malignant. As control group we included 115 hematuria samples with 
a non-malignant cause.
All patients were examined by cystoscopy, computer tomography of the abdomen, and 
renal ultrasound. In addition, urine cytology was performed. Bladder tumors were biopsied 
and confirmed by histology. Urine samples were collected prior cystoscopy and were processed 
within 12-hours after collection. Urine samples were centrifuged for 10 minutes at 2000*g. Cell 
pellets were re-suspended in 1ml PBS and centrifuged for minutes at 3000*g. Supernatant was 
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discarded and cell pellets were stored at -80°C until DNA isolation. DNA was extracted using 
the QIAamp mini and Blood kit (Qiagen) according to manufacturer’s protocol. Samples from 
Erasmus MC were used according to the code of secondary use of human tissue (www.federa.
org). All patients were checked in the Erasmus MC opt-out objection system. In case of objec-
tion, patients were excluded from analysis. For minors, parents or caretakers should have filled 
in the statement of objection. Informed written consent was obtained from patients at Aarhus 
University Hospital and the study was approved by the Central Denmark Region Committees on 
Biomedical Research Ethics (1994/2920).
Methylation analysis
Recently, we developed a multiplex methylation assay in order to detect bladder cancer in 
voided urine6. This assay consisted of probes covering CpG-sites in five different genes, namely 
OSR1, OTX1, ONECUT2, MEIS1 and SIM. Methylation analysis was performed using the EZ DNA 
Methylation-Gold™ Kit (Zymo Research Corporation, Irvine, California, USA) according to the 
manufacturer’s protocol. Briefly, DNA was treated with sodium bisulfite, followed by bisulfite-
specific PCR for the five regions of interest. For each PCR reaction a DNA input of 20ng and PCR 
primer concentration of 20 pM was required. After the PCR, a Single Nucleotide Primer Exten-
sion (SNuPE) analysis was performed, using primers that annealed to the PCR product adjacent 
to the cytosine of interest. SNuPE probes were extended with a labeled dideoxynucleotide and 
the products were analyzed on an automatic sequencer (ABI PRISM 3100 Genetic Analyzer, 
Applied Biosystems), with the label indicating the presence or absence of a methylated cytosine. 
See Kandimalla et al for details on the primers and probes used6. For each gene, the methylation 
percentage was calculated by dividing the height of the methylated peak by the sum of the 
height of the methylated and unmethylated peaks multiplied by hundred.
statistical analysis
Statistical analyses were performed using the Statistical Package for Social Sciences 20 (SPSS, 
Chicago) and R statistical Software for Statistical Computing (Vienna).
Univariable and multivariable logistic regression models were used to calculate the association 
between UCC and the predictor variables. The predictive accuracy of the model was determined 
by the area under the curve (AUC). The Bootstrap procedure was used for internal validation of 
the predictive model. P-values <0.05 were considered statistically significant.
results
A total of 169 patients with painless microscopic or macroscopic hematuria were included in 
this study, comprising 104 men and 65 women. The mean age was 59 years (range 17-92). Pa-
tients and tumor characteristics are depicted in Table 7.1. In 54 cases, a bladder tumor was the 
cause of hematuria. In the remaining 115 patients, the cause of hematuria was non-malignant. 
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Patients with UCC were significantly older and presented more frequent with macroscopic 
hematuria compared to patients with a non-malignant cause (p<0.001 and p=0.002). Cytology 
was performed in 81% of the patients. The sensitivity and specificity for cytology were 39% 
and 97, retrospectively.
Methylation analysis was performed for OSR1, SIM2, OTX1, MEIS1 and ONECUT2 and meth-
ylation percentages were calculated. Next, univariable logistic regression analysis was performed 
for the methylation percentages of the five different genes and the clinical variables age, gender, 
type of hematuria and cytology (Table 7.2). OSR1, SIM2, OTX1, MEIS1, ONECUT2, age, type of 
hematuria and cytology were all significant predictors for the presence of UCC. In order to calcu-
late the combined effect, multivariable logistic regression analysis was performed. First a model 
was developed, based on the methylation percentages of the five genes and the clinical variables 
age, gender and type of hematuria. This resulted in an apparent AUC of 0.88 (Figure 7.1). In 
this model age, type of hematuria, ONECUT2, OSR1 and SIM2 were independent predictors 
for the presence of UCC (Table 7.3). After internal validation by bootstrapping, the optimism-
corrected AUC was 0.84. To discriminate between patients at low-risk for UCC vs. patients at 
Table 7.1: Clinical and histopathological characteristics of 169 patients presenting with painless hematuria
hematuria uCC+ hematuria uCC-
n=54 n=115
age Mean (range) 67 (29-92) 55 (17-86)
n (%) n (%)
sex Male 37 (69) 67 (58)
Female 17 (31) 48 (42)
hematuria microscopic 18 (33) 68 (59)
macroscopic 36 (67) 47 (41)
Cytology no tumor cells 28 (52) 89 (77)
tumor cells 18 (33) 3 (3)
not performed 8 (15) 23 (20)
stage Ta 30 (55)
T1 7 (13)
>=T2 13 (24)
Tx 3 (6)
Tis 1 (2)
Grade
WHO1973 G1 6 (11)
G2 11 (20)
G3 19 (35)
Gx 4 (7,5)
WHO2004 Low Grade 10 (19)
  High Grade 4 (7,5)  
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high-risk for UCC, a cut-off value with optimal sensitivity and specificity was determined. Based 
on a cut-off of 0.307, 44/54 of patients with UCC were in the high-risk group, resulting in a 
sensitivity of 82%. 94/115 (82%) of patients without a malignancy were in the low-risk group. 
In figure 7.2, the predictive values are shown according to stage (Fig 7.2A) and grade (Fig 7.2B) 
of the detected tumors. Tumors that were detected in patients in the low-risk group were mostly 
low stage and low grade. However, there was also one patient with a grade 3 tumor. On the 
other hand, all patients with a ≥pT2 tumor were in the high-risk group. In order to determine 
the additional value of cytology, a second model was developed. This model resulted in an AUC 
of 0.89 as shown in table 7.3 and an optimism-corrected AUC of 0.85. Based on a cut-off of 
0.306, the sensitivity and specificity for the second model were 85% (39/46) and 87% (80/92), 
respectively.
Table 7.2: Univariable logistic regression analyses assessing the association between predictors and the pres-
ence of urothelial cell carcinoma
Or 95% CI p value auC
Age (continuous) 1.062 (1.033, 1.092) <0.001 0.72
Gender 0.641 (0.324, 1.270) 0.203 0.55
Type of hematuria 2.894 (1.033, 1.092) 0,002 0,63
Cytology 19.071 (5.229, 69.555) <0.001 0.68
OTX ratio 1.061 (1.031, 1.093) <0.001 0.69
ONECUT ratio 1.096 (1.050, 1.144) <0.001 0.78
OSR ratio 1.072 (1.041, 1.103) <0.001 0.75
SIM ratio 1.043 (1.021, 1.066) <0.001 0.60
MEIS ratio 1.069 (1.034, 1.105) <0.001 0.71
Figure 7.1 ROC of the multivariable model (AUC 0.88)
Urinary markers for patients with hematuria 133
7
Table 7.3: Multivariable logistic regression analyses assessing the association between predictors and the pres-
ence of urothelial cell carcinoma
Multivariable model 1 Or 95% CI p value auC (%)
Age (continuous) 1.047 1.014, 1.081 0.005 88.1
Gender 0.924 0.376, 2.275 0.864
Type of hematuria 3.743 1.521, 9.212 0.004
OTX ratio 1.038 0.936, 1.152 0.478
ONECUT ratio 1.117 1.015, 1.228 0.024
OSR ratio 1.010 1.010, 1.124 0.020
SIM ratio 0.829 0.829, 0.980 0.015
MEIS ratio 0.986 0.919, 1.057 0.686
Multivariable model 2 (including cytology) Or 95% CI p value auC (%)
Age (continuous) 1.032 0.997, 1.069 0.077 89.5
Gender 0.693 0.242, 1.989 0.496
Type of hematuria 2.347 0.866, 6.361 0.094
Cytology 10.956 2.269, 52.918 0.003
OTX ratio 1.053 0.938, 1.181 0.384
ONECUT ratio 1.085 0.981, 1.201 0.113
OSR ratio 1.080 1.018, 1.145 0.010
SIM ratio 0.875 0.786, 0.973 0.014
MEIS ratio 0.988 0.907, 1.076 0.784
Figure 7.2 Scatterplot of risk values for the detection of urothelial cell carcinoma (UCC) in patients presenting 
with painless hematuria: X-axis depicts stage (A) and grade (B) of the resected tumors. Y-axis depicts the risk 
value based on the developed logistic regression model. Patients with risk value > 0.307 were considered at 
high-risk for having UCC. Patients with a risk value < 0.307 were considered at low-risk. Each dot represents 
a urine sample.
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DIsCussION
Painless hematuria is a major problem in urological practice and the distinction between ma-
lignant and non-malignant causes is crucial. In this study, we developed a prediction model 
for the assessment of patients presenting with painless microscopic or macroscopic hematuria. 
With this newly developed model, the urologist will be able to adjust patient examination ac-
cording to patient risk, resulting in a reduction of costs and patients discomfort. Previously, 
the five methylation markers were proven to be sensitive for the detection of recurrent UCC6. 
The methylation assay also appeared highly reproducible between different investigators. In the 
current study, the five markers discriminated with a high sensitivity between patients with and 
those without primary bladder cancer. Addition of the clinical variables age, gender and type of 
hematuria increased the accuracy of the model. Age is one of the greatest risk factors for the 
development of bladder cancer and since men have a 3-4 times higher chance of developing 
UCC compared to women, gender also contributes significantly7. The use of cytology even more 
improved the diagnostic accuracy. Yet, we believe that the use of cytology as diagnostic test 
especially for the detection of low grade tumors is debatable. Therefore, we decided to calculate 
the first prediction model without the addition of cytology. Inclusion of smoking history may 
even improve the predictive value further, since previous studies demonstrated that a history 
of smoking is an important independent predictor in the evaluation of hematuria7-9. However, 
smoking history was unavailable for the patients in this study.
Up to now, multiple studies have been performed on the use of molecular tests in the 
diagnosis of bladder cancer in patients presenting with hematuria and some of these assays 
are already FDA approved10-13. However, due to suboptimal sensitivities and specificities, the 
analyses are mostly performed in addition to cystoscopy. Abogunrin et al. investigated whether 
biomarkers were able to improve the predictive power of a risk model which was based on 
clinical variables14. They considered the additional predictive value of nine different biomarkers 
to the prior predictive probability (PPP) that was based on age and smoking. They concluded 
that the addition of nuclear matrix protein 22 and vascular endothelial growth factor to the PPP 
improved the diagnostic accuracy from 0.76 to 0.90. In another study by Cha et al, the authors 
also combined molecular tests and clinical features into a multivariable regression model in 
order to predict the likelihood of having bladder cancer. They developed a nomogram based 
on the commercially available immunocytology assay (uCyt/ImmunoCyt), in combination with 
conventional cytology and clinical variables, i.e. age, gender, smoker, hematuria (microscopic 
vs. macroscopic)15. The AUC of this multivariable model was 0.904. However, cytology and 
immunocytology are highly dependent on the skills and experience of the pathologist16.
A limitation of the current study was the retrospective design. Since this was not a consecutive 
series of patients, the composition of the patient cohort does not reflect true clinical practice. 
In addition, this model was internally validated by using the bootstrap method17. Therefore 
we suggest this model should be externally validated in a large prospective patient cohort of 
patients presenting with painless microscopic or macroscopic hematuria.
Urinary markers for patients with hematuria 135
7
CONClusIONs
We developed an accurate risk model for the evaluation of patients presenting with painless 
hematuria. Predicting the risk of bladder cancer in these patients could be of great value, result-
ing in less extensive examination of low risk patients and reduction of costs. Further validation 
in a large prospective patient cohort is necessary to prove the true clinical value of this newly 
developed model.
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aBstraCt
Objective | Bladder tumors of patients <20yr have a low incidence of genetic and epigenetic 
aberrations typically found in older patients. One of the most common epigenetic aberrations 
in human malignancies is DNA hypermethylation. Polycomb group (PcG) complexes play an 
important role during lineage choices in embryogenesis and their target genes are 12 times 
more likely to be methylated than non-PcG target genes. We hypothesized that methylation of 
PcG target genes is an early event in urothelial carcinogenesis and thus might be observed in 
young patients.
Material and methods | Patients (n=167) were stratified according to age into four 
groups: <20yr (n=14), 20-40yr (n=48), 40-60yr (n=47) and >60yr (n=58). Five PcG target genes 
identified by Kandimalla et al (MEIS1, ONECUT2, OTX1, PCDH7 and SOX21) were selected for 
methylation analysis. Methylation ratios were calculated by using the unmethylated and methyl-
ated signal. The outcome represented the fraction of methylated cells within one tumor. Genes 
with similar methylation ratios in all age groups were considered as potential bladder cancer 
initiating candidates.
results | Three genes showed higher methylation ratios in tumors from older patients: ONE-
CUT2 (p<0.001), SOX21 (p<0.001) and OTX1 (p<0.001). MEIS1 displayed similar methylation 
ratios in all groups. However the median methylation ratio was low. PCDH7 exhibited similar 
median methylation percentages in all age categories, i.e. <20yr 54%; 20-40yr 59%; 40-60yr 
59%; >60yr 67% (p=0.1).
Conclusions | Tumors from young patients showed less methylation for most markers. PDH7 
showed high methylation ratios in all age categories and could therefore play an important role 
in early urothelial carcinogenesis.
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INtrODuCtION
Bladder cancer (BC) is a disease of the elderly with a peak incidence in the sixth decade of life 
and only 1-2.4% of all cases are under the age of 40.1-3 BC in patients younger than 20 years 
is even more uncommon with reported incidence rates of only 0.1-0.4%.2, 4 Conflicting results 
have been published regarding clinical outcome of these young patients. Some studies have 
observed a similar disease course in both young and older patients,2, 5 while other studies have 
reported a more favorable clinical outcome in younger patients with less recurrences and disease 
progression.1, 6-8 This discrepancy may be caused by the wide variation in the definition of a 
young patient; this ranges from <20 years to <40 years.
Patients with BC <20 years have mainly been described in smaller studies, including case 
reports and therefore bladder carcinogenesis in young patients is not well defined. It is still 
unclear whether BC arising in younger patients proceeds through the same molecular path-
ways as those seen in their older counterparts. Interestingly, tumors of patients <20 years are 
predominantly of low stage and grade with a lack or much lower incidence of epigenetic and 
genetic aberrations typical of bladder cancer in elderly patients.7, 9, 10 Since BC patients <20yr 
seem to be a biologically distinct group, we decided to investigate the underlying mechanism of 
bladder carcinogenesis in young patients.
Genetic and epigenetic aberrations play an important role in the formation of many carcino-
mas. The most common and best characterized epigenetic abnormality in human malignancies 
is DNA hypermethylation. Previous studies have reported polycomb group (PcG) target genes 
to be more frequent targets of aberrant silencing by DNA methylation than non-PcG target 
genes.11-13 These genes are targets for PcG complexes, which are the determining factor in cell 
lineage choices during embryogenesis. These proteins are needed to maintain the correct identi-
ties of stem cells, progenitor cells and differentiated cells. According to current hypotheses, 
deregulated repression of PcG target genes results in the accumulation of a population of cells 
which are not able to respond to differentiation signals, leading to loss of cell identity and 
ultimately to cancer.
Since it has been shown that this aberrant methylation of PcG target genes plays an important 
role in the formation of many carcinomas,14 we hypothesized that PcG target gene hypermeth-
ylation might be an early event in bladder carcinogenesis and that these epigenetic aberrations 
might therefore also be observed in tumors of young patients. In order to define epigenetic 
characteristics more specifically, we divided patients into four different age categories i.e. <20 
years, 20-40 years, 40-60 years and >60 years.
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MaterIal aND MethODs
Patient population and tissue collection
Patients 167 patients were included in this study and were divided according to age into four 
different age categories, i.e. <20 years (n=14), 20-40 years (n=52), 40-60 years (n=47) and >60 
years (n=58). Patients <20yr, treated between 1991 and 2009 for UCC, were retrieved from 
the PALGA-Database (The nationwide registry of histo- and cytopathology in the Netherlands). 
Tissue blocks from patients 20-40yr were collected from the pathological archive of the Leiden 
University Medical Centre, Leiden and from our own archive. Tumors from patients above the 
age of 40 were randomly included from our own pathological archive. These patients were all 
treated between 1990 and 2012. Urines from 35 healthy controls >50yr were retrieved from 
a previous study15 and served as the equivalent of normal urothelium. Tissue for DNA extrac-
tion was obtained by manual dissection from formalin-fixed, paraffin-embedded (FFPE) blocks, 
containing tumor areas that were selected by pathological examination of the corresponding 
histological slides. Tissue slides were deparaffinised with xylene and ethanol and DNA was 
isolated using the DNeasy Tissue kit (Qiagen, Hilden, Germany), according to manufacturers’ 
protocol.
Gene panel selection
Five PcG target genes were selected from the findings of a genome-wide methylation study in 
bladder cancer.16 Genes were selected based on two selection criteria. Firstly, genes with the 
highest average delta beta and beta ratio were selected. The beta-value could be interpreted as 
the percentage methylation at a certain CpG-site. The selected genes had the highest discrep-
ancy in methylation between cancer and urine from healthy controls. Secondly, the genes were 
down-regulated in bladder cancer according to the Oncomine Database™.
Methylation analysis
Methylation analysis was performed using the EZ DNA Methylation-Gold™ Kit (Zymo Research 
Corporation, Irvine, California, USA) according to the manufacturer’s protocol. Briefly, DNA 
was treated with sodium bisulfite, followed by bisulfite-specific PCR for the five regions of 
interest. For each PCR reaction a DNA input of 20ng and a PCR primer concentration of 20 pM 
was required. After PCR, a Single Nucleotide Primer Extension (SNuPE) analysis was performed, 
using primers that annealed to the PCR product adjacent to the cytosine of interest. SNuPE 
probes were extended with a labelled dideoxynucleotide and the products were analyzed on an 
automatic sequencer (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems), with the label in-
dicating the presence or absence of a methylated cytosine. For each gene, the methylation ratio 
was calculated by dividing the height of the methylated peak by the sum of the height of the 
methylated and unmethylated peaks. Primer and probe concentrations are given in table 8.1.
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statistical analysis
Data analysis was performed using the Statistical Package for the Social Sciences 17.0 (SPSS 
Statistics 17.0). The Kruskal-Wallis Test was used to determine the difference in methylation 
ratios between the age groups. Results were considered statistically significant if p<0.05.
results
Patient and tumor characteristics
A total of 167 patients with a primary bladder tumor were included in this study. Patients 
were divided into four different age groups; 14 patients in the group <20yr, 48 patients in 
the group 20-40yr, 47 in the 40-60yr patient group, and 58 patients in the age group >60yr. 
Patient and tumor characteristics are depicted in table 8.2. 130/167 (78%) patients were male. 
Male:female ratio was 3:1 in the highest three age groups. In the youngest age group more 
males were affected than females, with a male:female ratio of 13:1. Tumors in all age groups 
were predominantly of low stage (pTa; 65%) and grade (G1-2; 78%). Tumors in the youngest 
age group were of significantly lower stage and grade compared to the >60yr group (p<0.05).
Gene panel selection
Based on the selection criteria described above (see materials and method), five PcG target 
genes were selected i.e. MEIS1, ONECUT2, OTX1, PCDH7 and SOX21. Beta values of cancer 
Table 8.1: SNuPE primers and probes
BsP primers
MEIS1 GGGTTTTTAGAGGTTAGGGGAA
CAACTAAATAACCAAACCTCTCCTC
ONECUT2 GGGGTTTTTTGTTTTTTGTATTTTT
TCATTTTCAAACTTAAACTTAATCACC
OTX1 TTTTGAGAGGTATAGAGAGGGGTAGT
CCCCTAACAAACCCAAATCTC
PCDH7 TGATTGTTAAGGTGGGAGATATTAA
TATTAACCAAAATATCCCCAAAATC
SOX21 GGTTATTTAGTGTGTGTATATGAGAG
 AAAACCCTTATTTTCTAAAATCTAC      
sNuPe 
probes sequence (5’ > 3’) size (bp) strand uM M μM
MEIS1 T44 GGAGAGGGGGGTTATGATGTTAGG 68 Sense t C 0.2
ONDECUT2 T58 GTTTGGGYGGTTGGGTT 75 Sense t C 0.2
OTX1 T35 ATTTGTGGTTTTTTAGGTT 54 Sense t C 0.2
PCDH7 T18 CCCCATCACAAAAAAATCCAAC 40 Antisense a G 0.2
SOX21 T9 ATATTTAGTTTTGATATTTTT 30 Sense t C 0.2
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DNA in relation to beta values of urine DNA from healthy controls were derived from data from a 
genome-wide methylation study15 and are depicted in Figure 8.1. The selected PcG target genes 
had the highest beta-ratio and delta-beta values; these genes had the highest discrepancy in 
methylation between cancer DNA and urine DNA from healthy controls (Figure 8.1).
Table 8.2: Patient and tumor characteristics (n=167)
<20 yr 20-40 yr 40-60 yr >60 yr total
n (%) n (%) n (%) n (%) n (%)
Gender
Male 13 (93) 37 (77) 37 (79) 44 (76) 131 (78)
Female 1 (7) 11 (23) 10 (21) 14 (24) 36 (22)
stage
pTa 13 (93) 32 (67) 32 (68) 31 (53) 108 (65)
pT1 1 (7) 7 (14) 9 (19) 18 (31) 35 (21)
≥pT2 - 8 (17) 5 (11) 8 (14) 21 (12.5)
pTis - 1 (2) - - 1 (0.5)
pTx - - 1 (2) 1 (2) 2 (1)
Grade
G1 10 (71) 21 (44) 20 (43) 14(24) 65 (39)
G2 4 (29) 13 (27) 18 (38) 30 (52) 65 (39)
G3 - 13 (27) 7 (15) 13 (22) 33 (20)
 Gx - 1 (2) 2 (4) 1 (2) 4 (2)
Figure 8.1 Methylation ratios per gene in bladder cancer compared to urine from healthy controls. Data is 
derived from a genome wide methylation study (Kandimalla et al, Eur Urol, 2011)
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Methylation analysis
Methylation analysis was performed for each selected gene. Since we were looking for an 
initiating event in bladder carcinogenesis, genes with equal methylation ratios in all four age 
groups were of interest. ONCECUT2, OTX1 and SOX21 showed a significant difference in meth-
ylation ratios between the four age groups; ONECUT2 (p<0,001), OTX1 (p<0,001) and SOX21 
(p<0,001). As shown in figure 8.2A and 8.2B ONECUT2 and OTX1 had significantly less meth-
ylation in the <20yr group compared to the three older age groups. SOX21 (figure 8.2C) had 
significantly higher methylation ratios in the >60yr age group compared to the three younger 
age groups. MEIS1 and PCDH7 showed similar methylation ratios in all four age groups, p-value 
0.17 and 0.10 respectively. However the median methylation ratios for MEIS1 were low in all age 
groups (<20yr: 0.06, 20-40yr: 0.24, 40-60yr: 0.06 and >60yr: 0.18, figure 8.2D). PCDH7 showed 
high median methylation ratios in all four age groups as depicted in figure 8.3. Although, the 
median methylation ratio did increase with age, i.e. <20yr: 0.44, 20-40yr: 0.60, 40-60yr: 0.61 
and >60yr: 0.71. We therefore decided to perform additional methylation analysis for PCDH7 in 
35 urine samples from healthy controls (age >50yr). The amount of methylation in the healthy 
controls was significantly less than that in the four patient groups (median 0.22; p<0.001).
Figure 8.2 Methylation ratios by patient age for: (A) ONECUT2 (P<0,001), (B) OTX1 (P<0,001), (C) SOX21 
(P<0,001) and (D) MEIS1 (P=0,17). Boxplots indicate 25% to 75% quartile range. Horizontal lines indicate 
median.
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DIsCussION
Previous findings suggest that BC in patients <20 years comprise a biologically distinct group. 
These tumors seem to be genetically stable, they lack the typical genetic aberrations found in 
older patients and are often of low stage and low grade.9, 17 In this study we aimed to elucidate 
bladder carcinogenesis in young patients by investigating the methylation status of five PcG 
target genes. We divided the included patients into four different age categories, i.e. <20yr, 20-
40yr, 40-60yr and >60yr. Overall, tumors from young patients had substantially less methylation 
for most of the markers compared to tumors from patients in the older age groups. Only PCDH7 
showed high median methylation ratios in all four age groups.
To our knowledge, hypermethylation in patients <20yr has only been investigated in one 
previous study.10 Owen et al. studied the methylation status of eight genes that were already 
known to be associated with bladder carcinogenesis, i.e. TNRFSF25, EDNRB, WIF1, APC, BCL2, 
MGMT, Cyclin D2 and E-Cadherin. They analyzed tumors from 12 patients under the age of 
20 and compared the methylation results with those of tumors in patients aged 20-45 years 
and in patients aged above 45 years. Most markers had significantly less methylation in the 
youngest group. Only TNFRSF25 and cyclin D2 showed similar methylation rates in all age 
groups. However, overall methylation rates for cyclin D2 were low in all three age groups. 
Methylation rates for TNFRSF25 were high, suggesting a role in early development of bladder 
tumors. Yet, the authors did not include negative controls in their study. In a previous study,18 we 
found high methylation of TNFRSF25 in urine DNA from healthy controls, raising the hypothesis 
that TNFRSF25 does not play an important role in urothelial tumorigenesis. Furthermore, since 
Figure 8.3 Methylation ratios by patients age for PCDH7. Methylation ratios were not significantly different 
in the four age groups (p=0,10) Median of age groups are 0,44; 0,60; 0,61 and 0,71, respectively. There was 
significantly less methylation in the normal controls compared to the patient groups (median 0,22; p<0.001). 
Boxplots indicate 25% to 75% quartile range. Horizontal lines indicate median.
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TNFRSF25 and cyclin D2 are not regulated by PcG target genes, it was beyond the scope of our 
study to investigate their methylation rates.
We found PCDH7 with similar methylation ratios in all age groups. We therefore suggest 
that PCDH7 is an interesting candidate in early bladder tumorigenesis. PCDH7, also known as 
BH-PCDH, is a gene located on the p-arm of chromosome 4 and is a member of the protocad-
herin family, which is a subgroup of the cadherin superfamily. Protocadherins are predominantly 
expressed in the brain and they function as cell-cell recognition molecules.19, 20 There is less 
known about the function of the PCDH7 gene in bladder cancer. In a gene-profiling study 
Sanchez-Carbayo et al found significant downregulation of PCDH7 in bladder cancer by inves-
tigating tissue from 52 normal urothelium and 105 bladder tumors.21 Similarly, Djyrskøt et al 
analyzed 60 bladder tumors and also found PCDH7 underexpression.22 In our study we did not 
investigate PCDH7 gene expression, but only studied DNA-hypermethylation. However aber-
rant DNA-hypermethylation often results in gene silencing and this should be confirmed by 
functional studies.
The major limitations in this study were the small number of tumor samples from patients 
in the youngest age group and the fact that these samples were collected from the national 
pathological database. Since the database only provides anonymous pathological information, 
we were not able to complete follow-up of these patients with regard to disease recurrence and 
progression. Neither are we able to follow these patients over time.
CONClusIONs
Bladder cancer patients aged <20yr seem to form a clinically and molecularly distinct group. 
Epigenetically, most markers showed lower methylation rates in patients <20yr. Only PCDH7 
showed similar high methylation ratios in all age groups and therefore might play a role in 
early urothelial carcinogenesis. Future studies with larger patient populations may provide more 
insight into the role of epigenetic silencing of Polycomb target genes in tumorigenesis.
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Chapter 9
HRAS mutations in bladder cancer at an early age and 
the possible association with the Costello syndrome
W. Beukers, A. Hercegovac, E.C. Zwarthoff
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154 Chapter 9
aBstraCt
Bladder tumors of patients <20yr have a low incidence of genetic aberrations typically found 
in tumors in older patients. In this study, we investigated oncogene mutations in patients with 
bladder cancer <20yr and compared them to older age groups. Interestingly, we observed a 
relatively high number of HRAS mutations in tumor from young patients. These mutations were 
also highly uncommon in bladder cancers of older patients, i.e. p.(Gly12Ser) and p.(Gly12Ala). 
Germline mutations in the HRAS gene, especially p.(Gly12Ser/Ala) cause Costello Syndrome 
(CS), a severe congenital disorder. Indeed, one of the patients had been diagnosed with CS. 
We hypothesized that some of the other patients might be mosaic for the HRAS mutation and 
therefore could express some of the clinical features of CS, like tumor predisposition. Hence we 
isolated DNA from microdissected stroma and analyzed it for HRAS mutations. In the CS patient 
and in patient X the mutation was also highly expressed in normal stroma. We conclude that 
patient X is possibly mosaic for the HRAS mutation. These results suggest that mosaicism for 
oncogenic HRAS mutations may increase the risk for developing bladder cancer at a young age.
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INtrODuCtION
Bladder cancer (BC) is a disease of the elderly with a peak incidence in the sixth decade of 
life and only 1-2.4% of all cases present under the age of 40. BC in patients younger than 
20 years is even more uncommon with reported incidence rates of only 0.1-0.4%.1 Previous 
studies demonstrated that tumors of patients <20 years lack or have a much lower incidence of 
epigenetic and genetic aberrations typical of bladder cancer in elderly patients.2
Together with mutations in FGFR3 and PIK3CA, mutations in the RAS genes are the most 
common mutations found in BC and up to 13% of all bladder tumors harbour a mutation in 
HRAS, KRAS or NRAS.3 There is limited data available regarding these oncogenic mutations in BC 
of patients <20 years. Therefore, we aimed to investigate FGFR3, PIK3CA and RAS mutations in 
BC of patients <20 years and compared the results with the mutation status of a control group 
consisting of patients with BC >20 year.
MaterIal aND MethODs
Fourteen patients <20 years (median 16.5; range 11-19) were included. In addition, three dif-
ferent control groups were investigated, i.e. patients diagnosed with BC at 20-40 years (n=43), 
40-60 years (n=45), and >60 years (n=58). Tumor tissue was obtained from a previous study.41 
Normal surrounding stroma was microdissected ensuring >90% normal cells. Samples were used 
in accordance with the Dutch Code for “Proper secondary use of human tissues” (http://www.
federa.org). Tumor DNA was analyzed for mutations in HRAS, KRAS and NRAS with a multiplex 
Snapshot assay as described previously.5 This assay identifies 96% of the RAS mutations in BC, 
according to the Sanger institute. In addition, the DNA was screened using the Snapshot analysis 
for mutations in PIK3CA and FGFR3.5 Reference sequences are shown in supplementary file 9.1. 
Sequences and conditions of primers and probes are depicted in supplementary table 9.1 and 
9.2.
results
Table 9.1 shows the mutations found in the different age groups. FGFR3 and PIK3Ca mutations 
are more abundant in tumors from patients over 40 years of age. Overall, the FGFR3 mutation 
co-occurred with a mutation in PIK3CA in 24 cases, similar to previous observations. A mutation 
in the FGFR3 gene together with a mutation in KRAS was found in only one patient. In the 
youngest age group, no mutations were found in PIK3CA and only one mutation was observed 
in the FGFR3 gene. However, 4/14 (29%) of the young patients harboured a mutation in HRAS, 
a much higher percentage than in the older age groups (Table 9.1). Interestingly, not only did 
we observe this high number of HRAS mutations, but also 3/4 of these mutations were highly 
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uncommon in BC, i.e. c.34G>A (p.(Gly12Ser)) and c.35C>G (p.(Gly12Ala)). In addition, another 
p.(Gly12Ala) mutation was found in a bladder tumor of a 29yr-old patient from the control 
group. This patient was a known CS patient. The four patients with the uncommon p.(Gly12Ser/
Ala) mutation all had a solitary TaG1 bladder tumor. In these four patients RAS mutation analysis 
was performed on DNA isolated from microdissected tumor surrounding stroma. The areas 
of stroma used as normal surrounding tissue are depicted in Figure 9.1a. For both tumor and 
Table 9.1: Distribution of oncogene mutations in bladder tumours of different age categories
Mutation
age categories
<20yr 20-40yr 40-60yr >60yr
n=14 n=43 n=45 n=58
HRAS p.(Gly12Ala) 1
p.(Gly12Ser) 2 1
p.(Gly12Cys) 1
p.(Gly13Arg) 1
p.(Gln61Leu) 2 1
p.(Gln61Arg) 1 1 1 1
KRAS p.(Gly12Cys) 1 2 1
p.(Gly12Asp) 1 1 1
p.(Gly12Val) 1 1 1
Wild type  10 36 39 52
FGFR3 p.(Arg248Cys) 1 2 4
p.(Gly372Cys) 4 1
p.(Ser249Cys) 1 12 18 26
p.(Tyr375Cys) 8 5
p.(Arg248Cys)+ p.(Ser249Cys) 1
Wild type 13 29 13 21
Unknown   1   
PIK3CA p.(Glu542Lys) 2 2 3
p.(Glu545Gly) 1 1
p.(Glu545Lys) 1 6 8
p.(His1047Arg) 2 2
p.(His1047Leu) 2
Wild type 13 40 34 42
Unknown  1    
Co-occurrence of mutations
FGFR3 and PIK3CA mutation 2 8 14
FGFR3 and KRAS mutation 1
KRAS and PIK3CA mutation 1 1
HRAS and PIK3CA mutation 1
FGFR3, KRAS and PIK3CA mutation   1 1
Youngsters with bladder cancer and HRAS mutations 157
9
normal tissue, the results of the RAS mutation analysis are shown in Figure 9.1b. The stroma 
of patient #1, a 16yr-old boy with a p.(Gly12Ala) HRAS mutation in his bladder tumor, did also 
display this HRAS mutation. Likewise, although the signal was low, a p.(Gly12Ser) HRAS muta-
tion was found in the normal stroma of patient #2, an 18yr-old boy with a p.(Gly12Ser) HRAS 
mutation in his bladder tumor. There was no mutation found in the normal tissue of patient 
#3, a 16yr-old male. In the 29yr-old female CS patient (Patient #4) from the control group the 
p.(Gly12Ser) HRAS mutation was also found in the surrounding stroma.
DIsCussION
BC of patients <20 years seem to form a molecular distinct group compared to BC of the elderly. 
In this study we screened BC of patients <20 years for oncogenic mutations that are typically for 
found in BC of the elderly. As expected, no mutations were found in the PIK3CA gene, and only 
Figure 9.1 (A) Microdissected areas used as normal surrounding tissue in the SNaPshot analysis. Microdissec-
tion ensured >90% normal stromal cells. Stroma from patient #1, 2 and 4 was derived from the same side as 
the bladder tumour. Stroma from patient #3 was obtained from random bladder biopsies. (B) RAS snapshot 
analysis of four patients’ tumour tissue and normal surrounding stroma. T = Tumour tissue
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one mutation in the FGFR3 gene. However a high amount of uncommon p.(Gly12Ser/Ala) HRAS 
mutations were observed in the youngest age category.
Germline mutations in the HRAS gene are found in several developmental disorders, such as 
the Costello Syndrome (CS). CS is a rare syndrome with only 300-400 reported cases world-
wide. CS is caused by point mutations in the HRAS gene, mostly resulting in p.(Gly12Ser) or 
p.(Gly12Ala). This multisystem disorder causes mental retardation, distinctive facial appearance, 
cardiovascular abnormalities, skin and musculoskeletal abnormalities, and tumor predisposition. 
Most frequent malignancy found is the embryonal rhabdomyosarcoma, but also cases with BC 
have been described.6 It appeared that the 29 yr-old patient with a p.(Gly12Ser) HRAS mutation 
in the bladder tumor was known to have CS and therefore the p.(Gly12Ser) HRAS mutation 
could also be observed in the normal surrounding stroma. The mutation found in the normal 
tissue of patient #2 could be due to contamination of tumor cells, since the signal is mutant 
peak is low compared to the wild-type peak. However, the mutation signal in the normal tissue 
of patient #1 is too high to be caused by contamination of tumor cells during microdissec-
tion. This suggests that this patient could be mosaic for the p.(Gly12Ala) HRAS mutation and 
therefore might have some of the clinical features of CS, such as tumor predisposition. Blood or 
other patients’ tissue of would be necessary to strengthen this hypothesis. Unfortunately, due 
to ethical limitations in accessing clinical data, we were unable to obtain additional tissue or 
information on possible other CS-like features of patients #1 (and patient #2).
Mosaicism of HRAS mutations in relation with CS was described previously in a small number 
of patients.7, 8 The phenotype of patients with mosaicism may differ and the clinical mani-
festations could occur along a spectrum depending on the affected tissue compartments.9 In 
a recently published case report, mutant HRAS mosaicism was also described in relation to 
BC. The publication described a patient with an extensive mosaicism for a HRAS p.(Gly12Ser) 
mutation. This 49yr-old man presented with widespread congenital epidermal nevi, multiple 
bladder tumors and a BC lung metastasis. The HRAS p.(Gly12Ser) mutation was found in the 
epidermal nevi as well as in the multiple bladder tumors and lung metastasis.10 The authors 
concluded that these findings corroborate the theory that RAS mutations may occur during 
early embryogenesis and could contribute to carcinogenesis at later age. Our results contribute 
to this hypothesis and suggest that mosaicism for oncogenic HRAS mutations may even increase 
the risk for developing bladder cancer at very young age. Thus, RAS mutation analysis should be 
performed on bladder tumors of young patients and if positive, the patient should be screened 
for possible manifestations of CS.
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suPPleMeNtary fIles
Supplementary table 9.1: Primer sequences mutation analysis
fGfr3 PCr Primermix
Primer sequence (5’->3’)
Product size 
(bp)
Concentration 
in PCr mix (μM)
FGFR3 RI Fw AGTGGCGGTGGTGGTGAGGGAG 115 1.2
FGFR3 RI Rev GCACCGCCGTCTGGTTGG 1.2
FGFR3 RII Fw CAACGCCCATGTCTTTGCAG 138 0.7
FGFR3 RII Rev AGGCGGCAGAGCGTCACAG 0.7
FGFR3 RIII Fw GACCGAGGACAACGTGATG 160 0.7
FGFR3 RIII Rev GTGTGGGAAGGCGGTGTTG 0.7
Pan-ras PCr Primermix
Primer sequence (5’->3’)
Product size 
(bp)
Concentration 
in PCr mix (μM)
HRAS exon1 Fw CAGGAGACCCTGTAGGAGG 139 0.6
HRAS exon1 Rev TCGTCCACAAAATGGTTCTG 0.6
HRAS exon2 Fw GGAGACGTGCCTGTTGGA 140 0.3
HRAS exon2 Rev GGTGGATGTCCTCAAAAGAC 0.3
KRAS exon1 Fw GGCCTGCTGAAAATGACTG 163 0.3
KRAS exon1 Rev GGTCCTGCACCAGTAATATG 0.3
KRAS exon2 Fw CCAGACTGTGTTTCTCCCTT 155 0.3
KRAS exon2 Rev CACAAAGAAAGCCCTCCCCA 0.3
NRAS exon1 Fw GGTGTGAAATGACTGAGTAC 128 0.3
NRAS exon1 Rev GGGCCTCACCTCTATGGTG 0.3
NRAS exon2 Fw GGTGAAACCTGTTTGTTGGA 103 0.3
NRAS exon2 Rev ATACACAGAGGAAGCCTTCG 0.3
PIk3Ca/Nras PCr Primermix
Primer sequence (5’->3’)
Product size 
(bp)
Concentration 
in PCr mix 
(μM)
PIK3CA ex9-Fw AGTAACAGACTAGCTAGAGA 139 1
PIK3CA ex9-Rev ATTTTAGCACTTACCTGTGAC 1
PIK3CA ex20-Fw GACCCTAGCCTTAGATAAAAC 109 0.7
PIK3CA ex20-Rev GTGGAAGATCCAATCCATTT 0.7
NRAS ex.2 Fw GGTGTGAAATGACTGAGTAC 128 0.3
NRAS ex.2 Rev GGGCCTCACCTCTATGGTG 0.3
NRAS ex.3 Fw GGTGAAACCTGTTTGTTGGA 103 0.5
NRAS ex.3 Rev ATACACAGAGGAAGCCTTCG 0.5
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supplementary table 9.2: Probe sequences mutation analysis
fGfr3 Probe mix
Probe sequence (5’-> 3’) size (bp) strand Wt Mt μM*
S373C T19 GAGGATGCCTGCATACACAC 39 sense t a 0.4
K652M/T T20 CACAACCTCGACTACTACAAGA 42 sense a t/C 0.7
G372C T29 GGTGGAGGCTGACGAGGCG 48 sense G t 0.2
A393E T34 CCTGTTCATCCTGGTGGTGG 54 sense C a 0.7
R248C T46 CGTCATCTGCCCCCACAGAG 66 sense C t 0.4
Y375C T43 ACGAGGCGGGCAGTGTGT 61 sense a G 0.6
S249C T36TCTGCCCCCACAGAGCGCT 55 sense C G 0.8
K652Q/E T50 GCACAACCTCGACTACTACAAG 72 antisense a C/G 0.3
G382R T56 GAACAGGAAGAAGCCCACACC 76 antisense C t 0.4
ras set 1 Probe mix
Probe sequence (5’-> 3’) size (bp) strand Wt Mt μM*
HRAS pos.34 T17 CTGGTGGTGGTGGGCGCC 35 sense G C/t/a 0.5
HRAS pos.182 T18 GCATGGCGCTGTACTCCTCC 38 antisense t G/C/a 0.15
KRAS pos.34 T25 GGCACTCTTGCCTACGCCAC 45 antisense C G/a/t 0.5
HRAS pos.35 T31 CGCACTCTTGCCCACACCG 50 antisense C G/a/t 0.7
NRAS pos.182 T33 GACATACTGGATACAGCTGGAC 55 sense a G/C/t 0.5
KRAS pos.181 T41 CTCATTGCACTGTACTCCTCTT 63 antisense G t/C 0.2
HRAS pos.181 T46 CATCCTGGATACCGCCGGC 65 sense C a/G 0.7
KRAS pos.35 T49 AACTTGTGGTAGTTGGAGCTG 70 sense G C/t/a 0.2
HRAS pos 37 T55 CAGCGCACTCTTGCCCACAC 75 antisense C G/a/t 0.7
NRAS pos.34 T62 CTGGTGGTGGTTGGAGCA 80 sense G C/t/a 0.2
PIk3Ca/Nras Probe mix
Probe sequence (5’-> 3’) size (bp) strand Wt Mt μM*
E542K T17 ACACGAGATCCTCTCTCT 35 sense G a 0.15
E545G T21 CCTCTCTCTGAAATCACTG 40 sense a G 0.5
E545K T25 ATCCTCTCTCTGAAATCACT 45 sense G a 0.3
H1047R T30 GAAACAAATGAATGATGCAC 50 sense a G 0.3
NRAS pos.34 T34 GTGCGCTTTTCCCAACACCAC 55 antisense C G/a/t 0.5
NRAS pos.35 T41 CTGGTGGTGGTTGGAGCAG 60 sense G C/a/t 0.3
NRAS pos.37 T46 GGTGGTGGTTGGAGCAGGT 65 sense G C/a/t 0.1
NRAS pos.38 T49 GTCAGTGCGCTTTTCCCAACA 70 antisense C G/a/t 0.5
NRAS pos.180 T54 GGACATACTGGATACAGCTGG 75 sense a t 0.3
NRAS pos.181 T58 CTCATGGCACTGTACTCTTCTT 80 antisense G C/t 0.2
NRAS pos.182 T63 GACATACTGGATACAGCTGGAC 85 sense a C/G/t 0.2
NRAS pos.183 T68 CTCTCATGGCACTGTACTCTTC 90 antisense t a/G/C 0.7
* Concentration in reaction
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GeNeral DIsCussION
Bladder cancer is the fifth most common cancer in the western world.1 It is a disease of the 
elderly with a peak incidence in the 6th decade of life. Approximately 80% of the new cases will 
present as non-muscle invasive disease with an overall favorable prognosis. Yet, these tumors 
tend to recur with a 5-year recurrence rate varying between 31-78%.2 Furthermore, there is 
a chance of progression to muscle invasive disease with a much worse prognosis. The high 
recurrence rate and risk of progression necessitates life-long frequent follow-up by cystoscopy 
as recommended by the EAU guidelines.3, 4 The high recurrence rate together with overall good 
survival result in high costs and patient burden. Development of non-invasive tests and risk 
stratification at first diagnosis will contribute to reduction of costs and improvement of patient 
burden.
Part II of this thesis investigates molecular markers in relation to disease progression. It includes 
the validation of progression markers in patients with primary low-grade disease. Based on the 
results we defined new molecular grades in order to divide patients in different risk groups 
and determined whether these risk groups could predict patient outcome. Furthermore, the 
prevalence of TERT mutations in BC and its relation to patient outcome was studied. In part 
III we investigated the role of urinary markers in the follow-up of non-invasive bladder cancer 
patients. In addition, markers were tested on patients presenting with hematuria to study the 
value of urinary makers at initial diagnosis. Part Iv focuses on the genetic and epigenetic altera-
tions in patients with bladder cancer at an early age in order to get a better insight in early 
bladder carcinogenesis.
New molecular markers and their relation to disease progression
Ta–tumors form the largest group of bladder cancer, comprising approximately 70% of all 
NMIBC.5 Although recurrence rates are high, low-grade (G1/G2) Ta-tumors have an overall good 
prognosis with limited progression rates varying between 1-6%, based on the EORTC risk-scores 
developed by Sylvester et al.2 This risk calculation is highly dependent on pathological review. 
Previous research demonstrated that the pathological assessment is subject to high interobserver 
and intraobserver variability, resulting in poor reproducibility. Molecular markers could help to 
objectify tumor aggressiveness and improve the accuracy of risk-prediction. This could result in 
more adjusted follow-up schemes and decrease the number of cystoscopies in low-risk patients. 
Up to now, no molecular markers are implemented in the risk calculator included in the EAU 
guidelines. Kandimalla et al identified GATA2, TBX2, TBX3, and ZIC4 as progression markers for 
primary low-risk disease in a genome wide methylation study.6 In this study DNA of fresh frozen 
tissue was used. In Chapter 2 we validated these four methylation makers in a large set of 
Formalin-Fixed Paraffin-Embedded tissue from primary low-grade NMIBC. A total of 192 primary 
tumors from patients with grade 1 or 2 NMIBC were included of who 77 progressed to muscle 
invasive disease. Methylation analysis was done for all four markers by using the MS-SNaPshot: 
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an easy to perform test, which is highly reproducible. Cox-regression analysis was performed 
and showed the independent effect of TBX2, TBX3 and ZIC4 on progression-risk, with TBX2 and 
TBX3 as best predictors.
TBX2 and TBX3 play a critical role in embryonic development and deregulation of these two 
genes in relation to tumor progression is described in several cancer types. TBX2 and TBX3 are 
both interfering with the p53-pathway by repressing p14/ARF and p21/CIP1. P53 mutations are 
frequently found in aggressive bladder tumors. Inhibiting this pathway results in uncontrolled 
proliferation and cell survival. Methylation of TBX2/3 could be an alternative way of deactivating 
the p53 pathway.7, 8 Reinert et al also investigated methylation in relation to disease progression 
in pTa tumors and found that TBX4 was more frequently hypermethylated in progressive tumors 
compared to the non-progressive pTa-tumors.9 These findings in combination with our own 
results imply the role of T-Box genes in tumor progression.
Based on the methylation status of TBX2 and TBX3 we determined new molecular grades. 
High molecular grade (HmG) was defined as high methylation ratios for both TBX2 and TBX3. 
Hypermethylation of only TBX2 or TBX3 was labeled as intermediate molecular grade (ImG). Low 
molecular grade (LmG) included patients with low methylation rates for both TBX2 and TBX3. 
Progression-free survival was significantly better for patients in the LmG-group compared to 
patients with a tumor of ImG or HmG. Likewise, patients with ImG showed better progression-
free survival compared to the HmG-group. Previously, molecular grading was introduced by van 
Rhijn et al based on MIB-1 expression and FGFR3 mutation status.10 In that study, molecular 
grade 1 was defined as low expression of MIB-1 and FGFR3 mutant, molecular grade 2 included 
tumors with low expression of MIB-1 and FGFR3 wild-type or high expression of MIB-1 and 
FGFR3 mutant. Molecular grade 3 comprised tumors with high expression of MIB-1 and FGFR3 
wild-type. The combination of MIB-1 and FGFR3 mutation status was a significant predictor of 
progression and was superior to clinical tumor characteristics. In a next study, van Rhijn et al 
combined the molecular grade with the EORTC risk scores and showed increased accuracy of 
progression prediction based on the EORTC risk protocols in combination with molecular grade, 
compared to the EORTC risk protocol alone.11 We presume that our methylation markers could 
further improve the predictive accuracy. Still, these studies include relatively small retrospec-
tive patients series. Large prospective studies should investigate the additional value of these 
molecular markers in combination the EORTC risk protocol in order to justify adjustment of the 
current risk stratification. 
In chapter 3 the presence of TERT mutations in BC was examined in relation to patient 
outcome. We found a mutation frequency of 70% in 111 fresh frozen tumor samples of all 
stages, with C228T and C250T as most frequently observed mutations. Next, FFPE tissue from 
an independent set of 357 BC patients was investigated with the SNaPshot analysis including 
the two most frequent mutations and showed a percentage of TERT mutations of 79%. TERT 
mutation status was not associated with patient age, sex or smoking status. Heterogeneity was 
assessed by analyzing multiple areas within a tumor and revealed an overall consistency, sug-
gesting the early appearance of TERT mutations in bladder carcinogenesis. There was no relation 
Discussion 169
10
between the TERT mutation status and progression-free survival, disease-specific survival and 
overall survival. Urine analysis with the TERT SNaPshot assay showed a sensitivity for recurrence 
detection of 42%, which was superior to the FGFR3 analysis, with a sensitivity of 19%. Likewise, 
62% of the primary tumors were detected by the TERT assay, compared to 36% with the 
FGFR3 assay. The TERT and FGFR3 analysis combined identified 50% of all recurrent tumors 
and 70% of the initial BCs. Kinde et al also investigated the presence of TERT mutations in BC 
and found similar results with a reported mutation frequency of 74%, predominantly C228T 
and C250T. No relation with disease progression was found. Additionally, no mutations were 
observed in the normal surrounding urothelium. Moreover, urine samples from patients with 
a TERT mutant tumor were investigated and 7/7 of the patients with a positive urine sample 
developed a recurrence within 3.5 months.12 In the same line, Hurst et al found a TERT mutation 
frequency of 83% in BC independent from stage or grade and a sensitivity of 79% for the 
detection of BC in urine. Yet, they did not distinguish between primary and recurrent disease.13 
The presence of TERT mutation in both NMIBC and MIBC suggests the involvement of TERT in 
both pathways. The high frequency of TERT mutations in combination with the high sensitivity 
for tumor detection in urine makes the TERT mutation assay a promising tool for the diagnosis 
and follow-up of BC.
the use of molecular markers in the follow-up of non-muscle invasive bladder 
cancer
There is a need for highly sensitive and specific markers in order to safely reduce the number of 
cystoscopies during surveillance of patients with non-muscle invasive bladder cancer (NMIBC). In 
search for novel markers, it is important to include the correct urine samples in order to avoid un-
reliable results. Most studies include a mixture of primary and recurrent tumors. Primary tumors 
are often larger in size and less well-differentiated then their recurrent counterparts. Therefore, 
these tumors will shed more tumor cells compared to recurrent tumors, resulting in misleading 
high marker performance.14 For the development of urinary assays, which are intended for 
surveillance purposes, we advocate the use of urine samples collected during follow-up. In the 
same line, it is important to distinguish between patients with primary high-grade or low-grade 
disease for the calculation of marker performance. Patients with primary low-grade disease are 
most suitable for follow-up by urine analysis, yet their low-grade recurrences are mostly harder 
to detect. In all studies included in this thesis, we clearly distinguished between urines collected 
during follow-up or collected at first visit.
In chapter 4, we designed a bladder cancer specific MS-MLPA (BC MS-MLPA) for the detection 
of recurrent NMIBC. Multiple studies have shown the relation of promoter hypermethylation 
and bladder carcinogenesis, and several studies reported the use of methylation markers in 
order to detect bladder cancer in voided urine.15 The MS-MLPA analysis is based on a multiplex 
PCR to investigate multiple CpGs in one assay and requires only 50ng DNA. The BC MS-MLPA 
was constructed based on the commercially available MS-MLPA kits -001 and -002. In addition, 
genes were selected from the literature, that were known to be frequently methylated in blad-
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der cancer. The BC MS-MLPA included 23 probes for 12 different genes. We finally selected a 
four gene panel consisting of APC_a, TERT_a, TERT_b and EDNRB, which resulted in a sensitivity 
of 63% and specificity of 58% for recurrence detection in the test set, consisting of 49 pre-TUR 
urine samples and 60 urine samples from recurrence-free patients. In the control set, comprising 
65 pre-TUR samples and 29 recurrence-free samples, 72% of all recurrences were detected with 
the BC MS-MLPA, with a specificity of 55%. Interestingly, all high-grade recurrences were identi-
fied. We included urine samples derived from recurrence-free patients as negative controls, since 
we believe this reflects true clinical practice. Low specificity is observed for all biomarkers that 
have been investigated for follow up of NMIBC patients and is due to a variety of reasons such 
as the anticipatory effect. This will be discussed further below under chapter 6.
In chapter 5, we aimed to increase recurrence detection by combining multiple molecular 
assays, i.e. FGFR3, PIK3CA, RAS mutation assays, BC MS-MLPA and microsatellite analysis 
(MA). All assays previously proved their value as single assay for recurrence detection in voided 
urine.16-18 Urine samples were collected from a large retrospective patient cohort, which was 
part of the European FP7 UROMOL project. All patients initially presented with low-grade 
NMIBC and urine samples were collected during follow-up visits. A total of 136 patients were 
included with 716 urine samples and 552 recurrent tumors during a median follow-up of 3 
years. Patients were stratified based on the analysis of the primary tumor or tumor at first visit 
after study inclusion. Stratification depending on the molecular status of the primary tumor is 
based on the assumption that recurrent tumors will have similar molecular alterations as the 
previous initial tumor.19, 20 Hence, stratification should enhance recurrence detection. FGFR3 
analysis without stratification reached a sensitivity of 49% for recurrence detection. Including 
only patients with a primary FGFR3 mutant tumor improved recurrence detection to 66%. High-
est rate of recurrence detection was reached by the combination of MA and FGFR3 analysis 
(82%). All investigated molecular assays were superior to cytology for identifying recurrences. 
The addition of FGFR3 analysis to urine cytology increased sensitivity for detection of recurrent 
Ta disease from 54% to 75% and for grade 1 disease from 33% to 66%. We presume that 
recurrences were missed because of their relatively small size. A previous study by Zuiverloon 
et al revealed that sensitivity for recurrence detection by FGFR3 analysis improved with tumor 
size, suggesting that the amount of seeded tumor cells increases with tumor volume.21 They 
also argue that other urine based-assays depending on the number of tumor cells in urine will 
never reach a sensitivity of 100% for smaller tumors. They propose that multiple urine sampling 
would increase recurrence detection. Furthermore, we found relatively low specificity for all 
single and combined markers. We discussed that the low specificity could be partly due to the 
anticipatory effect of urine analysis, meaning that urine analysis detects the tumor before it is 
macroscopically visible by cystoscopy. For example, FGFR3 mutations are not found in sufficient 
amounts in normal urothelium.22 Therefore, the specificity of the FGFR3 assay should be 100%. 
Yet, it was only 66% in the current study. We showed that 85% of the ‘false’ positive FGFR3 
urines developed a recurrence within 12 months. A more extensive deliberation about the high 
false-positive rate is found under chapter 6.
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Although the results were promising, we believe that the investigated assays are not suitable 
for routine clinical practice. The MA consists of 12 individual polymerase chain reactions per 
sample, which is too laborious in combination with data analysis and needs automation. In ad-
dition, a large number of urine samples will not contain sufficient DNA for the MA. The custom 
MS-MLPA assay proved not to be very easy to handle in the laboratory and many samples 
failed, also the amount of DNA required was often prohibitive. For this reasons we decided not 
to proceed with this technology. Therefore, we decided to investigate new promising urinary 
assays in combination with the solid FGFR3 assay in chapter 6. In this study we investigated the 
FGFR3 analysis in combination with the recently developed TERT mutation assay and a methyla-
tion assay, which both showed promising results in previous reports.23, 24 The study was part 
of the European FP7 UROMOL project and included a multicenter prospective patient cohort 
comprising 1111 patients with primary or previously diagnosed bladder cancer: 720 patients 
with primary low-grade NMIBC (LG-NMIBC), 259 patients with primary high-grade NMIBC (HG-
NMIBC) and 215 patients with MIBC. A total of 2703 urine samples were collected during the 
first or regular follow-up visits. The main objective of this study was similar to chapter 5 and 
involved the validation of urinary assays for the follow-up of LG-NMIBC patients. Urine samples 
were analyzed for FGFR3 and TERT mutations and the methylation of OTX. This three-assay 
combination reached a sensitivity of 57% for the detection of concomitant recurrences from 
patients with a primary LG-NMIBC, with a specificity of 59%. Marker performance was superior 
to urine cytology. The detection rate for the three-assay combination increased with advanced 
stage and grade, identifying 87% of the T1, 77% of the muscle invasive tumors and 83% of 
the grade 3 tumors. Surprisingly, we found significant higher sensitivity in samples derived from 
male patients compared to urine samples from females, suggesting the disturbing influence of 
benign cells in female urine. As in chapter 5, we tried to improve sensitivity by stratification of 
the patients based on the molecular status of their tumor. This resulted in a slight improvement 
of marker performance to a sensitivity of 62% with the three-assay combination. Recurrence 
detection rate with the three-assay combination was significant higher in patients with pri-
mary HG-NMIBC compared to patients with primary LG-NMIBC. (57% vs 62%, p-value<0.05). 
Likewise, the detection rate of primary NMIBC was higher than the detection rate of recurrent 
tumors, detecting 81% of the primary LG-NMIBC and 94% of the primary HG-NMIBC. This 
again emphasizes the difficulties in the development of a sensitive urine test for the detection 
of low-grade recurrences. The additional value of analyzing multiple urine samples to reduce 
the chance of missing tumor cells in urine from patients with small low-grade recurrence should 
be investigated in future studies. Unfortunately, specificity of the three-assay combination was 
still relatively low. The high false-positive rate of urine analysis for concomitant tumor detec-
tion could be explained by several reasons. First, sensitivity of white-light cystoscopy is not 
optimal, ranging from 46%-80%.25 Therefore, several urine samples must have been mistakenly 
considered false-positive. In fact there was a tumor present, but it was missed by cystoscopy. 
Secondly, as mentioned in chapter 4 and 5, low specificity could be due to the anticipatory effect 
of urine analysis. We revealed that 87% of the FGFR3 positive urine samples were followed by 
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a recurrence within 5 years. Likewise, we found that 79% of the urine samples positive for the 
combination of assays developed a recurrence within 5 years. Remarkably, most high-stage 
recurrence were found within a year after urine analysis, proposing the additional value of 
urine analysis for the detection of high-risk recurrences. Furthermore, the low specificity might 
be due to our definition of recurrence. We defined recurrence as a histologically proven tumor. 
Yet, small recurrences are frequently coagulated without the collection of tissue for pathological 
review. These tumors were not included in our data analysis, which could lead to false-positive 
urine results. Finally, we would like to mention that a very small proportion of the recurrent 
tumors will appear in the upper urinary tract. Of course, these tumors are missed by cystoscopy.
This study supports the value of urine analysis as an alternative for cystoscopies in patients 
with LG-NMIBC and as a valuable addition to the surveillance of patients presenting with 
HG-NMIBC. A study by van der Aa et al showed that the knowledge of a positive urine test 
could improve the awareness of the urologist and thereby increase sensitivity of cystoscopy.26 
Moreover, the next follow-up visit could be adjusted to a shorter time-interval in case cystoscopy 
is negative. It would be very interesting to construct a recurrence-risk predictor based on urinary 
assays in combination with clinical and pathological findings.
risk assessment in patients presenting with hematuria
Patients presenting with microscopic or macroscopic hematuria form a large part of the uro-
logical practice.27 Most important in evaluation of these patients is to discriminate between a 
malignant and non-malignant cause. Therefore, these patients will undergo invasive examina-
tion, including cystoscopy, cytology and imaging of the upper urinary tract. In chapter 7 we 
aimed to investigate the predictive value of a urine-based methylation assay in combination with 
clinical characteristics for the detection of bladder cancer in patients presenting with hematuria. 
We included 169 patients presenting with microscopic or macroscopic hematuria in which n=54 
the cause was malignant. Urine samples were collected at first visit or prior to resection of the 
primary tumor. Methylation analysis was done for OSR1, SIM2, OTX1, MEIS1 and ONECUT2. The 
methylation results were combined with clinical variables (i.e. age, gender and type of hematuria) 
in a multivariable logistic regression model in order to calculate the combined predictive effect. 
This model determined type of hematuria, ONECUT2, OSR1 and SIM2 as independent predictors 
for the presence of BC. We presumed that the addition of smoking status could have further 
increased diagnostic accuracy, since previous studies showed the independent predictive value 
of smoking in the assessment of patients presenting with hematuria.28-30 Unfortunately, smoking 
data were not available in this study. Next, we determined a cut-off to discriminate between 
low-risk and high-risk patients. This resulted in 44/54 (82%) of the patients with BC in the 
high-risk group and 94/115 (82%) of the patients without a malignancy in the low-risk group. 
All patients with BC assigned to the low-risk group presented with a Ta-tumor and were mostly 
low-grade. In the current clinical practice, all patients with hematuria are evaluated according 
the same protocol, without considering the a priori chance according to clinical features. We 
concluded that our model might be a useful tool in the stratification of patients presenting 
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with hematuria, resulting in adjustment of patient examination according to patient’s risk, and 
subsequently reduction of costs and patient burden. Several other studies revealed the addi-
tional value of molecular markers and clinical characteristics in the evaluation of hematuria.31-33 
Recently, Lotan et al validated a nomogram based on clinical characteristics in combination with 
the FDA-approved NMP22 bladderchek test for risk prediction in a large prospective multicenter 
patient cohort presenting with hematuria.31 They again emphasized the importance of including 
molecular tests in combination of clinical characteristics, such as gender, age and smoking, in 
decision models in order to avoid extensive evaluation in low-risk patients.
Molecular make-up of bladder cancer under the age of 20: a rare and 
biological distinct group?
In chapter 8 and 9 we investigated the molecular status of tumors developed under the age 
of 20th. Normally, bladder cancer is a disease of the elderly, and is very rare in children with 
estimated incidence rates of 0.1-0.4%.34 These bladder tumors are mostly low stage and 
grade, and they are unlikely to recur. Conflicting results have been published regarding the 
molecular behavior of bladder cancer in younger patients. Yet, multiple studies showed that 
tumors of patients <20yr lack the common molecular aberrations as observed in the elderly, 
like FGFR3 mutations and hypermethylation of genes associated with bladder cancer in the 
elderly.35 These tumors seem to act through a different pathway and form a biologically distinct 
group compared to their older counterparts. In chapter 8 we focused on hypermethylation of 
polycomb group (PcG) target genes and their potential role in bladder carcinogenesis. These 
genes play an important role in cell lineage decisions in early embryogenesis and are frequently 
hypermethylated in multiple carcinomas.36 We hypothesized that hypermethylation of these 
PcG target genes might be an early event in bladder carcinogenesis and therefore could also 
be observed in bladder cancer of young patients. Five PcG target genes were selected from a 
previous genome-wide methylation study6, i.e. MEIS1, ONECUT2, OTX1, PCDH7 and SOX21, 
and a total of 167 patients with BC were included. These patients were divided in four dif-
ferent age groups, including <20 years n=14, 20-40yr n=48, 40-60 n=47 and >60yr n=58. 
Investigation of the tumor DNA revealed significant more methylation in the older age groups 
compared to the younger ones for 4/5 genes. Only, PCDH7 showed similar methylation ratios in 
all four age groups and low methylation in the negative controls i.e. urine from healthy controls. 
Therefore, we concluded that methylation of the PCHD7 gene may contribute to early bladder 
carcinogenesis. Only two studies previously reported about the role of PCDH7/ PCDH7 in bladder 
cancer. Djyrskøt et al found PCDH7 underexpression in 60 bladder tumors.37 Along the same 
line, Sanchez-Cabayo et al found downregulation of PCDH7 in 105 bladder tumors compared to 
tissue from 52 healthy controls. In our study, no functional experiments were performed.38 Yet, 
it is known that hypermethylation often results in gene silencing. To further investigate the role 
of PCDH7 in bladder carcinogenesis, functional studies are indicated. In chapter 9 patients with 
BC <20yr were screened for oncogenic mutations frequently observed in bladder tumors from 
the elderly i.e. FGFR3, PIK3CA and RAS mutations. Previously reported data about the mutation 
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status of bladder cancer in this young age group is very limited. We included 14 patients <20yr 
and in order to compare the results we included three different control group, similar to those 
in chapter 8: 20-40 years (n=43), 40-60 years (n=45), and >60 years (n=58). Tumor DNA was 
analysed for FGFR3, PIK3CA and RAS mutations. None of the 14 included tumors harbored a 
mutation for PIK3CA and only one tumor showed a FGFR3 mutation. Interestingly, in 4/14 (29%) 
patients <20yr a HRAS mutation was found. In contrast, only 13% (19/146) of the patients in 
the older control groups harbored a RAS mutation. Even more remarkable was the fact that 
3/4 observed HRAS mutations found in the youngsters were rarely described in tumors of the 
elderly i.e. c.34G>A (p.(Gly12Ser)) and c.35C>G (p.(Gly12Ala). Another c.35C>G HRAS muta-
tion was found in a bladder tumor of a 29yr-old patient from the control group. This patient was 
known to have the Costello Syndrome, a rare congenital disorder caused by germline mutations 
in the HRAS gene, with c.35C>A/G as most observed mutation. Based on these findings we 
hypothesized that the other four patients could be mosaic for the HRAS mutation and therefore 
display some of the clinical features of the Costello Syndrome such as tumor predisposition. In 
order to strengthen this hypothesis, normal surrounding bladder tissue was analysed for the RAS 
mutations which revealed similar HRAS mutations in the 29yr-old Costello patient, but also in 
2/4 of the other patients. Based on these results we concluded that these two patients could be 
mosaic for the HRAS mutation. The analysis of blood is necessary to fully prove this hypothesis. 
Unfortunately, this was not possible within the current study set-up due to ethical limitations. 
Hafner et al previously described HRAS mosaicism in relation to bladder cancer in a case report.39 
In this report, a 49yr-old patient is described with a congenial epidermal naevus and bladder 
cancer at the age of 19 which recurred after a 29yr recurrence-free interval. One year later a 
single lung metastasis was found. RAS mutation analysis revealed a p.Gly12Ser HRAS mutation 
in the epidermal naevus in the bladder tumors and lung metastasis, but also in the normal lung 
tissue, blood leucocytes and normal urothelium. No other features of the Costello Syndrome 
were observed. The authors concluded that these results support the theory that RAS mutations 
might occur during early embryogenesis, leading to mosaicism. Eventually, this could contribute 
to the development of cancer during life. Our results support these findings and suggest that 
the chance of developing bladder cancer at an early age is increased. Therefore, we believe that 
tumors from patients presenting with bladder cancer at a young age should be screened for 
HRAS mutations. In case of a mutation further investigation is recommended.
future perspectives and concluding remarks
Non-muscle invasive bladder cancer is a unique type of cancer with an overall favorable prog-
nosis, despite the high recurrence rate and chance of disease progression. Many studies investi-
gated the identification of new molecular markers to facilitate the intensive surveillance protocol 
and thereby improve costs and patient burden. In order to reach this goal it is crucial to precisely 
select patients suitable for urine surveillance. This group includes patients with a low risk of 
disease progression. Currently, this progression risk is still highly dependable on the pathologi-
cal characteristics, even though there is a huge interobserver and intraobserver variability. We 
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composed a new molecular grade to objectify tumor aggressiveness. We believe that this new 
molecular grade could improve progression prediction and therefore help us to stratify patients 
suitable for less invasive follow-up. This new molecular grade is currently being validated in a 
large prospective patient series. When this is successful, the test could be incorporated in the 
routine diagnostic work-up of patients presenting with pTa bladder cancer.
Up to now, no urinary assays are included in the guidelines, since the marker performance is 
deemed not to be high enough to safely reduce the amount of cystoscopies. One of the reasons, 
besides the sensitivity of the markers, is that one assumes that cystoscopy, the gold standard, 
has a sensitivity of 100%. Realizing that this is overoptimistic is important to rethink the contri-
bution that biomarkers can have in the follow-up of patients. In this thesis we combined several 
urinary tests in order to improve recurrence detection and proved that a combination of assays is 
sensitive for the detection of the most aggressive tumors. Yet, the detection of small low-grade 
recurrence remains challenging. Therefore we emphasize the need of multiple urine sampling to 
improve recurrence detection rate. Recently, a large multicenter randomized control trial (RCT) 
has started at the Erasmus Medical Center, Rotterdam. Patients with primary or recurrent NMIBC 
are included and double urine samples will be collected at each follow-up visit. Samples are 
investigated with the combination of markers discussed in this thesis. The main objective of the 
RCT is to prove that it is possibly to safely reduce the number of cystoscopies during follow-up 
in patients with a low-risk NMIBC. Furthermore, the study will also investigate the additional 
value of urine analysis in the follow-up of patients with high-risk NMIBC, assuming that urine 
analysis is able to earlier detect potential dangerous recurrences. Expectantly, results of this RCT 
will be able to change current bladder cancer follow-up. As future perspective, we advocate 
a urine-first strategy, meaning that the analysis of urine samples will reduce the number of 
cystoscopies, since only a positive urine test will be followed by cystoscopy.  This will be mostly 
relevant for patients with low-risk pTa-tumors, especially because the sensitivity of cystoscopy 
is relatively low for the detection of these pTa-tumors. Another possible development is the use 
of next generation sequencing on urinary DNA. With this technology multiple genes can be 
sequenced simultaneously using only a small amount of DNA. For instance it would be possible 
to include tumor suppressor genes such as TP53 and KDM6A, both frequently mutated in BCs.40
Furthermore, we presume that urinary markers could not only play a role in bladder cancer 
surveillance, but also in the initial diagnosis. Hematuria patients form a large part of the urologi-
cal population and unnecessary invasive investigation can be avoided by proper risk stratification 
based on an a priori chance calculated using clinical variables in combination with urine analysis. 
We proposed such a risk model in this thesis, which is currently validated in a larger group of 
patients.
As final remark, I would like to stress out that molecular analysis is justified in bladder tumors 
from patients <20yrs, even though the overall prognosis of this age group is favorable and 
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genetic aberrations are uncommon. We showed an unexpected high percentage of RAS muta-
tions in this age group and assume that this could be a sign of mosaicism. These patients need 
further clinical evaluation.
In summary, bladder cancer is a fascinating disease and there is a big role for molecular mark-
ers in the development, diagnosis and prognosis of this disease. In this thesis we investigated 
molecular markers in relation to these three different facets with improvement of patient care 
as ultimate goal. Stratification of patients prior to initial diagnosis as well as during follow-up 
in combination with surveillance by urinary markers will lead to less invasive investigations, 
resulting in reduction of costs and patient burden.
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suMMary
Bladder cancer is the 5th most common cancer in the western world. It could simply be divided 
into two different subgroups: non-muscle invasive BC and muscle-invasive BC. 75% of all BC 
patients will have non-muscle invasive disease at initial presentation. This type of BC has a 
favorable prognosis, although it is characterized by a high recurrence rate and a chance of 
progression into muscle invasive disease with much worse prognosis. Hence, these patients 
should be followed extensively by cystoscopy. Cystoscopy is an invasive unpleasant procedure 
causing patient discomfort. Furthermore, the frequent surveillance in combination with the high 
number of TUR’s results in high costs, making BC one of the most expensive cancer types. Using 
non-invasive tests for the detection and follow-up of BC patients could reduce costs and reduce 
patients burden. Moreover, molecular tests could be used for risk stratification by predicting 
prognosis. This could contribute to adjustment of the currently used surveillance protocols. In 
this thesis we studied the use of molecular markers in relation to these aspects. Furthermore, 
we investigated a particular subgroup of BC patients, namely patients with BC under the age of 
20 years. BC in this age group is very rare and therefore there is less known about the molecular 
characteristics in this specific patient group.
At first a short introduction is given about bladder cancer in chapter 1. It includes epidemiology, 
symptoms and diagnosis and the pathological assessment. Also treatment options and the use 
of molecular markers are discussed, followed by the scope of the thesis.
The second part includes chapter 2 and chapter 3 and investigates molecular markers in rela-
tion to tumor progression. Chapter 2 is a validation of the previously identified Ta-progression 
markers GATA2, TBX2, TBX3, ZIC4 in a large set of patients with primary Ta-BC. 77/192 of the 
included patients developed disease progression to muscle-invasive disease. The methylation 
results were combined in a Cox-regression analysis and showed the independent effect of TBX2, 
TBX3, ZIC4 on progression risk. Based on the best predictors TBX2 and TBX3 new molecular 
grades were defined. Progression-free survival was significant better in patients with low mo-
lecular grade compared to the higher molecular grades. Likewise, patients with intermediate 
molecular grade showed better progression-free survival compared to the high molecular grade 
group. This new molecular grade could be valuable for objective assessment of tumor aggres-
siveness. Chapter 3 investigated the prevalence of TERT mutations in BC and found that 79% 
of all BC harbored a TERT mutation independent of tumor stage. Most frequently observed 
mutations were C228T and C250T. There was no association with age, sex of smoking status. 
Furthermore, there was no relation between TERT mutation status and progression-free survival, 
disease-specific survival or overall survival. Urine analysis with the TERT SNaPshot assay revealed 
sensitivity for recurrence detection of 42% and 62% for the detection of the initial tumor. 
Specificity was 90% in patients without a history of BC and 73% for patients in follow-up for 
BC.
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In the third part we investigate the role of urine-based tests for primary diagnosis and follow-up 
of patients with NMIBC. Previous studies showed the diagnostic ability of methylation analysis 
for detection of BC in voided urine. In chapter 4 we designed a methylation analysis specifically 
for the detection of recurrent NMIBC. Genes methylated in recurrent NMIBC were selected for 
the BC-specific methylation analysis (BC MS-MLPA) comprising 23 different probes from 12 
different genes. Next, the assay was validated on urine from an independent set of patients with 
recurrent disease and urine from healthy controls. Based on these results a four-gene panel was 
selected including APC_a, TERT_a, TERT_b, and EDNRB. This panel reached an AUC of 0.82 in a 
test-set of patients and 0.69 in a validation set of patients. The sensitivity of this four-gene panel 
for the detection of recurrent BC in urine was 63% in the test-set and 72% in the validation-set, 
with specificity of 58% and 55%, respectively. Interestingly, most high-grade tumors (10/11) 
were detected with this BC-specific methylation assay. In chapter 5, this methylation assay was 
combined with other molecular assays (FGFR3, PIK3CA and RAS mutation analysis, MA) in order 
to improve sensitivity for recurrence detection. Patients with primary low-grade NMIBC were 
included and were stratified based on the molecular status of the primary tumor. FGFR3 analysis 
detected 66% of all recurrent tumors. The highest recurrence detection rate was observed with 
a combination of FGFR3 analysis and MA (82%). All molecular assays and combination of assays 
were superior to cytology. The addition of FGFR3 analysis to urine cytology improved sensitivity 
from 56 % to 76%. Overall the specificity was low, ranging from 34%-66%. Since the BC MS-
MSLPA and MA showed some flaws, we combined the FGFR3 analysis with two other promising 
molecular assays in chapter 6. This study was a large prospective multicenter patient cohort 
including 977 patients with NMIBC. 2496 urine samples were collected at primary visit or during 
follow-up and were examined with the FGFR3 and TERT mutation analysis in combination with 
OTX1 methylation analysis. This three-assay combination reached a sensitivity of 57% for the 
detection of a concomitant recurrence in patients with primary low-grade NMBIC (LG-NMIBC). 
The specificity was 58%. The sensitivity increased with advanced stage and grade (87% T1, 
77% ≥T2, 83% G3). Sensitivity for recurrence detection in patients with primary high-grade 
disease was 72%. Furthermore, we showed that a positive urine assay was associated with a 
recurrence over time in 76% of the cases. Especially high stage recurrences were diagnosed 
concomitantly or within 1 year after a positive urine assay. This emphasizes the anticipatory 
effect of urine analysis. This study supports the value of urine analysis as an alternative for 
cystoscopies in patients with LG-NMIBC and as a valuable addition to the surveillance of patients 
presenting with HG tumors. In chapter 7 we investigated whether the MS-SNaPshot, which 
was developed for recurrence detection, would be able to discriminate between malignant and 
non-malignant disease in patients presenting with hematuria. Methylation analysis on voided 
urine was performed for OSR1, SIM2, OTX1, MEIS1 and ONECUT2. Methylation results were 
combined with clinical variables (i.e. age, gender and type of hematuria) into a logistic regression 
model to calculate the combined predictive effect. Patients were divided into the low-risk group 
or high-risk group based on this model. 82% of the patients with BC as cause of hematuria were 
included in the high-risk group and 82% of the patients with hematuria due to a non-malignant 
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cause were assigned to the low-risk group. We concluded that risk assessment based on these 
molecular markers in combination with clinical variables could be useful in the stratification of 
patients presenting with hematuria.
The final part studies the molecular status of bladder cancer in patients under 20 years old. 
There is less known about BC in this young age group, but these tumors appearing to form 
a molecular distinct group. First, we analyzed the tumors from patients <20yrs for methyla-
tion of five polycomb group target genes (MEIS1, ONECUT2, OTX1, PCDH7 and SOX21) and 
compared the results to those from patients with BC in different age groups (chapter 8). Four 
out of five genes showed significant less methylation in the younger patients compared to the 
older ones. Only PCDH7 revealed similar high methylation ratios in all four age groups and low 
methylation ratios in the negative controls. Therefore, we presumed that PCHD7 might be a 
possible candidate in early bladder carcinogenesis. Chapter 9 investigated the mutation status 
of FGFR3, PIK3CA and RAS in BC from patients <20yr. No PIK3CA mutations and only one FGFR3 
mutation were observed. Interestingly a high amount of HRAS mutations were found (29%) and 
3/4 of the HRAS mutations were rarely described in tumors from older BC patients (c.34G>A 
and c.35C>G). We found another c.35C>G mutation in BC from one of the older patients. 
This patient was known to have the Costello syndrome. This is a rare congenital disorder and is 
associated with cancer predisposition like BC. It is caused by HRAS germline mutations (mainly 
c.34G>A and c.35C>G). We analyzed normal surrounding tissue for HRAS mutations and found 
similar HRAS mutations in tissue of the Costello patient, but also in 2/4 of the other patients. 
Based on these results we concluded that these two patients could be mosaic for the HRAS 
mutation and therefore might have some of the clinical features such as tumor predisposition.
186 Chapter 11
saMeNvattING (DutCh)
Blaaskanker (BK) is de vijfde meest voorkomende kanker in de westerse wereld. BK wordt over 
het algemeen in twee verschillende groepen verdeeld: niet-spierinvasief blaascarcinoom (NSIBC) 
en spierinvasief blaascarcinoom (SIBC). 75% van alle patiënten die zich voor het eerst presen-
teert met BK heeft NSIBC. Deze vorm van BK heeft een goede prognose, alhoewel dit type wordt 
gekarakteriseerd door een hoog aantal recidieven en de kans op progressie naar spierinvasieve 
ziekte met een veel slechtere prognose. Door deze typische karakteristieken moeten patiënten 
met NSIBC gedurende vele jaren regelmatig worden gecontroleerd door middel van cystoscopie. 
Dit is een invasieve procedure, die door patiënten vaak als onplezierig wordt ervaren. Deze 
intensieve manier van surveillance resulteert samen met het vele aantal TUR’s in hoge kosten. 
Dit maakt BK een van de duurste vormen van kanker om te behandelen. Kosten kunnen worden 
gereduceerd door het gebruik van niet-invasieve tests. Hierdoor kan ook de last voor de patiënt 
worden verminderd. Verder kunnen moleculaire markers bijdragen aan het stratificeren van pa-
tiënten door middel van een risico-inschatting (bijvoorbeeld de kans op progressie). Uiteindelijk 
zou dit kunnen leiden tot aanpassing en verbetering van het huidige surveillanceprotocol. In dit 
proefschrift hebben we het gebruik van moleculaire markers in relatie tot deze verschillende 
aspecten bestudeerd. Daarnaast hebben we een aparte groep van BK-patienten onderzocht. 
Deze groep bestaat uit patiënten met BK onder de 20 jaar. BK is in deze leeftijdsgroep zeer 
zeldzaam en daarom is er erg weinig bekend over de moleculaire status van deze tumoren.
Eerst wordt een korte introductie gegeven over blaaskanker in hoofdstuk 1. Hierin worden 
de epidemiologie, symptomen en diagnose, en pathologische beoordeling besproken. Verder 
wordt er aandacht besteed aan de behandelingsopties en het gebruik van moleculaire markers. 
Daarna volgt in het kort de strekking van dit proefschrift. Het tweede deel beslaat hoofdstuk 
2 en hoofdstuk 3 en onderzoekt de rol van moleculaire markers in relatie tot BK-progressie.
hoofdstuk 2 bestaat uit de validatie van de eerder geïdentificeerde progressie markers GATA2, 
TBX2, TBX3 en ZIC4 in een grote set van patiënten met een primair pTa-BK. Veertig procent 
(77/192) van de geïncludeerde patiënten ontwikkelde progressie naar spierinvasieve ziekte. De 
primaire tumoren van de patiënten werden geanalyseerd met de vier methyleringsmarkers en de 
resultaten werden gecombineerd in een Cox-regressie analyse. Deze analyse liet zien dat zowel 
TBX2, TBX3, als ook ZIC4 een onafhankelijk effect hadden op de progressiekans. TBX2 en TBX3 
waren de beste voorspellers en op basis van deze twee methyleringsmarkers definieerden we 
een nieuwe moleculaire gradering. De progressie-vrije overleving was significant beter in pati-
enten met een laag moleculair gegradeerde tumor ten opzichte van tumoren met een interme-
diaire of een hoge moleculaire gradering. Het zelfde gold voor tumoren met een intermediaire 
gradering in vergelijking tot tumoren met een hoge moleculaire gradering. Wij denken dat deze 
nieuwe moleculaire gradering goed bruikbaar is om de mate van tumoragressiviteit te bepalen. 
Mogelijk kan in de toekomst het surveillanceprotocol hierop aangepast worden.In hoofdstuk 
3 werd de prevalentie van TERT mutaties in BK onderzocht en vonden we dat 79% van alle BK, 
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onafhankelijk van het tumor stadium, een TERT mutatie had. De twee meest voorkomende TERT 
mutaties waren C228T en C250T. Er was geen associatie met leeftijd, geslacht, of roken. Verder 
was er geen relatie tussen TERT mutatie status en de progressie vrije overleving, ziekte-specifieke 
overleving, of totale overleving. De sensitiviteit voor het detecteren van een recidief in urine 
door middel van de TERT SNaPshot analyse was 42% en voor het detecteren van een primaire 
tumor was deze 62%. De specificiteit was 90% voor personen zonder een historie van BK en 
73% voor patiënten met een verleden van BK.
In het derde deel wordt ingegaan op het gebruik van urinediagnostiek voor het stellen van 
de initiële diagnose of voor de follow-up van patiënten met NSIBC. Eerdere studies hebben 
aangetoond dat analyse van urine met methyleringsmarkers gebruikt kan worden voor het 
detecteren van BK. In hoofdstuk 4 hebben we een methylatie-assay (BC MS-MLPA) ontwikkeld 
speciaal voor het detecteren van recidiverend NSIBC. Voor dit methylatie-assay werden er genen 
geselecteerd die gemethyleerd zijn in recidiverend NSIBC. Dit assay bestond uiteindelijk uit 23 
verschillende probes voor 12 verschillende genen. Dit assay is vervolgens gevalideerd op urine 
van een onafhankelijke groep patiënten met recidiverend BK. Urines van gezonde patiënten fun-
geerden als controle. Op basis van deze resultaten werden er vier genen geselecteerd (APC_a, 
TERT_a, TERT_b, en EDNRB). Dit 4-genenpanel behaalde een AUC van 0.82 in de testgroep en 
0.69 in de validatiegroep. In de testgroep was de sensitiviteit voor het detecteren van recidive-
rend BK 63% en in de validatiegroep was dit 72%. De specificiteit was respectievelijk 58% en 
55%. Verrassend genoeg werden bijna alle hooggradige tumoren (10/11) gedetecteerd met dit 
4-genenpanel. In hoofdstuk 5 werd de BC MS-MLPA gecombineerd met andere moleculaire 
tests (FGFR3, PIK3CA, RAS mutatie analyse, MA) om zo de sensitiviteit voor het detecteren 
van recidieven te vergroten. Patiënten werden geïncludeerd met een primair laaggradig NSIBC 
en gestratificeerd op basis van de moleculaire status van hun primaire tumor. FGFR3 analyse 
detecteerde 66% van alle tumorrecidieven. Het hoogste aantal recidieven werd gedetecteerd 
door middel van de combinatie MA en FGFR3 analyse (82%). Alle individuele markers en com-
binaties van assays waren beter in het detecteren van recidieven ten opzichte van cytologie. De 
toevoeging van FGFR3 analyse aan cytologie resulteerde in een verbetering van de sensitiviteit 
van 56% naar 76%. De specificiteit was in alle gevallen vrij laag, variërend van 34% tot 66%. 
Omdat zowel de BC MS-MLPA als de MA enkele gebreken vertoonde, hebben we besloten om 
in hoofdstuk 6 de FGFR3 analyse met twee andere veelbelovende urine-assays te combineren. 
Deze studie betrof een groot prospectief multicenter cohort met 977 patiënten geïncludeerd 
met NSIBC. 2496 urines werden verzameld bij eerste polibezoek of gedurende follow-up. De 
urine werd vervolgens geanalyseerd met de FGFR3 en TERT mutatuie-analyse en de OTX1 
methylatie-analyse. Deze combinatie van drie assays resulteerde in een sensitiviteit van 57% 
voor de detectie van een gelijktijdig recidief in patiënten met een primair laaggradig NSIBC. De 
specificiteit was 58%. De sensitiviteit verbeterde naar mate het stadium of de gradering van 
het recidief toenam (87% T1, 77% ≥T2, 83% G3). Dezelfde combinatie van assays detecteerde 
72% van de recidieven in patiënten met een primair hooggradig NSIBC. Daarnaast toonden 
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we aan dat 76% van de positieve urines binnen 5 jaar werd gevolgd door een recidief en dat 
recidieven met een hoog stadium bijna allemaal binnen 1 jaar na positieve urine-analyse werden 
gediagnosticeerd. Dit benadrukt het voorspellende effect van urinediagnostiek. In deze studie 
lieten we zien dat met een combinatie van urine-assays de detectiekans van een recidief wordt 
vergroot. Voor patiënten met een primair laaggradig NSIBC kan urinediagnostiek dienen als 
goed alternatief voor cystoscopie. Daarnaast kan urinediagnostiek in verband met zijn voor-
spellende waarde van aanvullende betekenis zijn in de follow-up van patiënten met primair 
hooggradig NSIBC. In hoofdstuk 7 van dit proefschrift onderzochten we of de MS-SNaPshot, 
die in eerste instantie ontwikkeld was voor het detecteren van BK recidieven, ook ingezet kan 
worden voor het diagnosticeren van BK in patiënten die zich presenteerden met hematurie. 
Urine werd geanalyseerd met de MS-SNaPshot voor de genen OSR1, SIM2, OTX1, MEIS1 en 
ONECUT2. Deze resultaten werden samen met klinische variabelen (leeftijd, geslacht en type 
hematurie) gecombineerd in een logistisch regressie model om zo de voorspellende waarde voor 
aanwezigheid van een maligniteit te berekenen. Op basis van het model werden de hematurie-
patienten verdeeld tussen een hoogrisico- en een laagrisicogroep. 82% van de patiënten met 
BK als oorzaak van de hematurie zaten in de hoogrisicogroep en 82% van de patiënten met een 
niet-maligne oorzaak van de hematurie werden aan de laagrisicogroep toebedeeld. Wij con-
cludeerden dat risico inschatting op basis van moleculaire markers in combinatie met klinische 
variabelen van belang kunnen zijn voor het stratificeren van patiënten die zich presenteren met 
hematurie. Hierdoor kunnen onnodige onderzoeken in laagrisicopatienten worden voorkomen.
Het laatste deel van het proefschrift bestudeert de moleculaire status van BK in patiënten jonger 
dan 20 jaar. Er is weinig bekend over BK in deze jonge leeftijdsgroep, maar het lijkt erop dat 
tumoren in deze groep zich moleculair apart gedragen ten opzichte van BK in oudere leeftijds-
genoten. Eerst hebben we tumoren van deze jonge patiënten geanalyseerd op de aanwezigheid 
van methylering van vijf zogenaamde polycombgroep targetgenen (MEIS1, ONECUT2, OTX1, 
PCDH7 en SOX21). Vervolgens hebben we de resultaten vergeleken met de resultaten van 
oudere patiënten met BK (hoofdstuk 8). Vier van de vijf genen toonden significant minder 
methylatie in de tumoren van de jongere patiënten vergeleken met de ouderen. Alleen PCDH7 
toonde vergelijkbare methyleringsratio’s in alle leeftijdsgroepen. Tevens werden er lage methy-
leringsratio’s gevonden in urine van de gezonde controle patiënten. Daarom concludeerden we 
dat PCDH7 mogelijk een rol zou kunnen spelen in de vroege blaascarcinogenese. hoofdstuk 9 
onderzoekt de mutatiestatus van FGFR3, PIK3CA en RAS in dezelfde leeftijdsgroep. Er werden 
geen PIK3CA mutaties gevonden en 1 FGFR3 mutatie. Echter werden echter wel een hoog 
aantal HRAS mutaties gevonden (29%) en 3/4 HRAS mutaties waren zelden beschreven in BK 
van oudere patiënten (c.34G>A en c.35C>G). Er werd ook eenzelfde c.35C>G mutatie gevon-
den in 1 van de patiënten in de controlegroep. Deze patiënt bleek het Costellosyndroom te 
hebben. Dit is een zeer zeldzaam aangeboren syndroom, dat onder andere gekenmerkt wordt 
door een predispositie voor het ontwikkelen van tumoren (o.a. blaaskanker). Dit syndroom 
wordt veroorzaakt door kiemlijn mutaties in HRAS (voornamelijk c.34G>A en c.35C>G). Hierop 
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besloten wij om ook normaal omliggend weefsel te analyseren op de aanwezigheid van deze 
HRAS mutaties. Zoals verwacht werd er ook een HRAS mutatie in het gezonde weefsel van 
de Costello patiënt gevonden. Daarnaast toonden 2 van de 4 van de jonge patiënten met 
een HRAS mutatie in de tumor ook een HRAS mutatie in het gezonde weefsel. Gebaseerd op 
deze resultaten concludeerden we dat deze patiënten mogelijk mozaïek zouden kunnen zijn 
voor deze HRAS mutatie en daardoor mogelijk enkele verschijnselen van het Costellosyndroom 
kunnen vertonen, zoals tumorpredispositie.
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List of abbreviations
lIst Of aBBrevIatIONs
AUC Area Under the Curve
BC Bladder Cancer
BCG Bacillus Calmette-Guérin
CIS Carcinoma In Situ
EAU European Association of Urology
EDNRB Endothelin Receptor Type B
EORTC European Organization for Research and Treatment of Cancer
FGFR Fibroblast Growth Factor Receptor
LOH Loss Of Heterozygosity
MA Microsatellite Analysis
MIBC Muscle-Invasive Bladder Cancer
MS-MLPA Methylation-Specific Multiplex Ligation-dependent Probe
 Amplification
NMIBC Non-Muscle Invasive Bladder Cancer
ONECUT One Cut Homeobox
OSR Odd-Skipped Related
OTX Orthodenticle homeobox
PCDH Protocadherin
PCG Polycomb group target genes
PIK3CA Phosphatidylinositol-3,4 -bisphosphate 3-kinase
TERT Telomerase Reverse Transcriptase
TUR TransUrethral Resection
WHO World Health Organization
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alleen een collega en ben ik heel erg blij dat je mijn paranimf bent. Ten eerste ben ik je natuurlijk 
heel erg dankbaar voor al het werk dat je voor dit proefschrift hebt verricht. Zonder jouw hulp 
was dit boekje er niet geweest. Maar daarnaast, nog veel belangrijker, ben ik je dankbaar voor 
al onze mooie momentjes samen, voor alle gezelligheid op het lab, onze koffietjes, radiomo-
mentjes met Koen&Sander en Frank<3 en onze feestjes buiten het werk. Zonder jou waren de 
afgelopen jaren een heel stuk minder leuk geweest. Ook nu het onderzoek klaar is hoop ik dat 
we elkaar nog heel veel blijven zien!
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Tahlita, jouw enthousiasme voor het onderzoek werkt aanstekelijk. Jij hebt er uiteindelijk voor 
gezorgd dat ik begonnen ben aan dit proefschrift. We hebben mooie tijden beleefd zowel op 
als buiten het werk. 
Hedietje, mijn Be 332a-roomie, lief en leed hebben we gedeeld op onze kamer. Break-ups, 
onze nieuwe huisjes op de Jensiusstraat, en nieuwe liefdes, we hebben het allemaal samen 
meegemaakt. Af en toe heb je het wel met me te verduren gehad; kwam er geen geluid uit mijn 
snaveltje, dan kwam het wel uit mijn speakertjes, maar het was altijd feest bij ons op de kamer.
Steph, het was altijd fijn om samen met jou te zijn. Je ben de grootste goedzak die ik ken.
Alexander, mister Olympia, twee hoofdstukken in dit boekje zijn mede tot stand gekomen 
dankzij jouw hulp. Alhoewel ik een beetje teleurgesteld ben dat je nog steeds niet zo breed 
bent als Arnold, toch ben je een mooie vent. Dank voor al je hulp.
Cheno, samen met Steph begonnen we in Tahlita’s legertje, dank voor je bijdrage aan het 
feestgedruis in Be-304.
Raju, you were always willing to help me out, if needed. Thank you.
Irene, Lucy, Marcel, Magda, Angela, ook bij jullie kon ik altijd terecht wanneer ik hulp nodig 
had. Dank jullie wel!
Diandra, de eerste student die ik voor langere tijd mocht begeleiden. Uiteindelijk is er een mooi 
stuk uitgekomen. Dank voor je bijdrage.
Jie-fen en Hrvoje, mijn lichtpuntjes aan het eind van elke werkdag. Jullie maakten me telkens 
weer blij, wanneer jullie me rond 5-en weer even gezelschap kwamen houden. Dank voor de 
hulp bij het inzamelen en verwerken van alle urines.
De collega’s van MGZ: Hester, dank voor al je hulp bij de statistiek. Hoe druk je het ook had, 
je was altijd bereid te helpen. En natuurlijk ook Ewout, Yvonne en Daan, zodra het voor mij te 
moeilijk werd kon ik op bij jullie terecht. Dank.
All members from the UROMOL-project group thank you for your contribution.
Collega’s van de urologie promotiegroep: Yin, Robert, Suus, Matthijs, Elaine, Meelan, Xavier, 
Jos, Diederick. Dank voor alle gezelligheid tijdens de verschillende congressen, donderdagmid-
daglunches, promovendi-avonden, etentjes, borrels en ons Alpe d’huZes avontuur.
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Verpleegkundigen en poli-dames van de urologie. Jullie hebben een grote rol gespeeld in het 
verzamelen van alle urines. Dank daarvoor.
Alle overige co-auteurs, bedankt voor jullie bijdrage.
En dan natuurlijk alle andere mensen buiten het werk: vrienden, clubgenootjes, de Kenia-groep, 
party-family, iedereen die ervoor gezorgd heeft dat ik ook een leuk leven na werktijd heb gehad, 
dank jullie wel!
In het bijzonder mijn BFFs. Denise, ik kan niet vaak genoeg zeggen hoe belangrijk je door de 
jaren heen voor me bent geweest. Ik ben zo blij dat we de afgelopen jaren samen synchroon 
doorlopen hebben. Ook al zeggen we vaak dat we niet zoveel koffie hadden moeten drinken 
tijdens onze promotietijd, zonder onze Doppio–momentjes, etentjes en onze legendarische 
vrijdagmiddagborrels bij het Schaap was het allemaal een stuk minder leuk geweest.
Mies, als ik bedenk hoeveel toffe dingen wij samen hebben gedaan en meegemaakt de afge-
lopen 10 jaar kan ik niet anders dan aan een stuk door blijven stralen. Je bent fantastisch en ik 
hoop de komende jaren er nog heel veel festivals, feestjes, etentjes, borrels en weekendjes weg 
aan toe te kunnen voegen. First stop London!
Tot slot lieve familie. Big Sis, ik ben supertrots op je hoe je je leventje heb opgebouwd in 
Noorwegen en wat een lieve en goede moeder je bent sinds Noralie er is. Ik ben heel blij met 
de mooie voorkant die je ontworpen hebt en vind het heel bijzonder dat jij straks als paranimf 
naast me staat tijdens mijn verdediging.
Hans, jij gaat heerlijk je eigen weg. Ik ben heel blij dat je weer in Nederland komt wonen, zodat 
we weer samen Amsterdam in kunnen.
Papa, jij bent voor mij altijd de voorbeeld dokter geweest. De rustige lieve arts die alle tijd neemt 
voor zijn patiënten. Ik blijf me elke keer weer verbazen over je bodemloze put aan kennis en 
feitjes. Het is een fijn gevoel dat ik altijd een hulplijn heb, die ik kan bereiken. Samen met mama 
heb je me altijd onvoorwaardelijk gesteund en daar ben ik jullie beiden heel erg dankbaar voor.
Lieve mama, met het ouder worden is mijn bewondering voor jou steeds verder gegroeid. Jij 
hebt ons geleerd trots te zijn op wie je bent en niet bang te zijn je te onderscheiden van de rest. 
Je gaat voor ons door het vuur en het feit dat wij alle drie goed terecht zijn gekomen is voor het 
grootste deel aan jou te danken. Ik ben heel erg blij met een mama zoals jij.
Lieve Ra, samen zijn we Yin en Yang en zolang wij af en toe blijven dansen, dan worden we 
samen 100.
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